,source,target,value,type,source layer,target layer,normalized value
0,KVD20,Initial triggering of complement,0.01723656688525892,0,0,1,0.019218797340132265
1,KVD20,Initial triggering of complement,0.016506757168016674,1,0,1,0.018405058435749088
2,KVD20,Regulation of Complement cascade,0.01723656688525892,0,0,1,0.019218797340132265
3,KVD20,Regulation of Complement cascade,0.016506757168016674,1,0,1,0.018405058435749088
4,KVD20,FCGR activation,0.01723656688525892,0,0,1,0.019218797340132265
5,KVD20,FCGR activation,0.016506757168016674,1,0,1,0.018405058435749088
6,KVD20,Regulation of actin dynamics for phagocytic cup formation,0.01723656688525892,0,0,1,0.019218797340132265
7,KVD20,Regulation of actin dynamics for phagocytic cup formation,0.016506757168016674,1,0,1,0.018405058435749088
8,KVD20,Role of phospholipids in phagocytosis,0.01723656688525892,0,0,1,0.019218797340132265
9,KVD20,Role of phospholipids in phagocytosis,0.016506757168016674,1,0,1,0.018405058435749088
10,KVD20,Role of LAT2/NTAL/LAB on calcium mobilization,0.01723656688525892,0,0,1,0.019218797340132265
11,KVD20,Role of LAT2/NTAL/LAB on calcium mobilization,0.016506757168016674,1,0,1,0.018405058435749088
12,KVD20,FCERI mediated MAPK activation,0.01723656688525892,0,0,1,0.019218797340132265
13,KVD20,FCERI mediated MAPK activation,0.016506757168016674,1,0,1,0.018405058435749088
14,KVD20,FCERI mediated Ca+2 mobilization,0.01723656688525892,0,0,1,0.019218797340132265
15,KVD20,FCERI mediated Ca+2 mobilization,0.016506757168016674,1,0,1,0.018405058435749088
16,KVD20,FCERI mediated NF-kB activation,0.01723656688525892,0,0,1,0.019218797340132265
17,KVD20,FCERI mediated NF-kB activation,0.016506757168016674,1,0,1,0.018405058435749088
18,KVD20,Parasite infection,0.01723656688525892,0,0,1,0.019218797340132265
19,KVD20,Parasite infection,0.016506757168016674,1,0,1,0.018405058435749088
20,KVD20,Leishmania parasite growth and survival,0.01723656688525892,0,0,1,0.019218797340132265
21,KVD20,Leishmania parasite growth and survival,0.016506757168016674,1,0,1,0.018405058435749088
22,KVD20,Potential therapeutics for SARS,0.01723656688525892,0,0,1,0.019218797340132265
23,KVD20,Potential therapeutics for SARS,0.016506757168016674,1,0,1,0.018405058435749088
24,KVD20,CD22 mediated BCR regulation,0.01723656688525892,0,0,1,0.019218797340132265
25,KVD20,CD22 mediated BCR regulation,0.016506757168016674,1,0,1,0.018405058435749088
26,KVD20,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01723656688525892,0,0,1,0.019218797340132265
27,KVD20,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.016506757168016674,1,0,1,0.018405058435749088
28,KVD20,Cell surface interactions at the vascular wall,0.01723656688525892,0,0,1,0.019218797340132265
29,KVD20,Cell surface interactions at the vascular wall,0.016506757168016674,1,0,1,0.018405058435749088
30,KVD20,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01723656688525892,0,0,1,0.019218797340132265
31,KVD20,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.016506757168016674,1,0,1,0.018405058435749088
32,KVD20,Scavenging of heme from plasma,0.01723656688525892,0,0,1,0.019218797340132265
33,KVD20,Scavenging of heme from plasma,0.016506757168016674,1,0,1,0.018405058435749088
34,IGLC7,Initial triggering of complement,0.007557856389218867,0,0,1,0.008427020951280303
35,IGLC7,Initial triggering of complement,0.007309800303984926,1,0,1,0.008150438052676822
36,IGLC7,Regulation of Complement cascade,0.007557856389218867,0,0,1,0.008427020951280303
37,IGLC7,Regulation of Complement cascade,0.007309800303984926,1,0,1,0.008150438052676822
38,IGLC7,FCGR activation,0.007557856389218867,0,0,1,0.008427020951280303
39,IGLC7,FCGR activation,0.007309800303984926,1,0,1,0.008150438052676822
40,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.007557856389218867,0,0,1,0.008427020951280303
41,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.007309800303984926,1,0,1,0.008150438052676822
42,IGLC7,Role of phospholipids in phagocytosis,0.007557856389218867,0,0,1,0.008427020951280303
43,IGLC7,Role of phospholipids in phagocytosis,0.007309800303984926,1,0,1,0.008150438052676822
44,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.007557856389218867,0,0,1,0.008427020951280303
45,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.007309800303984926,1,0,1,0.008150438052676822
46,IGLC7,FCERI mediated MAPK activation,0.007557856389218867,0,0,1,0.008427020951280303
47,IGLC7,FCERI mediated MAPK activation,0.007309800303984926,1,0,1,0.008150438052676822
48,IGLC7,FCERI mediated Ca+2 mobilization,0.007557856389218867,0,0,1,0.008427020951280303
49,IGLC7,FCERI mediated Ca+2 mobilization,0.007309800303984926,1,0,1,0.008150438052676822
50,IGLC7,FCERI mediated NF-kB activation,0.007557856389218867,0,0,1,0.008427020951280303
51,IGLC7,FCERI mediated NF-kB activation,0.007309800303984926,1,0,1,0.008150438052676822
52,IGLC7,Parasite infection,0.007557856389218867,0,0,1,0.008427020951280303
53,IGLC7,Parasite infection,0.007309800303984926,1,0,1,0.008150438052676822
54,IGLC7,Leishmania parasite growth and survival,0.007557856389218867,0,0,1,0.008427020951280303
55,IGLC7,Leishmania parasite growth and survival,0.007309800303984926,1,0,1,0.008150438052676822
56,IGLC7,Potential therapeutics for SARS,0.007557856389218867,0,0,1,0.008427020951280303
57,IGLC7,Potential therapeutics for SARS,0.007309800303984926,1,0,1,0.008150438052676822
58,IGLC7,CD22 mediated BCR regulation,0.007557856389218867,0,0,1,0.008427020951280303
59,IGLC7,CD22 mediated BCR regulation,0.007309800303984926,1,0,1,0.008150438052676822
60,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007557856389218867,0,0,1,0.008427020951280303
61,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007309800303984926,1,0,1,0.008150438052676822
62,IGLC7,Cell surface interactions at the vascular wall,0.007557856389218867,0,0,1,0.008427020951280303
63,IGLC7,Cell surface interactions at the vascular wall,0.007309800303984926,1,0,1,0.008150438052676822
64,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007557856389218867,0,0,1,0.008427020951280303
65,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007309800303984926,1,0,1,0.008150438052676822
66,IGLC7,Scavenging of heme from plasma,0.007557856389218867,0,0,1,0.008427020951280303
67,IGLC7,Scavenging of heme from plasma,0.007309800303984926,1,0,1,0.008150438052676822
68,FCN3,Initial triggering of complement,0.0005007037133943315,0,0,1,0.0005582853742996266
69,FCN3,Initial triggering of complement,0.0005271848854322065,1,0,1,0.0005878119199344392
70,CERU,Metal ion SLC transporters,0.012590252353828074,0,0,1,0.014038149827636643
71,CERU,Metal ion SLC transporters,0.013161761378285643,1,0,1,0.014675383227548792
72,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.012590252353828074,0,0,1,0.014038149827636643
73,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.013161761378285643,1,0,1,0.014675383227548792
74,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.012590252353828074,0,0,1,0.014038149827636643
75,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.013161761378285643,1,0,1,0.014675383227548792
76,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.012590252353828074,0,0,1,0.014038149827636643
77,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.013161761378285643,1,0,1,0.014675383227548792
78,CERU,Post-translational protein phosphorylation,0.012590252353828074,0,0,1,0.014038149827636643
79,CERU,Post-translational protein phosphorylation,0.013161761378285643,1,0,1,0.014675383227548792
80,F13A,Interleukin-4 and Interleukin-13 signaling,0.010467631855780273,0,0,1,0.011671424861258368
81,F13A,Interleukin-4 and Interleukin-13 signaling,0.010292808773494096,1,0,1,0.011476496868276845
82,F13A,Platelet degranulation ,0.010467631855780273,0,0,1,0.011671424861258368
83,F13A,Platelet degranulation ,0.010292808773494096,1,0,1,0.011476496868276845
84,F13A,Common Pathway of Fibrin Clot Formation,0.010467631855780273,0,0,1,0.011671424861258368
85,F13A,Common Pathway of Fibrin Clot Formation,0.010292808773494096,1,0,1,0.011476496868276845
86,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.021432049626747558,0,0,1,0.023896766746073016
87,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.02217467408001812,1,0,1,0.024724794099909898
88,THRB,Regulation of Complement cascade,0.021432049626747558,0,0,1,0.023896766746073016
89,THRB,Regulation of Complement cascade,0.02217467408001812,1,0,1,0.024724794099909898
90,THRB,Class A/1 (Rhodopsin-like receptors),0.021432049626747558,0,0,1,0.023896766746073016
91,THRB,Class A/1 (Rhodopsin-like receptors),0.02217467408001812,1,0,1,0.024724794099909898
92,THRB,G alpha (q) signalling events,0.021432049626747558,0,0,1,0.023896766746073016
93,THRB,G alpha (q) signalling events,0.02217467408001812,1,0,1,0.024724794099909898
94,THRB,Defective factor XII causes hereditary angioedema,0.021432049626747558,0,0,1,0.023896766746073016
95,THRB,Defective factor XII causes hereditary angioedema,0.02217467408001812,1,0,1,0.024724794099909898
96,THRB,Defective factor VIII causes hemophilia A,0.021432049626747558,0,0,1,0.023896766746073016
97,THRB,Defective factor VIII causes hemophilia A,0.02217467408001812,1,0,1,0.024724794099909898
98,THRB,Cell surface interactions at the vascular wall,0.021432049626747558,0,0,1,0.023896766746073016
99,THRB,Cell surface interactions at the vascular wall,0.02217467408001812,1,0,1,0.024724794099909898
100,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.021432049626747558,0,0,1,0.023896766746073016
101,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.02217467408001812,1,0,1,0.024724794099909898
102,THRB,Common Pathway of Fibrin Clot Formation,0.021432049626747558,0,0,1,0.023896766746073016
103,THRB,Common Pathway of Fibrin Clot Formation,0.02217467408001812,1,0,1,0.024724794099909898
104,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.021432049626747558,0,0,1,0.023896766746073016
105,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.02217467408001812,1,0,1,0.024724794099909898
106,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.021432049626747558,0,0,1,0.023896766746073016
107,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.02217467408001812,1,0,1,0.024724794099909898
108,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.02368604263557315,0,0,1,0.02640997225451689
109,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.022972106077000662,1,0,1,0.02561393194531526
110,FA9,Defective factor VIII causes hemophilia A,0.02368604263557315,0,0,1,0.02640997225451689
111,FA9,Defective factor VIII causes hemophilia A,0.022972106077000662,1,0,1,0.02561393194531526
112,FA9,Defective factor IX causes hemophilia B,0.02368604263557315,0,0,1,0.02640997225451689
113,FA9,Defective factor IX causes hemophilia B,0.022972106077000662,1,0,1,0.02561393194531526
114,FA9,Defective factor IX causes thrombophilia,0.02368604263557315,0,0,1,0.02640997225451689
115,FA9,Defective factor IX causes thrombophilia,0.022972106077000662,1,0,1,0.02561393194531526
116,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.02368604263557315,0,0,1,0.02640997225451689
117,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.022972106077000662,1,0,1,0.02561393194531526
118,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.02368604263557315,0,0,1,0.02640997225451689
119,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.022972106077000662,1,0,1,0.02561393194531526
120,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.002988355164484115,0,0,1,0.003332020388333561
121,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.003328401210213978,1,0,1,0.0037111722277166515
122,FA10,Defective factor VIII causes hemophilia A,0.002988355164484115,0,0,1,0.003332020388333561
123,FA10,Defective factor VIII causes hemophilia A,0.003328401210213978,1,0,1,0.0037111722277166515
124,FA10,Defective factor IX causes hemophilia B,0.002988355164484115,0,0,1,0.003332020388333561
125,FA10,Defective factor IX causes hemophilia B,0.003328401210213978,1,0,1,0.0037111722277166515
126,FA10,Defective factor IX causes thrombophilia,0.002988355164484115,0,0,1,0.003332020388333561
127,FA10,Defective factor IX causes thrombophilia,0.003328401210213978,1,0,1,0.0037111722277166515
128,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.002988355164484115,0,0,1,0.003332020388333561
129,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.003328401210213978,1,0,1,0.0037111722277166515
130,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.002988355164484115,0,0,1,0.003332020388333561
131,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.003328401210213978,1,0,1,0.0037111722277166515
132,FA10,Common Pathway of Fibrin Clot Formation,0.002988355164484115,0,0,1,0.003332020388333561
133,FA10,Common Pathway of Fibrin Clot Formation,0.003328401210213978,1,0,1,0.0037111722277166515
134,PLMN,Platelet degranulation ,0.009603526687987786,0,0,1,0.010707946332679252
135,PLMN,Platelet degranulation ,0.01140084947319589,1,0,1,0.012711963872463115
136,PLMN,Dissolution of Fibrin Clot,0.009603526687987786,0,0,1,0.010707946332679252
137,PLMN,Dissolution of Fibrin Clot,0.01140084947319589,1,0,1,0.012711963872463115
138,PLMN,Activation of Matrix Metalloproteinases,0.009603526687987786,0,0,1,0.010707946332679252
139,PLMN,Activation of Matrix Metalloproteinases,0.01140084947319589,1,0,1,0.012711963872463115
140,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.009603526687987786,0,0,1,0.010707946332679252
141,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.01140084947319589,1,0,1,0.012711963872463115
142,PLMN,Signaling by PDGF,0.009603526687987786,0,0,1,0.010707946332679252
143,PLMN,Signaling by PDGF,0.01140084947319589,1,0,1,0.012711963872463115
144,FA12,Defective factor XII causes hereditary angioedema,0.0051732831404864175,0,0,1,0.0057682182839531235
145,FA12,Defective factor XII causes hereditary angioedema,0.005869454282682874,1,0,1,0.006544450127857295
146,FA12,Defective SERPING1 causes hereditary angioedema,0.0051732831404864175,0,0,1,0.0057682182839531235
147,FA12,Defective SERPING1 causes hereditary angioedema,0.005869454282682874,1,0,1,0.006544450127857295
148,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.0051732831404864175,0,0,1,0.0057682182839531235
149,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.005869454282682874,1,0,1,0.006544450127857295
150,CAH2,Reversible hydration of carbon dioxide,0.011159422914829685,0,0,1,0.012442772906033841
151,CAH2,Reversible hydration of carbon dioxide,0.010326144438348114,1,0,1,0.011513666183448061
152,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.011159422914829685,0,0,1,0.012442772906033841
153,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.010326144438348114,1,0,1,0.011513666183448061
154,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.011159422914829685,0,0,1,0.012442772906033841
155,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.010326144438348114,1,0,1,0.011513666183448061
156,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.015822853891421202,0,0,1,0.01764250527997062
157,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.016235558036172538,1,0,1,0.018102671006255237
158,ANT3,Common Pathway of Fibrin Clot Formation,0.015822853891421202,0,0,1,0.01764250527997062
159,ANT3,Common Pathway of Fibrin Clot Formation,0.016235558036172538,1,0,1,0.018102671006255237
160,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.015822853891421202,0,0,1,0.01764250527997062
161,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.016235558036172538,1,0,1,0.018102671006255237
162,ANT3,Post-translational protein phosphorylation,0.015822853891421202,0,0,1,0.01764250527997062
163,ANT3,Post-translational protein phosphorylation,0.016235558036172538,1,0,1,0.018102671006255237
164,ANGT,Class A/1 (Rhodopsin-like receptors),0.014081054704289416,0,0,1,0.01570039663342096
165,ANGT,Class A/1 (Rhodopsin-like receptors),0.014147915682949016,1,0,1,0.01577494672262235
166,ANGT,G alpha (q) signalling events,0.014081054704289416,0,0,1,0.01570039663342096
167,ANGT,G alpha (q) signalling events,0.014147915682949016,1,0,1,0.01577494672262235
168,ANGT,G alpha (i) signalling events,0.014081054704289416,0,0,1,0.01570039663342096
169,ANGT,G alpha (i) signalling events,0.014147915682949016,1,0,1,0.01577494672262235
170,ANGT,PPARA activates gene expression,0.014081054704289416,0,0,1,0.01570039663342096
171,ANGT,PPARA activates gene expression,0.014147915682949016,1,0,1,0.01577494672262235
172,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.014081054704289416,0,0,1,0.01570039663342096
173,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.014147915682949016,1,0,1,0.01577494672262235
174,A2MG,Platelet degranulation ,0.013511980222131,0,0,1,0.015065877751740592
175,A2MG,Platelet degranulation ,0.013309528808735475,1,0,1,0.014840144129078211
176,A2MG,HDL assembly,0.013511980222131,0,0,1,0.015065877751740592
177,A2MG,HDL assembly,0.013309528808735475,1,0,1,0.014840144129078211
178,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.013511980222131,0,0,1,0.015065877751740592
179,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.013309528808735475,1,0,1,0.014840144129078211
180,CO3,Initial triggering of complement,0.03496516380534943,0,0,1,0.038986208890253976
181,CO3,Initial triggering of complement,0.03835517893550159,1,0,1,0.04276608072900719
182,CO3,Activation of C3 and C5,0.03496516380534943,0,0,1,0.038986208890253976
183,CO3,Activation of C3 and C5,0.03835517893550159,1,0,1,0.04276608072900719
184,CO3,Regulation of Complement cascade,0.03496516380534943,0,0,1,0.038986208890253976
185,CO3,Regulation of Complement cascade,0.03835517893550159,1,0,1,0.04276608072900719
186,CO3,Class A/1 (Rhodopsin-like receptors),0.03496516380534943,0,0,1,0.038986208890253976
187,CO3,Class A/1 (Rhodopsin-like receptors),0.03835517893550159,1,0,1,0.04276608072900719
188,CO3,G alpha (i) signalling events,0.03496516380534943,0,0,1,0.038986208890253976
189,CO3,G alpha (i) signalling events,0.03835517893550159,1,0,1,0.04276608072900719
190,CO3,Cell recruitment (pro-inflammatory response),0.03496516380534943,0,0,1,0.038986208890253976
191,CO3,Cell recruitment (pro-inflammatory response),0.03835517893550159,1,0,1,0.04276608072900719
192,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.03496516380534943,0,0,1,0.038986208890253976
193,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.03835517893550159,1,0,1,0.04276608072900719
194,CO3,Neutrophil degranulation,0.03496516380534943,0,0,1,0.038986208890253976
195,CO3,Neutrophil degranulation,0.03835517893550159,1,0,1,0.04276608072900719
196,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03496516380534943,0,0,1,0.038986208890253976
197,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03835517893550159,1,0,1,0.04276608072900719
198,CO3,Post-translational protein phosphorylation,0.03496516380534943,0,0,1,0.038986208890253976
199,CO3,Post-translational protein phosphorylation,0.03835517893550159,1,0,1,0.04276608072900719
200,CO5,Terminal pathway of complement,0.003056460123000561,0,0,1,0.003407957516898594
201,CO5,Terminal pathway of complement,0.0027633684921224686,1,0,1,0.0030811599188947675
202,CO5,Activation of C3 and C5,0.003056460123000561,0,0,1,0.003407957516898594
203,CO5,Activation of C3 and C5,0.0027633684921224686,1,0,1,0.0030811599188947675
204,CO5,Regulation of Complement cascade,0.003056460123000561,0,0,1,0.003407957516898594
205,CO5,Regulation of Complement cascade,0.0027633684921224686,1,0,1,0.0030811599188947675
206,CO5,Class A/1 (Rhodopsin-like receptors),0.003056460123000561,0,0,1,0.003407957516898594
207,CO5,Class A/1 (Rhodopsin-like receptors),0.0027633684921224686,1,0,1,0.0030811599188947675
208,CO5,G alpha (i) signalling events,0.003056460123000561,0,0,1,0.003407957516898594
209,CO5,G alpha (i) signalling events,0.0027633684921224686,1,0,1,0.0030811599188947675
210,CYTC,Neutrophil degranulation,0.02161520041301451,0,0,1,0.02410098014119874
211,CYTC,Neutrophil degranulation,0.022014388138434007,1,0,1,0.024546075040117788
212,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.02161520041301451,0,0,1,0.02410098014119874
213,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.022014388138434007,1,0,1,0.024546075040117788
214,CYTC,Amyloid fiber formation,0.02161520041301451,0,0,1,0.02410098014119874
215,CYTC,Amyloid fiber formation,0.022014388138434007,1,0,1,0.024546075040117788
216,CYTC,Post-translational protein phosphorylation,0.02161520041301451,0,0,1,0.02410098014119874
217,CYTC,Post-translational protein phosphorylation,0.022014388138434007,1,0,1,0.024546075040117788
218,KNG1,Class A/1 (Rhodopsin-like receptors),0.010515983594009405,0,0,1,0.011725337120251401
219,KNG1,Class A/1 (Rhodopsin-like receptors),0.010597238281885435,1,0,1,0.011815936216325495
220,KNG1,G alpha (q) signalling events,0.010515983594009405,0,0,1,0.011725337120251401
221,KNG1,G alpha (q) signalling events,0.010597238281885435,1,0,1,0.011815936216325495
222,KNG1,G alpha (i) signalling events,0.010515983594009405,0,0,1,0.011725337120251401
223,KNG1,G alpha (i) signalling events,0.010597238281885435,1,0,1,0.011815936216325495
224,KNG1,Platelet degranulation ,0.010515983594009405,0,0,1,0.011725337120251401
225,KNG1,Platelet degranulation ,0.010597238281885435,1,0,1,0.011815936216325495
226,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.010515983594009405,0,0,1,0.011725337120251401
227,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.010597238281885435,1,0,1,0.011815936216325495
228,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.010515983594009405,0,0,1,0.011725337120251401
229,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.010597238281885435,1,0,1,0.011815936216325495
230,KNG1,Post-translational protein phosphorylation,0.010515983594009405,0,0,1,0.011725337120251401
231,KNG1,Post-translational protein phosphorylation,0.010597238281885435,1,0,1,0.011815936216325495
232,IGJ,Cell surface interactions at the vascular wall,0.0010760536377117616,0,0,1,0.0011998013831850019
233,IGJ,Cell surface interactions at the vascular wall,0.0008719644902649082,1,0,1,0.0009722416846550166
234,IGJ,Scavenging of heme from plasma,0.0010760536377117616,0,0,1,0.0011998013831850019
235,IGJ,Scavenging of heme from plasma,0.0008719644902649082,1,0,1,0.0009722416846550166
236,KV117,Initial triggering of complement,0.01114335081062525,0,0,1,0.012424852486289542
237,KV117,Initial triggering of complement,0.011554373181467823,1,0,1,0.012883143032200967
238,KV117,Regulation of Complement cascade,0.01114335081062525,0,0,1,0.012424852486289542
239,KV117,Regulation of Complement cascade,0.011554373181467823,1,0,1,0.012883143032200967
240,KV117,FCGR activation,0.01114335081062525,0,0,1,0.012424852486289542
241,KV117,FCGR activation,0.011554373181467823,1,0,1,0.012883143032200967
242,KV117,Regulation of actin dynamics for phagocytic cup formation,0.01114335081062525,0,0,1,0.012424852486289542
243,KV117,Regulation of actin dynamics for phagocytic cup formation,0.011554373181467823,1,0,1,0.012883143032200967
244,KV117,Role of phospholipids in phagocytosis,0.01114335081062525,0,0,1,0.012424852486289542
245,KV117,Role of phospholipids in phagocytosis,0.011554373181467823,1,0,1,0.012883143032200967
246,KV117,Role of LAT2/NTAL/LAB on calcium mobilization,0.01114335081062525,0,0,1,0.012424852486289542
247,KV117,Role of LAT2/NTAL/LAB on calcium mobilization,0.011554373181467823,1,0,1,0.012883143032200967
248,KV117,FCERI mediated MAPK activation,0.01114335081062525,0,0,1,0.012424852486289542
249,KV117,FCERI mediated MAPK activation,0.011554373181467823,1,0,1,0.012883143032200967
250,KV117,FCERI mediated Ca+2 mobilization,0.01114335081062525,0,0,1,0.012424852486289542
251,KV117,FCERI mediated Ca+2 mobilization,0.011554373181467823,1,0,1,0.012883143032200967
252,KV117,FCERI mediated NF-kB activation,0.01114335081062525,0,0,1,0.012424852486289542
253,KV117,FCERI mediated NF-kB activation,0.011554373181467823,1,0,1,0.012883143032200967
254,KV117,Parasite infection,0.01114335081062525,0,0,1,0.012424852486289542
255,KV117,Parasite infection,0.011554373181467823,1,0,1,0.012883143032200967
256,KV117,Leishmania parasite growth and survival,0.01114335081062525,0,0,1,0.012424852486289542
257,KV117,Leishmania parasite growth and survival,0.011554373181467823,1,0,1,0.012883143032200967
258,KV117,Potential therapeutics for SARS,0.01114335081062525,0,0,1,0.012424852486289542
259,KV117,Potential therapeutics for SARS,0.011554373181467823,1,0,1,0.012883143032200967
260,KV117,CD22 mediated BCR regulation,0.01114335081062525,0,0,1,0.012424852486289542
261,KV117,CD22 mediated BCR regulation,0.011554373181467823,1,0,1,0.012883143032200967
262,KV117,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01114335081062525,0,0,1,0.012424852486289542
263,KV117,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.011554373181467823,1,0,1,0.012883143032200967
264,KV117,Cell surface interactions at the vascular wall,0.01114335081062525,0,0,1,0.012424852486289542
265,KV117,Cell surface interactions at the vascular wall,0.011554373181467823,1,0,1,0.012883143032200967
266,KV117,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01114335081062525,0,0,1,0.012424852486289542
267,KV117,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.011554373181467823,1,0,1,0.012883143032200967
268,KV117,Scavenging of heme from plasma,0.01114335081062525,0,0,1,0.012424852486289542
269,KV117,Scavenging of heme from plasma,0.011554373181467823,1,0,1,0.012883143032200967
270,KVD16,Initial triggering of complement,0.0039902529008198516,0,0,1,0.004449137832796432
271,KVD16,Initial triggering of complement,0.004617686529326615,1,0,1,0.005148727248190284
272,KVD16,Regulation of Complement cascade,0.0039902529008198516,0,0,1,0.004449137832796432
273,KVD16,Regulation of Complement cascade,0.004617686529326615,1,0,1,0.005148727248190284
274,KVD16,FCGR activation,0.0039902529008198516,0,0,1,0.004449137832796432
275,KVD16,FCGR activation,0.004617686529326615,1,0,1,0.005148727248190284
276,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.0039902529008198516,0,0,1,0.004449137832796432
277,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.004617686529326615,1,0,1,0.005148727248190284
278,KVD16,Role of phospholipids in phagocytosis,0.0039902529008198516,0,0,1,0.004449137832796432
279,KVD16,Role of phospholipids in phagocytosis,0.004617686529326615,1,0,1,0.005148727248190284
280,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.0039902529008198516,0,0,1,0.004449137832796432
281,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.004617686529326615,1,0,1,0.005148727248190284
282,KVD16,FCERI mediated MAPK activation,0.0039902529008198516,0,0,1,0.004449137832796432
283,KVD16,FCERI mediated MAPK activation,0.004617686529326615,1,0,1,0.005148727248190284
284,KVD16,FCERI mediated Ca+2 mobilization,0.0039902529008198516,0,0,1,0.004449137832796432
285,KVD16,FCERI mediated Ca+2 mobilization,0.004617686529326615,1,0,1,0.005148727248190284
286,KVD16,FCERI mediated NF-kB activation,0.0039902529008198516,0,0,1,0.004449137832796432
287,KVD16,FCERI mediated NF-kB activation,0.004617686529326615,1,0,1,0.005148727248190284
288,KVD16,Parasite infection,0.0039902529008198516,0,0,1,0.004449137832796432
289,KVD16,Parasite infection,0.004617686529326615,1,0,1,0.005148727248190284
290,KVD16,Leishmania parasite growth and survival,0.0039902529008198516,0,0,1,0.004449137832796432
291,KVD16,Leishmania parasite growth and survival,0.004617686529326615,1,0,1,0.005148727248190284
292,KVD16,Potential therapeutics for SARS,0.0039902529008198516,0,0,1,0.004449137832796432
293,KVD16,Potential therapeutics for SARS,0.004617686529326615,1,0,1,0.005148727248190284
294,KVD16,CD22 mediated BCR regulation,0.0039902529008198516,0,0,1,0.004449137832796432
295,KVD16,CD22 mediated BCR regulation,0.004617686529326615,1,0,1,0.005148727248190284
296,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0039902529008198516,0,0,1,0.004449137832796432
297,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004617686529326615,1,0,1,0.005148727248190284
298,KVD16,Cell surface interactions at the vascular wall,0.0039902529008198516,0,0,1,0.004449137832796432
299,KVD16,Cell surface interactions at the vascular wall,0.004617686529326615,1,0,1,0.005148727248190284
300,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0039902529008198516,0,0,1,0.004449137832796432
301,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004617686529326615,1,0,1,0.005148727248190284
302,KVD16,Scavenging of heme from plasma,0.0039902529008198516,0,0,1,0.004449137832796432
303,KVD16,Scavenging of heme from plasma,0.004617686529326615,1,0,1,0.005148727248190284
304,KV105,Initial triggering of complement,0.012468269190226417,0,0,1,0.013902138421434089
305,KV105,Initial triggering of complement,0.011987906596005567,1,0,1,0.013366533424826202
306,KV105,Regulation of Complement cascade,0.012468269190226417,0,0,1,0.013902138421434089
307,KV105,Regulation of Complement cascade,0.011987906596005567,1,0,1,0.013366533424826202
308,KV105,FCGR activation,0.012468269190226417,0,0,1,0.013902138421434089
309,KV105,FCGR activation,0.011987906596005567,1,0,1,0.013366533424826202
310,KV105,Regulation of actin dynamics for phagocytic cup formation,0.012468269190226417,0,0,1,0.013902138421434089
311,KV105,Regulation of actin dynamics for phagocytic cup formation,0.011987906596005567,1,0,1,0.013366533424826202
312,KV105,Role of phospholipids in phagocytosis,0.012468269190226417,0,0,1,0.013902138421434089
313,KV105,Role of phospholipids in phagocytosis,0.011987906596005567,1,0,1,0.013366533424826202
314,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.012468269190226417,0,0,1,0.013902138421434089
315,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.011987906596005567,1,0,1,0.013366533424826202
316,KV105,FCERI mediated MAPK activation,0.012468269190226417,0,0,1,0.013902138421434089
317,KV105,FCERI mediated MAPK activation,0.011987906596005567,1,0,1,0.013366533424826202
318,KV105,FCERI mediated Ca+2 mobilization,0.012468269190226417,0,0,1,0.013902138421434089
319,KV105,FCERI mediated Ca+2 mobilization,0.011987906596005567,1,0,1,0.013366533424826202
320,KV105,FCERI mediated NF-kB activation,0.012468269190226417,0,0,1,0.013902138421434089
321,KV105,FCERI mediated NF-kB activation,0.011987906596005567,1,0,1,0.013366533424826202
322,KV105,Parasite infection,0.012468269190226417,0,0,1,0.013902138421434089
323,KV105,Parasite infection,0.011987906596005567,1,0,1,0.013366533424826202
324,KV105,Leishmania parasite growth and survival,0.012468269190226417,0,0,1,0.013902138421434089
325,KV105,Leishmania parasite growth and survival,0.011987906596005567,1,0,1,0.013366533424826202
326,KV105,Potential therapeutics for SARS,0.012468269190226417,0,0,1,0.013902138421434089
327,KV105,Potential therapeutics for SARS,0.011987906596005567,1,0,1,0.013366533424826202
328,KV105,CD22 mediated BCR regulation,0.012468269190226417,0,0,1,0.013902138421434089
329,KV105,CD22 mediated BCR regulation,0.011987906596005567,1,0,1,0.013366533424826202
330,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.012468269190226417,0,0,1,0.013902138421434089
331,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.011987906596005567,1,0,1,0.013366533424826202
332,KV105,Cell surface interactions at the vascular wall,0.012468269190226417,0,0,1,0.013902138421434089
333,KV105,Cell surface interactions at the vascular wall,0.011987906596005567,1,0,1,0.013366533424826202
334,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012468269190226417,0,0,1,0.013902138421434089
335,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.011987906596005567,1,0,1,0.013366533424826202
336,KV105,Scavenging of heme from plasma,0.012468269190226417,0,0,1,0.013902138421434089
337,KV105,Scavenging of heme from plasma,0.011987906596005567,1,0,1,0.013366533424826202
338,KV320,Initial triggering of complement,0.002017195432112934,0,0,1,0.00224917586334285
339,KV320,Initial triggering of complement,0.0024676087141259784,1,0,1,0.002751387332943312
340,KV320,Regulation of Complement cascade,0.002017195432112934,0,0,1,0.00224917586334285
341,KV320,Regulation of Complement cascade,0.0024676087141259784,1,0,1,0.002751387332943312
342,KV320,FCGR activation,0.002017195432112934,0,0,1,0.00224917586334285
343,KV320,FCGR activation,0.0024676087141259784,1,0,1,0.002751387332943312
344,KV320,Regulation of actin dynamics for phagocytic cup formation,0.002017195432112934,0,0,1,0.00224917586334285
345,KV320,Regulation of actin dynamics for phagocytic cup formation,0.0024676087141259784,1,0,1,0.002751387332943312
346,KV320,Role of phospholipids in phagocytosis,0.002017195432112934,0,0,1,0.00224917586334285
347,KV320,Role of phospholipids in phagocytosis,0.0024676087141259784,1,0,1,0.002751387332943312
348,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.002017195432112934,0,0,1,0.00224917586334285
349,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.0024676087141259784,1,0,1,0.002751387332943312
350,KV320,FCERI mediated MAPK activation,0.002017195432112934,0,0,1,0.00224917586334285
351,KV320,FCERI mediated MAPK activation,0.0024676087141259784,1,0,1,0.002751387332943312
352,KV320,FCERI mediated Ca+2 mobilization,0.002017195432112934,0,0,1,0.00224917586334285
353,KV320,FCERI mediated Ca+2 mobilization,0.0024676087141259784,1,0,1,0.002751387332943312
354,KV320,FCERI mediated NF-kB activation,0.002017195432112934,0,0,1,0.00224917586334285
355,KV320,FCERI mediated NF-kB activation,0.0024676087141259784,1,0,1,0.002751387332943312
356,KV320,Parasite infection,0.002017195432112934,0,0,1,0.00224917586334285
357,KV320,Parasite infection,0.0024676087141259784,1,0,1,0.002751387332943312
358,KV320,Leishmania parasite growth and survival,0.002017195432112934,0,0,1,0.00224917586334285
359,KV320,Leishmania parasite growth and survival,0.0024676087141259784,1,0,1,0.002751387332943312
360,KV320,Potential therapeutics for SARS,0.002017195432112934,0,0,1,0.00224917586334285
361,KV320,Potential therapeutics for SARS,0.0024676087141259784,1,0,1,0.002751387332943312
362,KV320,CD22 mediated BCR regulation,0.002017195432112934,0,0,1,0.00224917586334285
363,KV320,CD22 mediated BCR regulation,0.0024676087141259784,1,0,1,0.002751387332943312
364,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002017195432112934,0,0,1,0.00224917586334285
365,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0024676087141259784,1,0,1,0.002751387332943312
366,KV320,Cell surface interactions at the vascular wall,0.002017195432112934,0,0,1,0.00224917586334285
367,KV320,Cell surface interactions at the vascular wall,0.0024676087141259784,1,0,1,0.002751387332943312
368,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002017195432112934,0,0,1,0.00224917586334285
369,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0024676087141259784,1,0,1,0.002751387332943312
370,KV320,Scavenging of heme from plasma,0.002017195432112934,0,0,1,0.00224917586334285
371,KV320,Scavenging of heme from plasma,0.0024676087141259784,1,0,1,0.002751387332943312
372,LV151,Initial triggering of complement,0.0037421322291554425,0,0,1,0.004172482920228316
373,LV151,Initial triggering of complement,0.0032963629307412668,1,0,1,0.003675449499147127
374,LV151,Regulation of Complement cascade,0.0037421322291554425,0,0,1,0.004172482920228316
375,LV151,Regulation of Complement cascade,0.0032963629307412668,1,0,1,0.003675449499147127
376,LV151,FCGR activation,0.0037421322291554425,0,0,1,0.004172482920228316
377,LV151,FCGR activation,0.0032963629307412668,1,0,1,0.003675449499147127
378,LV151,Regulation of actin dynamics for phagocytic cup formation,0.0037421322291554425,0,0,1,0.004172482920228316
379,LV151,Regulation of actin dynamics for phagocytic cup formation,0.0032963629307412668,1,0,1,0.003675449499147127
380,LV151,Role of phospholipids in phagocytosis,0.0037421322291554425,0,0,1,0.004172482920228316
381,LV151,Role of phospholipids in phagocytosis,0.0032963629307412668,1,0,1,0.003675449499147127
382,LV151,Role of LAT2/NTAL/LAB on calcium mobilization,0.0037421322291554425,0,0,1,0.004172482920228316
383,LV151,Role of LAT2/NTAL/LAB on calcium mobilization,0.0032963629307412668,1,0,1,0.003675449499147127
384,LV151,FCERI mediated MAPK activation,0.0037421322291554425,0,0,1,0.004172482920228316
385,LV151,FCERI mediated MAPK activation,0.0032963629307412668,1,0,1,0.003675449499147127
386,LV151,FCERI mediated Ca+2 mobilization,0.0037421322291554425,0,0,1,0.004172482920228316
387,LV151,FCERI mediated Ca+2 mobilization,0.0032963629307412668,1,0,1,0.003675449499147127
388,LV151,FCERI mediated NF-kB activation,0.0037421322291554425,0,0,1,0.004172482920228316
389,LV151,FCERI mediated NF-kB activation,0.0032963629307412668,1,0,1,0.003675449499147127
390,LV151,Parasite infection,0.0037421322291554425,0,0,1,0.004172482920228316
391,LV151,Parasite infection,0.0032963629307412668,1,0,1,0.003675449499147127
392,LV151,Leishmania parasite growth and survival,0.0037421322291554425,0,0,1,0.004172482920228316
393,LV151,Leishmania parasite growth and survival,0.0032963629307412668,1,0,1,0.003675449499147127
394,LV151,Potential therapeutics for SARS,0.0037421322291554425,0,0,1,0.004172482920228316
395,LV151,Potential therapeutics for SARS,0.0032963629307412668,1,0,1,0.003675449499147127
396,LV151,CD22 mediated BCR regulation,0.0037421322291554425,0,0,1,0.004172482920228316
397,LV151,CD22 mediated BCR regulation,0.0032963629307412668,1,0,1,0.003675449499147127
398,LV151,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0037421322291554425,0,0,1,0.004172482920228316
399,LV151,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0032963629307412668,1,0,1,0.003675449499147127
400,LV151,Cell surface interactions at the vascular wall,0.0037421322291554425,0,0,1,0.004172482920228316
401,LV151,Cell surface interactions at the vascular wall,0.0032963629307412668,1,0,1,0.003675449499147127
402,LV151,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0037421322291554425,0,0,1,0.004172482920228316
403,LV151,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0032963629307412668,1,0,1,0.003675449499147127
404,LV151,Scavenging of heme from plasma,0.0037421322291554425,0,0,1,0.004172482920228316
405,LV151,Scavenging of heme from plasma,0.0032963629307412668,1,0,1,0.003675449499147127
406,LV140,Initial triggering of complement,0.0070201204353911055,0,0,1,0.007827444574620467
407,LV140,Initial triggering of complement,0.006691850115593664,1,0,1,0.00746142268691132
408,LV140,Regulation of Complement cascade,0.0070201204353911055,0,0,1,0.007827444574620467
409,LV140,Regulation of Complement cascade,0.006691850115593664,1,0,1,0.00746142268691132
410,LV140,FCGR activation,0.0070201204353911055,0,0,1,0.007827444574620467
411,LV140,FCGR activation,0.006691850115593664,1,0,1,0.00746142268691132
412,LV140,Regulation of actin dynamics for phagocytic cup formation,0.0070201204353911055,0,0,1,0.007827444574620467
413,LV140,Regulation of actin dynamics for phagocytic cup formation,0.006691850115593664,1,0,1,0.00746142268691132
414,LV140,Role of phospholipids in phagocytosis,0.0070201204353911055,0,0,1,0.007827444574620467
415,LV140,Role of phospholipids in phagocytosis,0.006691850115593664,1,0,1,0.00746142268691132
416,LV140,Role of LAT2/NTAL/LAB on calcium mobilization,0.0070201204353911055,0,0,1,0.007827444574620467
417,LV140,Role of LAT2/NTAL/LAB on calcium mobilization,0.006691850115593664,1,0,1,0.00746142268691132
418,LV140,FCERI mediated MAPK activation,0.0070201204353911055,0,0,1,0.007827444574620467
419,LV140,FCERI mediated MAPK activation,0.006691850115593664,1,0,1,0.00746142268691132
420,LV140,FCERI mediated Ca+2 mobilization,0.0070201204353911055,0,0,1,0.007827444574620467
421,LV140,FCERI mediated Ca+2 mobilization,0.006691850115593664,1,0,1,0.00746142268691132
422,LV140,FCERI mediated NF-kB activation,0.0070201204353911055,0,0,1,0.007827444574620467
423,LV140,FCERI mediated NF-kB activation,0.006691850115593664,1,0,1,0.00746142268691132
424,LV140,Parasite infection,0.0070201204353911055,0,0,1,0.007827444574620467
425,LV140,Parasite infection,0.006691850115593664,1,0,1,0.00746142268691132
426,LV140,Leishmania parasite growth and survival,0.0070201204353911055,0,0,1,0.007827444574620467
427,LV140,Leishmania parasite growth and survival,0.006691850115593664,1,0,1,0.00746142268691132
428,LV140,Potential therapeutics for SARS,0.0070201204353911055,0,0,1,0.007827444574620467
429,LV140,Potential therapeutics for SARS,0.006691850115593664,1,0,1,0.00746142268691132
430,LV140,CD22 mediated BCR regulation,0.0070201204353911055,0,0,1,0.007827444574620467
431,LV140,CD22 mediated BCR regulation,0.006691850115593664,1,0,1,0.00746142268691132
432,LV140,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0070201204353911055,0,0,1,0.007827444574620467
433,LV140,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006691850115593664,1,0,1,0.00746142268691132
434,LV140,Cell surface interactions at the vascular wall,0.0070201204353911055,0,0,1,0.007827444574620467
435,LV140,Cell surface interactions at the vascular wall,0.006691850115593664,1,0,1,0.00746142268691132
436,LV140,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0070201204353911055,0,0,1,0.007827444574620467
437,LV140,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006691850115593664,1,0,1,0.00746142268691132
438,LV140,Scavenging of heme from plasma,0.0070201204353911055,0,0,1,0.007827444574620467
439,LV140,Scavenging of heme from plasma,0.006691850115593664,1,0,1,0.00746142268691132
440,LV214,Initial triggering of complement,0.010198390560042996,0,0,1,0.011371220421893202
441,LV214,Initial triggering of complement,0.009776620368515256,1,0,1,0.010900946040165088
442,LV214,Regulation of Complement cascade,0.010198390560042996,0,0,1,0.011371220421893202
443,LV214,Regulation of Complement cascade,0.009776620368515256,1,0,1,0.010900946040165088
444,LV214,FCGR activation,0.010198390560042996,0,0,1,0.011371220421893202
445,LV214,FCGR activation,0.009776620368515256,1,0,1,0.010900946040165088
446,LV214,Regulation of actin dynamics for phagocytic cup formation,0.010198390560042996,0,0,1,0.011371220421893202
447,LV214,Regulation of actin dynamics for phagocytic cup formation,0.009776620368515256,1,0,1,0.010900946040165088
448,LV214,Role of phospholipids in phagocytosis,0.010198390560042996,0,0,1,0.011371220421893202
449,LV214,Role of phospholipids in phagocytosis,0.009776620368515256,1,0,1,0.010900946040165088
450,LV214,Role of LAT2/NTAL/LAB on calcium mobilization,0.010198390560042996,0,0,1,0.011371220421893202
451,LV214,Role of LAT2/NTAL/LAB on calcium mobilization,0.009776620368515256,1,0,1,0.010900946040165088
452,LV214,FCERI mediated MAPK activation,0.010198390560042996,0,0,1,0.011371220421893202
453,LV214,FCERI mediated MAPK activation,0.009776620368515256,1,0,1,0.010900946040165088
454,LV214,FCERI mediated Ca+2 mobilization,0.010198390560042996,0,0,1,0.011371220421893202
455,LV214,FCERI mediated Ca+2 mobilization,0.009776620368515256,1,0,1,0.010900946040165088
456,LV214,FCERI mediated NF-kB activation,0.010198390560042996,0,0,1,0.011371220421893202
457,LV214,FCERI mediated NF-kB activation,0.009776620368515256,1,0,1,0.010900946040165088
458,LV214,Parasite infection,0.010198390560042996,0,0,1,0.011371220421893202
459,LV214,Parasite infection,0.009776620368515256,1,0,1,0.010900946040165088
460,LV214,Leishmania parasite growth and survival,0.010198390560042996,0,0,1,0.011371220421893202
461,LV214,Leishmania parasite growth and survival,0.009776620368515256,1,0,1,0.010900946040165088
462,LV214,Potential therapeutics for SARS,0.010198390560042996,0,0,1,0.011371220421893202
463,LV214,Potential therapeutics for SARS,0.009776620368515256,1,0,1,0.010900946040165088
464,LV214,CD22 mediated BCR regulation,0.010198390560042996,0,0,1,0.011371220421893202
465,LV214,CD22 mediated BCR regulation,0.009776620368515256,1,0,1,0.010900946040165088
466,LV214,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.010198390560042996,0,0,1,0.011371220421893202
467,LV214,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.009776620368515256,1,0,1,0.010900946040165088
468,LV214,Cell surface interactions at the vascular wall,0.010198390560042996,0,0,1,0.011371220421893202
469,LV214,Cell surface interactions at the vascular wall,0.009776620368515256,1,0,1,0.010900946040165088
470,LV214,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010198390560042996,0,0,1,0.011371220421893202
471,LV214,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009776620368515256,1,0,1,0.010900946040165088
472,LV214,Scavenging of heme from plasma,0.010198390560042996,0,0,1,0.011371220421893202
473,LV214,Scavenging of heme from plasma,0.009776620368515256,1,0,1,0.010900946040165088
474,LV211,Initial triggering of complement,0.002937523398281982,0,0,1,0.0032753428945157368
475,LV211,Initial triggering of complement,0.0026840952730343135,1,0,1,0.002992770163423327
476,LV211,Regulation of Complement cascade,0.002937523398281982,0,0,1,0.0032753428945157368
477,LV211,Regulation of Complement cascade,0.0026840952730343135,1,0,1,0.002992770163423327
478,LV211,FCGR activation,0.002937523398281982,0,0,1,0.0032753428945157368
479,LV211,FCGR activation,0.0026840952730343135,1,0,1,0.002992770163423327
480,LV211,Regulation of actin dynamics for phagocytic cup formation,0.002937523398281982,0,0,1,0.0032753428945157368
481,LV211,Regulation of actin dynamics for phagocytic cup formation,0.0026840952730343135,1,0,1,0.002992770163423327
482,LV211,Role of phospholipids in phagocytosis,0.002937523398281982,0,0,1,0.0032753428945157368
483,LV211,Role of phospholipids in phagocytosis,0.0026840952730343135,1,0,1,0.002992770163423327
484,LV211,Role of LAT2/NTAL/LAB on calcium mobilization,0.002937523398281982,0,0,1,0.0032753428945157368
485,LV211,Role of LAT2/NTAL/LAB on calcium mobilization,0.0026840952730343135,1,0,1,0.002992770163423327
486,LV211,FCERI mediated MAPK activation,0.002937523398281982,0,0,1,0.0032753428945157368
487,LV211,FCERI mediated MAPK activation,0.0026840952730343135,1,0,1,0.002992770163423327
488,LV211,FCERI mediated Ca+2 mobilization,0.002937523398281982,0,0,1,0.0032753428945157368
489,LV211,FCERI mediated Ca+2 mobilization,0.0026840952730343135,1,0,1,0.002992770163423327
490,LV211,FCERI mediated NF-kB activation,0.002937523398281982,0,0,1,0.0032753428945157368
491,LV211,FCERI mediated NF-kB activation,0.0026840952730343135,1,0,1,0.002992770163423327
492,LV211,Parasite infection,0.002937523398281982,0,0,1,0.0032753428945157368
493,LV211,Parasite infection,0.0026840952730343135,1,0,1,0.002992770163423327
494,LV211,Leishmania parasite growth and survival,0.002937523398281982,0,0,1,0.0032753428945157368
495,LV211,Leishmania parasite growth and survival,0.0026840952730343135,1,0,1,0.002992770163423327
496,LV211,Potential therapeutics for SARS,0.002937523398281982,0,0,1,0.0032753428945157368
497,LV211,Potential therapeutics for SARS,0.0026840952730343135,1,0,1,0.002992770163423327
498,LV211,CD22 mediated BCR regulation,0.002937523398281982,0,0,1,0.0032753428945157368
499,LV211,CD22 mediated BCR regulation,0.0026840952730343135,1,0,1,0.002992770163423327
500,LV211,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002937523398281982,0,0,1,0.0032753428945157368
501,LV211,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0026840952730343135,1,0,1,0.002992770163423327
502,LV211,Cell surface interactions at the vascular wall,0.002937523398281982,0,0,1,0.0032753428945157368
503,LV211,Cell surface interactions at the vascular wall,0.0026840952730343135,1,0,1,0.002992770163423327
504,LV211,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002937523398281982,0,0,1,0.0032753428945157368
505,LV211,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0026840952730343135,1,0,1,0.002992770163423327
506,LV211,Scavenging of heme from plasma,0.002937523398281982,0,0,1,0.0032753428945157368
507,LV211,Scavenging of heme from plasma,0.0026840952730343135,1,0,1,0.002992770163423327
508,LV208,Initial triggering of complement,0.01821837219633812,0,0,1,0.02031351170098529
509,LV208,Initial triggering of complement,0.017122785078211748,1,0,1,0.01909193045850842
510,LV208,Regulation of Complement cascade,0.01821837219633812,0,0,1,0.02031351170098529
511,LV208,Regulation of Complement cascade,0.017122785078211748,1,0,1,0.01909193045850842
512,LV208,FCGR activation,0.01821837219633812,0,0,1,0.02031351170098529
513,LV208,FCGR activation,0.017122785078211748,1,0,1,0.01909193045850842
514,LV208,Regulation of actin dynamics for phagocytic cup formation,0.01821837219633812,0,0,1,0.02031351170098529
515,LV208,Regulation of actin dynamics for phagocytic cup formation,0.017122785078211748,1,0,1,0.01909193045850842
516,LV208,Role of phospholipids in phagocytosis,0.01821837219633812,0,0,1,0.02031351170098529
517,LV208,Role of phospholipids in phagocytosis,0.017122785078211748,1,0,1,0.01909193045850842
518,LV208,Role of LAT2/NTAL/LAB on calcium mobilization,0.01821837219633812,0,0,1,0.02031351170098529
519,LV208,Role of LAT2/NTAL/LAB on calcium mobilization,0.017122785078211748,1,0,1,0.01909193045850842
520,LV208,FCERI mediated MAPK activation,0.01821837219633812,0,0,1,0.02031351170098529
521,LV208,FCERI mediated MAPK activation,0.017122785078211748,1,0,1,0.01909193045850842
522,LV208,FCERI mediated Ca+2 mobilization,0.01821837219633812,0,0,1,0.02031351170098529
523,LV208,FCERI mediated Ca+2 mobilization,0.017122785078211748,1,0,1,0.01909193045850842
524,LV208,FCERI mediated NF-kB activation,0.01821837219633812,0,0,1,0.02031351170098529
525,LV208,FCERI mediated NF-kB activation,0.017122785078211748,1,0,1,0.01909193045850842
526,LV208,Parasite infection,0.01821837219633812,0,0,1,0.02031351170098529
527,LV208,Parasite infection,0.017122785078211748,1,0,1,0.01909193045850842
528,LV208,Leishmania parasite growth and survival,0.01821837219633812,0,0,1,0.02031351170098529
529,LV208,Leishmania parasite growth and survival,0.017122785078211748,1,0,1,0.01909193045850842
530,LV208,Potential therapeutics for SARS,0.01821837219633812,0,0,1,0.02031351170098529
531,LV208,Potential therapeutics for SARS,0.017122785078211748,1,0,1,0.01909193045850842
532,LV208,CD22 mediated BCR regulation,0.01821837219633812,0,0,1,0.02031351170098529
533,LV208,CD22 mediated BCR regulation,0.017122785078211748,1,0,1,0.01909193045850842
534,LV208,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01821837219633812,0,0,1,0.02031351170098529
535,LV208,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.017122785078211748,1,0,1,0.01909193045850842
536,LV208,Cell surface interactions at the vascular wall,0.01821837219633812,0,0,1,0.02031351170098529
537,LV208,Cell surface interactions at the vascular wall,0.017122785078211748,1,0,1,0.01909193045850842
538,LV208,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01821837219633812,0,0,1,0.02031351170098529
539,LV208,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.017122785078211748,1,0,1,0.01909193045850842
540,LV208,Scavenging of heme from plasma,0.01821837219633812,0,0,1,0.02031351170098529
541,LV208,Scavenging of heme from plasma,0.017122785078211748,1,0,1,0.01909193045850842
542,LV319,Initial triggering of complement,0.002894458828335452,0,0,1,0.003227325835907033
543,LV319,Initial triggering of complement,0.0025231948116242,1,0,1,0.002813365913124542
544,LV319,Regulation of Complement cascade,0.002894458828335452,0,0,1,0.003227325835907033
545,LV319,Regulation of Complement cascade,0.0025231948116242,1,0,1,0.002813365913124542
546,LV319,FCGR activation,0.002894458828335452,0,0,1,0.003227325835907033
547,LV319,FCGR activation,0.0025231948116242,1,0,1,0.002813365913124542
548,LV319,Regulation of actin dynamics for phagocytic cup formation,0.002894458828335452,0,0,1,0.003227325835907033
549,LV319,Regulation of actin dynamics for phagocytic cup formation,0.0025231948116242,1,0,1,0.002813365913124542
550,LV319,Role of phospholipids in phagocytosis,0.002894458828335452,0,0,1,0.003227325835907033
551,LV319,Role of phospholipids in phagocytosis,0.0025231948116242,1,0,1,0.002813365913124542
552,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.002894458828335452,0,0,1,0.003227325835907033
553,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.0025231948116242,1,0,1,0.002813365913124542
554,LV319,FCERI mediated MAPK activation,0.002894458828335452,0,0,1,0.003227325835907033
555,LV319,FCERI mediated MAPK activation,0.0025231948116242,1,0,1,0.002813365913124542
556,LV319,FCERI mediated Ca+2 mobilization,0.002894458828335452,0,0,1,0.003227325835907033
557,LV319,FCERI mediated Ca+2 mobilization,0.0025231948116242,1,0,1,0.002813365913124542
558,LV319,FCERI mediated NF-kB activation,0.002894458828335452,0,0,1,0.003227325835907033
559,LV319,FCERI mediated NF-kB activation,0.0025231948116242,1,0,1,0.002813365913124542
560,LV319,Parasite infection,0.002894458828335452,0,0,1,0.003227325835907033
561,LV319,Parasite infection,0.0025231948116242,1,0,1,0.002813365913124542
562,LV319,Leishmania parasite growth and survival,0.002894458828335452,0,0,1,0.003227325835907033
563,LV319,Leishmania parasite growth and survival,0.0025231948116242,1,0,1,0.002813365913124542
564,LV319,Potential therapeutics for SARS,0.002894458828335452,0,0,1,0.003227325835907033
565,LV319,Potential therapeutics for SARS,0.0025231948116242,1,0,1,0.002813365913124542
566,LV319,CD22 mediated BCR regulation,0.002894458828335452,0,0,1,0.003227325835907033
567,LV319,CD22 mediated BCR regulation,0.0025231948116242,1,0,1,0.002813365913124542
568,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002894458828335452,0,0,1,0.003227325835907033
569,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0025231948116242,1,0,1,0.002813365913124542
570,LV319,Cell surface interactions at the vascular wall,0.002894458828335452,0,0,1,0.003227325835907033
571,LV319,Cell surface interactions at the vascular wall,0.0025231948116242,1,0,1,0.002813365913124542
572,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002894458828335452,0,0,1,0.003227325835907033
573,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0025231948116242,1,0,1,0.002813365913124542
574,LV319,Scavenging of heme from plasma,0.002894458828335452,0,0,1,0.003227325835907033
575,LV319,Scavenging of heme from plasma,0.0025231948116242,1,0,1,0.002813365913124542
576,LV301,Initial triggering of complement,0.00046595069255698146,0,0,1,0.000519535705129623
577,LV301,Initial triggering of complement,0.0004033152309567139,1,0,1,0.0004496970736425908
578,LV301,Regulation of Complement cascade,0.00046595069255698146,0,0,1,0.000519535705129623
579,LV301,Regulation of Complement cascade,0.0004033152309567139,1,0,1,0.0004496970736425908
580,LV301,FCGR activation,0.00046595069255698146,0,0,1,0.000519535705129623
581,LV301,FCGR activation,0.0004033152309567139,1,0,1,0.0004496970736425908
582,LV301,Regulation of actin dynamics for phagocytic cup formation,0.00046595069255698146,0,0,1,0.000519535705129623
583,LV301,Regulation of actin dynamics for phagocytic cup formation,0.0004033152309567139,1,0,1,0.0004496970736425908
584,LV301,Role of phospholipids in phagocytosis,0.00046595069255698146,0,0,1,0.000519535705129623
585,LV301,Role of phospholipids in phagocytosis,0.0004033152309567139,1,0,1,0.0004496970736425908
586,LV301,Role of LAT2/NTAL/LAB on calcium mobilization,0.00046595069255698146,0,0,1,0.000519535705129623
587,LV301,Role of LAT2/NTAL/LAB on calcium mobilization,0.0004033152309567139,1,0,1,0.0004496970736425908
588,LV301,FCERI mediated MAPK activation,0.00046595069255698146,0,0,1,0.000519535705129623
589,LV301,FCERI mediated MAPK activation,0.0004033152309567139,1,0,1,0.0004496970736425908
590,LV301,FCERI mediated Ca+2 mobilization,0.00046595069255698146,0,0,1,0.000519535705129623
591,LV301,FCERI mediated Ca+2 mobilization,0.0004033152309567139,1,0,1,0.0004496970736425908
592,LV301,FCERI mediated NF-kB activation,0.00046595069255698146,0,0,1,0.000519535705129623
593,LV301,FCERI mediated NF-kB activation,0.0004033152309567139,1,0,1,0.0004496970736425908
594,LV301,Parasite infection,0.00046595069255698146,0,0,1,0.000519535705129623
595,LV301,Parasite infection,0.0004033152309567139,1,0,1,0.0004496970736425908
596,LV301,Leishmania parasite growth and survival,0.00046595069255698146,0,0,1,0.000519535705129623
597,LV301,Leishmania parasite growth and survival,0.0004033152309567139,1,0,1,0.0004496970736425908
598,LV301,Potential therapeutics for SARS,0.00046595069255698146,0,0,1,0.000519535705129623
599,LV301,Potential therapeutics for SARS,0.0004033152309567139,1,0,1,0.0004496970736425908
600,LV301,CD22 mediated BCR regulation,0.00046595069255698146,0,0,1,0.000519535705129623
601,LV301,CD22 mediated BCR regulation,0.0004033152309567139,1,0,1,0.0004496970736425908
602,LV301,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00046595069255698146,0,0,1,0.000519535705129623
603,LV301,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0004033152309567139,1,0,1,0.0004496970736425908
604,LV301,Cell surface interactions at the vascular wall,0.00046595069255698146,0,0,1,0.000519535705129623
605,LV301,Cell surface interactions at the vascular wall,0.0004033152309567139,1,0,1,0.0004496970736425908
606,LV301,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00046595069255698146,0,0,1,0.000519535705129623
607,LV301,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004033152309567139,1,0,1,0.0004496970736425908
608,LV301,Scavenging of heme from plasma,0.00046595069255698146,0,0,1,0.000519535705129623
609,LV301,Scavenging of heme from plasma,0.0004033152309567139,1,0,1,0.0004496970736425908
610,LV325,Initial triggering of complement,0.014979575002098964,0,0,1,0.01670224808241022
611,LV325,Initial triggering of complement,0.013811656514569382,1,0,1,0.015400017257035064
612,LV325,Regulation of Complement cascade,0.014979575002098964,0,0,1,0.01670224808241022
613,LV325,Regulation of Complement cascade,0.013811656514569382,1,0,1,0.015400017257035064
614,LV325,FCGR activation,0.014979575002098964,0,0,1,0.01670224808241022
615,LV325,FCGR activation,0.013811656514569382,1,0,1,0.015400017257035064
616,LV325,Regulation of actin dynamics for phagocytic cup formation,0.014979575002098964,0,0,1,0.01670224808241022
617,LV325,Regulation of actin dynamics for phagocytic cup formation,0.013811656514569382,1,0,1,0.015400017257035064
618,LV325,Role of phospholipids in phagocytosis,0.014979575002098964,0,0,1,0.01670224808241022
619,LV325,Role of phospholipids in phagocytosis,0.013811656514569382,1,0,1,0.015400017257035064
620,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.014979575002098964,0,0,1,0.01670224808241022
621,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.013811656514569382,1,0,1,0.015400017257035064
622,LV325,FCERI mediated MAPK activation,0.014979575002098964,0,0,1,0.01670224808241022
623,LV325,FCERI mediated MAPK activation,0.013811656514569382,1,0,1,0.015400017257035064
624,LV325,FCERI mediated Ca+2 mobilization,0.014979575002098964,0,0,1,0.01670224808241022
625,LV325,FCERI mediated Ca+2 mobilization,0.013811656514569382,1,0,1,0.015400017257035064
626,LV325,FCERI mediated NF-kB activation,0.014979575002098964,0,0,1,0.01670224808241022
627,LV325,FCERI mediated NF-kB activation,0.013811656514569382,1,0,1,0.015400017257035064
628,LV325,Parasite infection,0.014979575002098964,0,0,1,0.01670224808241022
629,LV325,Parasite infection,0.013811656514569382,1,0,1,0.015400017257035064
630,LV325,Leishmania parasite growth and survival,0.014979575002098964,0,0,1,0.01670224808241022
631,LV325,Leishmania parasite growth and survival,0.013811656514569382,1,0,1,0.015400017257035064
632,LV325,Potential therapeutics for SARS,0.014979575002098964,0,0,1,0.01670224808241022
633,LV325,Potential therapeutics for SARS,0.013811656514569382,1,0,1,0.015400017257035064
634,LV325,CD22 mediated BCR regulation,0.014979575002098964,0,0,1,0.01670224808241022
635,LV325,CD22 mediated BCR regulation,0.013811656514569382,1,0,1,0.015400017257035064
636,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.014979575002098964,0,0,1,0.01670224808241022
637,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.013811656514569382,1,0,1,0.015400017257035064
638,LV325,Cell surface interactions at the vascular wall,0.014979575002098964,0,0,1,0.01670224808241022
639,LV325,Cell surface interactions at the vascular wall,0.013811656514569382,1,0,1,0.015400017257035064
640,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.014979575002098964,0,0,1,0.01670224808241022
641,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.013811656514569382,1,0,1,0.015400017257035064
642,LV325,Scavenging of heme from plasma,0.014979575002098964,0,0,1,0.01670224808241022
643,LV325,Scavenging of heme from plasma,0.013811656514569382,1,0,1,0.015400017257035064
644,LV327,Initial triggering of complement,0.0007978357992668778,0,0,1,0.000889588085544231
645,LV327,Initial triggering of complement,0.0011407638414955203,1,0,1,0.001271953355247508
646,LV327,Regulation of Complement cascade,0.0007978357992668778,0,0,1,0.000889588085544231
647,LV327,Regulation of Complement cascade,0.0011407638414955203,1,0,1,0.001271953355247508
648,LV327,FCGR activation,0.0007978357992668778,0,0,1,0.000889588085544231
649,LV327,FCGR activation,0.0011407638414955203,1,0,1,0.001271953355247508
650,LV327,Regulation of actin dynamics for phagocytic cup formation,0.0007978357992668778,0,0,1,0.000889588085544231
651,LV327,Regulation of actin dynamics for phagocytic cup formation,0.0011407638414955203,1,0,1,0.001271953355247508
652,LV327,Role of phospholipids in phagocytosis,0.0007978357992668778,0,0,1,0.000889588085544231
653,LV327,Role of phospholipids in phagocytosis,0.0011407638414955203,1,0,1,0.001271953355247508
654,LV327,Role of LAT2/NTAL/LAB on calcium mobilization,0.0007978357992668778,0,0,1,0.000889588085544231
655,LV327,Role of LAT2/NTAL/LAB on calcium mobilization,0.0011407638414955203,1,0,1,0.001271953355247508
656,LV327,FCERI mediated MAPK activation,0.0007978357992668778,0,0,1,0.000889588085544231
657,LV327,FCERI mediated MAPK activation,0.0011407638414955203,1,0,1,0.001271953355247508
658,LV327,FCERI mediated Ca+2 mobilization,0.0007978357992668778,0,0,1,0.000889588085544231
659,LV327,FCERI mediated Ca+2 mobilization,0.0011407638414955203,1,0,1,0.001271953355247508
660,LV327,FCERI mediated NF-kB activation,0.0007978357992668778,0,0,1,0.000889588085544231
661,LV327,FCERI mediated NF-kB activation,0.0011407638414955203,1,0,1,0.001271953355247508
662,LV327,Parasite infection,0.0007978357992668778,0,0,1,0.000889588085544231
663,LV327,Parasite infection,0.0011407638414955203,1,0,1,0.001271953355247508
664,LV327,Leishmania parasite growth and survival,0.0007978357992668778,0,0,1,0.000889588085544231
665,LV327,Leishmania parasite growth and survival,0.0011407638414955203,1,0,1,0.001271953355247508
666,LV327,Potential therapeutics for SARS,0.0007978357992668778,0,0,1,0.000889588085544231
667,LV327,Potential therapeutics for SARS,0.0011407638414955203,1,0,1,0.001271953355247508
668,LV327,CD22 mediated BCR regulation,0.0007978357992668778,0,0,1,0.000889588085544231
669,LV327,CD22 mediated BCR regulation,0.0011407638414955203,1,0,1,0.001271953355247508
670,LV327,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0007978357992668778,0,0,1,0.000889588085544231
671,LV327,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0011407638414955203,1,0,1,0.001271953355247508
672,LV327,Cell surface interactions at the vascular wall,0.0007978357992668778,0,0,1,0.000889588085544231
673,LV327,Cell surface interactions at the vascular wall,0.0011407638414955203,1,0,1,0.001271953355247508
674,LV327,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007978357992668778,0,0,1,0.000889588085544231
675,LV327,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0011407638414955203,1,0,1,0.001271953355247508
676,LV327,Scavenging of heme from plasma,0.0007978357992668778,0,0,1,0.000889588085544231
677,LV327,Scavenging of heme from plasma,0.0011407638414955203,1,0,1,0.001271953355247508
678,LV657,Initial triggering of complement,0.01699683968766743,0,0,1,0.018951501163457493
679,LV657,Initial triggering of complement,0.017587145551865625,1,0,1,0.019609693067230347
680,LV657,Regulation of Complement cascade,0.01699683968766743,0,0,1,0.018951501163457493
681,LV657,Regulation of Complement cascade,0.017587145551865625,1,0,1,0.019609693067230347
682,LV657,FCGR activation,0.01699683968766743,0,0,1,0.018951501163457493
683,LV657,FCGR activation,0.017587145551865625,1,0,1,0.019609693067230347
684,LV657,Regulation of actin dynamics for phagocytic cup formation,0.01699683968766743,0,0,1,0.018951501163457493
685,LV657,Regulation of actin dynamics for phagocytic cup formation,0.017587145551865625,1,0,1,0.019609693067230347
686,LV657,Role of phospholipids in phagocytosis,0.01699683968766743,0,0,1,0.018951501163457493
687,LV657,Role of phospholipids in phagocytosis,0.017587145551865625,1,0,1,0.019609693067230347
688,LV657,Role of LAT2/NTAL/LAB on calcium mobilization,0.01699683968766743,0,0,1,0.018951501163457493
689,LV657,Role of LAT2/NTAL/LAB on calcium mobilization,0.017587145551865625,1,0,1,0.019609693067230347
690,LV657,FCERI mediated MAPK activation,0.01699683968766743,0,0,1,0.018951501163457493
691,LV657,FCERI mediated MAPK activation,0.017587145551865625,1,0,1,0.019609693067230347
692,LV657,FCERI mediated Ca+2 mobilization,0.01699683968766743,0,0,1,0.018951501163457493
693,LV657,FCERI mediated Ca+2 mobilization,0.017587145551865625,1,0,1,0.019609693067230347
694,LV657,FCERI mediated NF-kB activation,0.01699683968766743,0,0,1,0.018951501163457493
695,LV657,FCERI mediated NF-kB activation,0.017587145551865625,1,0,1,0.019609693067230347
696,LV657,Parasite infection,0.01699683968766743,0,0,1,0.018951501163457493
697,LV657,Parasite infection,0.017587145551865625,1,0,1,0.019609693067230347
698,LV657,Leishmania parasite growth and survival,0.01699683968766743,0,0,1,0.018951501163457493
699,LV657,Leishmania parasite growth and survival,0.017587145551865625,1,0,1,0.019609693067230347
700,LV657,Potential therapeutics for SARS,0.01699683968766743,0,0,1,0.018951501163457493
701,LV657,Potential therapeutics for SARS,0.017587145551865625,1,0,1,0.019609693067230347
702,LV657,CD22 mediated BCR regulation,0.01699683968766743,0,0,1,0.018951501163457493
703,LV657,CD22 mediated BCR regulation,0.017587145551865625,1,0,1,0.019609693067230347
704,LV657,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01699683968766743,0,0,1,0.018951501163457493
705,LV657,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.017587145551865625,1,0,1,0.019609693067230347
706,LV657,Cell surface interactions at the vascular wall,0.01699683968766743,0,0,1,0.018951501163457493
707,LV657,Cell surface interactions at the vascular wall,0.017587145551865625,1,0,1,0.019609693067230347
708,LV657,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01699683968766743,0,0,1,0.018951501163457493
709,LV657,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.017587145551865625,1,0,1,0.019609693067230347
710,LV657,Scavenging of heme from plasma,0.01699683968766743,0,0,1,0.018951501163457493
711,LV657,Scavenging of heme from plasma,0.017587145551865625,1,0,1,0.019609693067230347
712,HV169,Initial triggering of complement,0.0046018063659232335,0,0,1,0.005131020842720481
713,HV169,Initial triggering of complement,0.004750032768003075,1,0,1,0.005296293498290061
714,HV169,Regulation of Complement cascade,0.0046018063659232335,0,0,1,0.005131020842720481
715,HV169,Regulation of Complement cascade,0.004750032768003075,1,0,1,0.005296293498290061
716,HV169,FCGR activation,0.0046018063659232335,0,0,1,0.005131020842720481
717,HV169,FCGR activation,0.004750032768003075,1,0,1,0.005296293498290061
718,HV169,Regulation of actin dynamics for phagocytic cup formation,0.0046018063659232335,0,0,1,0.005131020842720481
719,HV169,Regulation of actin dynamics for phagocytic cup formation,0.004750032768003075,1,0,1,0.005296293498290061
720,HV169,Role of phospholipids in phagocytosis,0.0046018063659232335,0,0,1,0.005131020842720481
721,HV169,Role of phospholipids in phagocytosis,0.004750032768003075,1,0,1,0.005296293498290061
722,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.0046018063659232335,0,0,1,0.005131020842720481
723,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.004750032768003075,1,0,1,0.005296293498290061
724,HV169,FCERI mediated MAPK activation,0.0046018063659232335,0,0,1,0.005131020842720481
725,HV169,FCERI mediated MAPK activation,0.004750032768003075,1,0,1,0.005296293498290061
726,HV169,FCERI mediated Ca+2 mobilization,0.0046018063659232335,0,0,1,0.005131020842720481
727,HV169,FCERI mediated Ca+2 mobilization,0.004750032768003075,1,0,1,0.005296293498290061
728,HV169,FCERI mediated NF-kB activation,0.0046018063659232335,0,0,1,0.005131020842720481
729,HV169,FCERI mediated NF-kB activation,0.004750032768003075,1,0,1,0.005296293498290061
730,HV169,Parasite infection,0.0046018063659232335,0,0,1,0.005131020842720481
731,HV169,Parasite infection,0.004750032768003075,1,0,1,0.005296293498290061
732,HV169,Leishmania parasite growth and survival,0.0046018063659232335,0,0,1,0.005131020842720481
733,HV169,Leishmania parasite growth and survival,0.004750032768003075,1,0,1,0.005296293498290061
734,HV169,Potential therapeutics for SARS,0.0046018063659232335,0,0,1,0.005131020842720481
735,HV169,Potential therapeutics for SARS,0.004750032768003075,1,0,1,0.005296293498290061
736,HV169,CD22 mediated BCR regulation,0.0046018063659232335,0,0,1,0.005131020842720481
737,HV169,CD22 mediated BCR regulation,0.004750032768003075,1,0,1,0.005296293498290061
738,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0046018063659232335,0,0,1,0.005131020842720481
739,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004750032768003075,1,0,1,0.005296293498290061
740,HV169,Cell surface interactions at the vascular wall,0.0046018063659232335,0,0,1,0.005131020842720481
741,HV169,Cell surface interactions at the vascular wall,0.004750032768003075,1,0,1,0.005296293498290061
742,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0046018063659232335,0,0,1,0.005131020842720481
743,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004750032768003075,1,0,1,0.005296293498290061
744,HV169,Scavenging of heme from plasma,0.0046018063659232335,0,0,1,0.005131020842720481
745,HV169,Scavenging of heme from plasma,0.004750032768003075,1,0,1,0.005296293498290061
746,HV146,Initial triggering of complement,0.012452494588158348,0,0,1,0.013884549717007876
747,HV146,Initial triggering of complement,0.012262902115207709,1,0,1,0.013673153831788468
748,HV146,Regulation of Complement cascade,0.012452494588158348,0,0,1,0.013884549717007876
749,HV146,Regulation of Complement cascade,0.012262902115207709,1,0,1,0.013673153831788468
750,HV146,FCGR activation,0.012452494588158348,0,0,1,0.013884549717007876
751,HV146,FCGR activation,0.012262902115207709,1,0,1,0.013673153831788468
752,HV146,Regulation of actin dynamics for phagocytic cup formation,0.012452494588158348,0,0,1,0.013884549717007876
753,HV146,Regulation of actin dynamics for phagocytic cup formation,0.012262902115207709,1,0,1,0.013673153831788468
754,HV146,Role of phospholipids in phagocytosis,0.012452494588158348,0,0,1,0.013884549717007876
755,HV146,Role of phospholipids in phagocytosis,0.012262902115207709,1,0,1,0.013673153831788468
756,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.012452494588158348,0,0,1,0.013884549717007876
757,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.012262902115207709,1,0,1,0.013673153831788468
758,HV146,FCERI mediated MAPK activation,0.012452494588158348,0,0,1,0.013884549717007876
759,HV146,FCERI mediated MAPK activation,0.012262902115207709,1,0,1,0.013673153831788468
760,HV146,FCERI mediated Ca+2 mobilization,0.012452494588158348,0,0,1,0.013884549717007876
761,HV146,FCERI mediated Ca+2 mobilization,0.012262902115207709,1,0,1,0.013673153831788468
762,HV146,FCERI mediated NF-kB activation,0.012452494588158348,0,0,1,0.013884549717007876
763,HV146,FCERI mediated NF-kB activation,0.012262902115207709,1,0,1,0.013673153831788468
764,HV146,Parasite infection,0.012452494588158348,0,0,1,0.013884549717007876
765,HV146,Parasite infection,0.012262902115207709,1,0,1,0.013673153831788468
766,HV146,Leishmania parasite growth and survival,0.012452494588158348,0,0,1,0.013884549717007876
767,HV146,Leishmania parasite growth and survival,0.012262902115207709,1,0,1,0.013673153831788468
768,HV146,Potential therapeutics for SARS,0.012452494588158348,0,0,1,0.013884549717007876
769,HV146,Potential therapeutics for SARS,0.012262902115207709,1,0,1,0.013673153831788468
770,HV146,CD22 mediated BCR regulation,0.012452494588158348,0,0,1,0.013884549717007876
771,HV146,CD22 mediated BCR regulation,0.012262902115207709,1,0,1,0.013673153831788468
772,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.012452494588158348,0,0,1,0.013884549717007876
773,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.012262902115207709,1,0,1,0.013673153831788468
774,HV146,Cell surface interactions at the vascular wall,0.012452494588158348,0,0,1,0.013884549717007876
775,HV146,Cell surface interactions at the vascular wall,0.012262902115207709,1,0,1,0.013673153831788468
776,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012452494588158348,0,0,1,0.013884549717007876
777,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012262902115207709,1,0,1,0.013673153831788468
778,HV146,Scavenging of heme from plasma,0.012452494588158348,0,0,1,0.013884549717007876
779,HV146,Scavenging of heme from plasma,0.012262902115207709,1,0,1,0.013673153831788468
780,HV348,Initial triggering of complement,9.853072887248497e-05,0,0,1,0.0001098619071060659
781,HV348,Initial triggering of complement,7.982320992050348e-05,1,0,1,8.900299605561197e-05
782,HV348,Regulation of Complement cascade,9.853072887248497e-05,0,0,1,0.0001098619071060659
783,HV348,Regulation of Complement cascade,7.982320992050348e-05,1,0,1,8.900299605561197e-05
784,HV348,FCGR activation,9.853072887248497e-05,0,0,1,0.0001098619071060659
785,HV348,FCGR activation,7.982320992050348e-05,1,0,1,8.900299605561197e-05
786,HV348,Regulation of actin dynamics for phagocytic cup formation,9.853072887248497e-05,0,0,1,0.0001098619071060659
787,HV348,Regulation of actin dynamics for phagocytic cup formation,7.982320992050348e-05,1,0,1,8.900299605561197e-05
788,HV348,Role of phospholipids in phagocytosis,9.853072887248497e-05,0,0,1,0.0001098619071060659
789,HV348,Role of phospholipids in phagocytosis,7.982320992050348e-05,1,0,1,8.900299605561197e-05
790,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,9.853072887248497e-05,0,0,1,0.0001098619071060659
791,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,7.982320992050348e-05,1,0,1,8.900299605561197e-05
792,HV348,FCERI mediated MAPK activation,9.853072887248497e-05,0,0,1,0.0001098619071060659
793,HV348,FCERI mediated MAPK activation,7.982320992050348e-05,1,0,1,8.900299605561197e-05
794,HV348,FCERI mediated Ca+2 mobilization,9.853072887248497e-05,0,0,1,0.0001098619071060659
795,HV348,FCERI mediated Ca+2 mobilization,7.982320992050348e-05,1,0,1,8.900299605561197e-05
796,HV348,FCERI mediated NF-kB activation,9.853072887248497e-05,0,0,1,0.0001098619071060659
797,HV348,FCERI mediated NF-kB activation,7.982320992050348e-05,1,0,1,8.900299605561197e-05
798,HV348,Parasite infection,9.853072887248497e-05,0,0,1,0.0001098619071060659
799,HV348,Parasite infection,7.982320992050348e-05,1,0,1,8.900299605561197e-05
800,HV348,Leishmania parasite growth and survival,9.853072887248497e-05,0,0,1,0.0001098619071060659
801,HV348,Leishmania parasite growth and survival,7.982320992050348e-05,1,0,1,8.900299605561197e-05
802,HV348,Potential therapeutics for SARS,9.853072887248497e-05,0,0,1,0.0001098619071060659
803,HV348,Potential therapeutics for SARS,7.982320992050348e-05,1,0,1,8.900299605561197e-05
804,HV348,CD22 mediated BCR regulation,9.853072887248497e-05,0,0,1,0.0001098619071060659
805,HV348,CD22 mediated BCR regulation,7.982320992050348e-05,1,0,1,8.900299605561197e-05
806,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,9.853072887248497e-05,0,0,1,0.0001098619071060659
807,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,7.982320992050348e-05,1,0,1,8.900299605561197e-05
808,HV348,Cell surface interactions at the vascular wall,9.853072887248497e-05,0,0,1,0.0001098619071060659
809,HV348,Cell surface interactions at the vascular wall,7.982320992050348e-05,1,0,1,8.900299605561197e-05
810,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,9.853072887248497e-05,0,0,1,0.0001098619071060659
811,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,7.982320992050348e-05,1,0,1,8.900299605561197e-05
812,HV348,Scavenging of heme from plasma,9.853072887248497e-05,0,0,1,0.0001098619071060659
813,HV348,Scavenging of heme from plasma,7.982320992050348e-05,1,0,1,8.900299605561197e-05
814,HV323,Initial triggering of complement,0.010527662323741674,0,0,1,0.011738358921020011
815,HV323,Initial triggering of complement,0.010919076462288756,1,0,1,0.012174786259182823
816,HV323,Regulation of Complement cascade,0.010527662323741674,0,0,1,0.011738358921020011
817,HV323,Regulation of Complement cascade,0.010919076462288756,1,0,1,0.012174786259182823
818,HV323,FCGR activation,0.010527662323741674,0,0,1,0.011738358921020011
819,HV323,FCGR activation,0.010919076462288756,1,0,1,0.012174786259182823
820,HV323,Regulation of actin dynamics for phagocytic cup formation,0.010527662323741674,0,0,1,0.011738358921020011
821,HV323,Regulation of actin dynamics for phagocytic cup formation,0.010919076462288756,1,0,1,0.012174786259182823
822,HV323,Role of phospholipids in phagocytosis,0.010527662323741674,0,0,1,0.011738358921020011
823,HV323,Role of phospholipids in phagocytosis,0.010919076462288756,1,0,1,0.012174786259182823
824,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.010527662323741674,0,0,1,0.011738358921020011
825,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.010919076462288756,1,0,1,0.012174786259182823
826,HV323,FCERI mediated MAPK activation,0.010527662323741674,0,0,1,0.011738358921020011
827,HV323,FCERI mediated MAPK activation,0.010919076462288756,1,0,1,0.012174786259182823
828,HV323,FCERI mediated Ca+2 mobilization,0.010527662323741674,0,0,1,0.011738358921020011
829,HV323,FCERI mediated Ca+2 mobilization,0.010919076462288756,1,0,1,0.012174786259182823
830,HV323,FCERI mediated NF-kB activation,0.010527662323741674,0,0,1,0.011738358921020011
831,HV323,FCERI mediated NF-kB activation,0.010919076462288756,1,0,1,0.012174786259182823
832,HV323,Parasite infection,0.010527662323741674,0,0,1,0.011738358921020011
833,HV323,Parasite infection,0.010919076462288756,1,0,1,0.012174786259182823
834,HV323,Leishmania parasite growth and survival,0.010527662323741674,0,0,1,0.011738358921020011
835,HV323,Leishmania parasite growth and survival,0.010919076462288756,1,0,1,0.012174786259182823
836,HV323,Potential therapeutics for SARS,0.010527662323741674,0,0,1,0.011738358921020011
837,HV323,Potential therapeutics for SARS,0.010919076462288756,1,0,1,0.012174786259182823
838,HV323,CD22 mediated BCR regulation,0.010527662323741674,0,0,1,0.011738358921020011
839,HV323,CD22 mediated BCR regulation,0.010919076462288756,1,0,1,0.012174786259182823
840,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.010527662323741674,0,0,1,0.011738358921020011
841,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.010919076462288756,1,0,1,0.012174786259182823
842,HV323,Cell surface interactions at the vascular wall,0.010527662323741674,0,0,1,0.011738358921020011
843,HV323,Cell surface interactions at the vascular wall,0.010919076462288756,1,0,1,0.012174786259182823
844,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010527662323741674,0,0,1,0.011738358921020011
845,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010919076462288756,1,0,1,0.012174786259182823
846,HV323,Scavenging of heme from plasma,0.010527662323741674,0,0,1,0.011738358921020011
847,HV323,Scavenging of heme from plasma,0.010919076462288756,1,0,1,0.012174786259182823
848,HV313,Initial triggering of complement,0.0059134173516570635,0,0,1,0.006593469014198738
849,HV313,Initial triggering of complement,0.005889883512903698,1,0,1,0.006567228749495964
850,HV313,Regulation of Complement cascade,0.0059134173516570635,0,0,1,0.006593469014198738
851,HV313,Regulation of Complement cascade,0.005889883512903698,1,0,1,0.006567228749495964
852,HV313,FCGR activation,0.0059134173516570635,0,0,1,0.006593469014198738
853,HV313,FCGR activation,0.005889883512903698,1,0,1,0.006567228749495964
854,HV313,Regulation of actin dynamics for phagocytic cup formation,0.0059134173516570635,0,0,1,0.006593469014198738
855,HV313,Regulation of actin dynamics for phagocytic cup formation,0.005889883512903698,1,0,1,0.006567228749495964
856,HV313,Role of phospholipids in phagocytosis,0.0059134173516570635,0,0,1,0.006593469014198738
857,HV313,Role of phospholipids in phagocytosis,0.005889883512903698,1,0,1,0.006567228749495964
858,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.0059134173516570635,0,0,1,0.006593469014198738
859,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.005889883512903698,1,0,1,0.006567228749495964
860,HV313,FCERI mediated MAPK activation,0.0059134173516570635,0,0,1,0.006593469014198738
861,HV313,FCERI mediated MAPK activation,0.005889883512903698,1,0,1,0.006567228749495964
862,HV313,FCERI mediated Ca+2 mobilization,0.0059134173516570635,0,0,1,0.006593469014198738
863,HV313,FCERI mediated Ca+2 mobilization,0.005889883512903698,1,0,1,0.006567228749495964
864,HV313,FCERI mediated NF-kB activation,0.0059134173516570635,0,0,1,0.006593469014198738
865,HV313,FCERI mediated NF-kB activation,0.005889883512903698,1,0,1,0.006567228749495964
866,HV313,Parasite infection,0.0059134173516570635,0,0,1,0.006593469014198738
867,HV313,Parasite infection,0.005889883512903698,1,0,1,0.006567228749495964
868,HV313,Leishmania parasite growth and survival,0.0059134173516570635,0,0,1,0.006593469014198738
869,HV313,Leishmania parasite growth and survival,0.005889883512903698,1,0,1,0.006567228749495964
870,HV313,Potential therapeutics for SARS,0.0059134173516570635,0,0,1,0.006593469014198738
871,HV313,Potential therapeutics for SARS,0.005889883512903698,1,0,1,0.006567228749495964
872,HV313,CD22 mediated BCR regulation,0.0059134173516570635,0,0,1,0.006593469014198738
873,HV313,CD22 mediated BCR regulation,0.005889883512903698,1,0,1,0.006567228749495964
874,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0059134173516570635,0,0,1,0.006593469014198738
875,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005889883512903698,1,0,1,0.006567228749495964
876,HV313,Cell surface interactions at the vascular wall,0.0059134173516570635,0,0,1,0.006593469014198738
877,HV313,Cell surface interactions at the vascular wall,0.005889883512903698,1,0,1,0.006567228749495964
878,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0059134173516570635,0,0,1,0.006593469014198738
879,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005889883512903698,1,0,1,0.006567228749495964
880,HV313,Scavenging of heme from plasma,0.0059134173516570635,0,0,1,0.006593469014198738
881,HV313,Scavenging of heme from plasma,0.005889883512903698,1,0,1,0.006567228749495964
882,HV353,Initial triggering of complement,0.0013633667775911885,0,0,1,0.001520155955255972
883,HV353,Initial triggering of complement,0.0009105179920112712,1,0,1,0.0010152288956088093
884,HV353,Regulation of Complement cascade,0.0013633667775911885,0,0,1,0.001520155955255972
885,HV353,Regulation of Complement cascade,0.0009105179920112712,1,0,1,0.0010152288956088093
886,HV353,FCGR activation,0.0013633667775911885,0,0,1,0.001520155955255972
887,HV353,FCGR activation,0.0009105179920112712,1,0,1,0.0010152288956088093
888,HV353,Regulation of actin dynamics for phagocytic cup formation,0.0013633667775911885,0,0,1,0.001520155955255972
889,HV353,Regulation of actin dynamics for phagocytic cup formation,0.0009105179920112712,1,0,1,0.0010152288956088093
890,HV353,Role of phospholipids in phagocytosis,0.0013633667775911885,0,0,1,0.001520155955255972
891,HV353,Role of phospholipids in phagocytosis,0.0009105179920112712,1,0,1,0.0010152288956088093
892,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.0013633667775911885,0,0,1,0.001520155955255972
893,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.0009105179920112712,1,0,1,0.0010152288956088093
894,HV353,FCERI mediated MAPK activation,0.0013633667775911885,0,0,1,0.001520155955255972
895,HV353,FCERI mediated MAPK activation,0.0009105179920112712,1,0,1,0.0010152288956088093
896,HV353,FCERI mediated Ca+2 mobilization,0.0013633667775911885,0,0,1,0.001520155955255972
897,HV353,FCERI mediated Ca+2 mobilization,0.0009105179920112712,1,0,1,0.0010152288956088093
898,HV353,FCERI mediated NF-kB activation,0.0013633667775911885,0,0,1,0.001520155955255972
899,HV353,FCERI mediated NF-kB activation,0.0009105179920112712,1,0,1,0.0010152288956088093
900,HV353,Parasite infection,0.0013633667775911885,0,0,1,0.001520155955255972
901,HV353,Parasite infection,0.0009105179920112712,1,0,1,0.0010152288956088093
902,HV353,Leishmania parasite growth and survival,0.0013633667775911885,0,0,1,0.001520155955255972
903,HV353,Leishmania parasite growth and survival,0.0009105179920112712,1,0,1,0.0010152288956088093
904,HV353,Potential therapeutics for SARS,0.0013633667775911885,0,0,1,0.001520155955255972
905,HV353,Potential therapeutics for SARS,0.0009105179920112712,1,0,1,0.0010152288956088093
906,HV353,CD22 mediated BCR regulation,0.0013633667775911885,0,0,1,0.001520155955255972
907,HV353,CD22 mediated BCR regulation,0.0009105179920112712,1,0,1,0.0010152288956088093
908,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0013633667775911885,0,0,1,0.001520155955255972
909,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0009105179920112712,1,0,1,0.0010152288956088093
910,HV353,Cell surface interactions at the vascular wall,0.0013633667775911885,0,0,1,0.001520155955255972
911,HV353,Cell surface interactions at the vascular wall,0.0009105179920112712,1,0,1,0.0010152288956088093
912,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0013633667775911885,0,0,1,0.001520155955255972
913,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0009105179920112712,1,0,1,0.0010152288956088093
914,HV353,Scavenging of heme from plasma,0.0013633667775911885,0,0,1,0.001520155955255972
915,HV353,Scavenging of heme from plasma,0.0009105179920112712,1,0,1,0.0010152288956088093
916,HV307,Initial triggering of complement,0.012645546958181254,0,0,1,0.014099803392533918
917,HV307,Initial triggering of complement,0.012267202150436909,1,0,1,0.013677948377371447
918,HV307,Regulation of Complement cascade,0.012645546958181254,0,0,1,0.014099803392533918
919,HV307,Regulation of Complement cascade,0.012267202150436909,1,0,1,0.013677948377371447
920,HV307,FCGR activation,0.012645546958181254,0,0,1,0.014099803392533918
921,HV307,FCGR activation,0.012267202150436909,1,0,1,0.013677948377371447
922,HV307,Regulation of actin dynamics for phagocytic cup formation,0.012645546958181254,0,0,1,0.014099803392533918
923,HV307,Regulation of actin dynamics for phagocytic cup formation,0.012267202150436909,1,0,1,0.013677948377371447
924,HV307,Role of phospholipids in phagocytosis,0.012645546958181254,0,0,1,0.014099803392533918
925,HV307,Role of phospholipids in phagocytosis,0.012267202150436909,1,0,1,0.013677948377371447
926,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.012645546958181254,0,0,1,0.014099803392533918
927,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.012267202150436909,1,0,1,0.013677948377371447
928,HV307,FCERI mediated MAPK activation,0.012645546958181254,0,0,1,0.014099803392533918
929,HV307,FCERI mediated MAPK activation,0.012267202150436909,1,0,1,0.013677948377371447
930,HV307,FCERI mediated Ca+2 mobilization,0.012645546958181254,0,0,1,0.014099803392533918
931,HV307,FCERI mediated Ca+2 mobilization,0.012267202150436909,1,0,1,0.013677948377371447
932,HV307,FCERI mediated NF-kB activation,0.012645546958181254,0,0,1,0.014099803392533918
933,HV307,FCERI mediated NF-kB activation,0.012267202150436909,1,0,1,0.013677948377371447
934,HV307,Parasite infection,0.012645546958181254,0,0,1,0.014099803392533918
935,HV307,Parasite infection,0.012267202150436909,1,0,1,0.013677948377371447
936,HV307,Leishmania parasite growth and survival,0.012645546958181254,0,0,1,0.014099803392533918
937,HV307,Leishmania parasite growth and survival,0.012267202150436909,1,0,1,0.013677948377371447
938,HV307,Potential therapeutics for SARS,0.012645546958181254,0,0,1,0.014099803392533918
939,HV307,Potential therapeutics for SARS,0.012267202150436909,1,0,1,0.013677948377371447
940,HV307,CD22 mediated BCR regulation,0.012645546958181254,0,0,1,0.014099803392533918
941,HV307,CD22 mediated BCR regulation,0.012267202150436909,1,0,1,0.013677948377371447
942,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.012645546958181254,0,0,1,0.014099803392533918
943,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.012267202150436909,1,0,1,0.013677948377371447
944,HV307,Cell surface interactions at the vascular wall,0.012645546958181254,0,0,1,0.014099803392533918
945,HV307,Cell surface interactions at the vascular wall,0.012267202150436909,1,0,1,0.013677948377371447
946,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012645546958181254,0,0,1,0.014099803392533918
947,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012267202150436909,1,0,1,0.013677948377371447
948,HV307,Scavenging of heme from plasma,0.012645546958181254,0,0,1,0.014099803392533918
949,HV307,Scavenging of heme from plasma,0.012267202150436909,1,0,1,0.013677948377371447
950,HV205,Initial triggering of complement,0.009843887437915828,0,0,1,0.010975948921137854
951,HV205,Initial triggering of complement,0.009349542627588261,1,0,1,0.010424753733077706
952,HV205,Regulation of Complement cascade,0.009843887437915828,0,0,1,0.010975948921137854
953,HV205,Regulation of Complement cascade,0.009349542627588261,1,0,1,0.010424753733077706
954,HV205,FCGR activation,0.009843887437915828,0,0,1,0.010975948921137854
955,HV205,FCGR activation,0.009349542627588261,1,0,1,0.010424753733077706
956,HV205,Regulation of actin dynamics for phagocytic cup formation,0.009843887437915828,0,0,1,0.010975948921137854
957,HV205,Regulation of actin dynamics for phagocytic cup formation,0.009349542627588261,1,0,1,0.010424753733077706
958,HV205,Role of phospholipids in phagocytosis,0.009843887437915828,0,0,1,0.010975948921137854
959,HV205,Role of phospholipids in phagocytosis,0.009349542627588261,1,0,1,0.010424753733077706
960,HV205,Role of LAT2/NTAL/LAB on calcium mobilization,0.009843887437915828,0,0,1,0.010975948921137854
961,HV205,Role of LAT2/NTAL/LAB on calcium mobilization,0.009349542627588261,1,0,1,0.010424753733077706
962,HV205,FCERI mediated MAPK activation,0.009843887437915828,0,0,1,0.010975948921137854
963,HV205,FCERI mediated MAPK activation,0.009349542627588261,1,0,1,0.010424753733077706
964,HV205,FCERI mediated Ca+2 mobilization,0.009843887437915828,0,0,1,0.010975948921137854
965,HV205,FCERI mediated Ca+2 mobilization,0.009349542627588261,1,0,1,0.010424753733077706
966,HV205,FCERI mediated NF-kB activation,0.009843887437915828,0,0,1,0.010975948921137854
967,HV205,FCERI mediated NF-kB activation,0.009349542627588261,1,0,1,0.010424753733077706
968,HV205,Parasite infection,0.009843887437915828,0,0,1,0.010975948921137854
969,HV205,Parasite infection,0.009349542627588261,1,0,1,0.010424753733077706
970,HV205,Leishmania parasite growth and survival,0.009843887437915828,0,0,1,0.010975948921137854
971,HV205,Leishmania parasite growth and survival,0.009349542627588261,1,0,1,0.010424753733077706
972,HV205,Potential therapeutics for SARS,0.009843887437915828,0,0,1,0.010975948921137854
973,HV205,Potential therapeutics for SARS,0.009349542627588261,1,0,1,0.010424753733077706
974,HV205,CD22 mediated BCR regulation,0.009843887437915828,0,0,1,0.010975948921137854
975,HV205,CD22 mediated BCR regulation,0.009349542627588261,1,0,1,0.010424753733077706
976,HV205,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.009843887437915828,0,0,1,0.010975948921137854
977,HV205,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.009349542627588261,1,0,1,0.010424753733077706
978,HV205,Cell surface interactions at the vascular wall,0.009843887437915828,0,0,1,0.010975948921137854
979,HV205,Cell surface interactions at the vascular wall,0.009349542627588261,1,0,1,0.010424753733077706
980,HV205,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009843887437915828,0,0,1,0.010975948921137854
981,HV205,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009349542627588261,1,0,1,0.010424753733077706
982,HV205,Scavenging of heme from plasma,0.009843887437915828,0,0,1,0.010975948921137854
983,HV205,Scavenging of heme from plasma,0.009349542627588261,1,0,1,0.010424753733077706
984,PIGR,Neutrophil degranulation,0.004278994013012705,0,0,1,0.004771084596089805
985,PIGR,Neutrophil degranulation,0.004560605807218459,1,0,1,0.0050850821593783554
986,IGKC,Initial triggering of complement,0.016742851945039598,0,0,1,0.018668304458165988
987,IGKC,Initial triggering of complement,0.01651036199072974,1,0,1,0.018409077818357624
988,IGKC,Regulation of Complement cascade,0.016742851945039598,0,0,1,0.018668304458165988
989,IGKC,Regulation of Complement cascade,0.01651036199072974,1,0,1,0.018409077818357624
990,IGKC,FCGR activation,0.016742851945039598,0,0,1,0.018668304458165988
991,IGKC,FCGR activation,0.01651036199072974,1,0,1,0.018409077818357624
992,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.016742851945039598,0,0,1,0.018668304458165988
993,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.01651036199072974,1,0,1,0.018409077818357624
994,IGKC,Role of phospholipids in phagocytosis,0.016742851945039598,0,0,1,0.018668304458165988
995,IGKC,Role of phospholipids in phagocytosis,0.01651036199072974,1,0,1,0.018409077818357624
996,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.016742851945039598,0,0,1,0.018668304458165988
997,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.01651036199072974,1,0,1,0.018409077818357624
998,IGKC,FCERI mediated MAPK activation,0.016742851945039598,0,0,1,0.018668304458165988
999,IGKC,FCERI mediated MAPK activation,0.01651036199072974,1,0,1,0.018409077818357624
1000,IGKC,FCERI mediated Ca+2 mobilization,0.016742851945039598,0,0,1,0.018668304458165988
1001,IGKC,FCERI mediated Ca+2 mobilization,0.01651036199072974,1,0,1,0.018409077818357624
1002,IGKC,FCERI mediated NF-kB activation,0.016742851945039598,0,0,1,0.018668304458165988
1003,IGKC,FCERI mediated NF-kB activation,0.01651036199072974,1,0,1,0.018409077818357624
1004,IGKC,Parasite infection,0.016742851945039598,0,0,1,0.018668304458165988
1005,IGKC,Parasite infection,0.01651036199072974,1,0,1,0.018409077818357624
1006,IGKC,Leishmania parasite growth and survival,0.016742851945039598,0,0,1,0.018668304458165988
1007,IGKC,Leishmania parasite growth and survival,0.01651036199072974,1,0,1,0.018409077818357624
1008,IGKC,Potential therapeutics for SARS,0.016742851945039598,0,0,1,0.018668304458165988
1009,IGKC,Potential therapeutics for SARS,0.01651036199072974,1,0,1,0.018409077818357624
1010,IGKC,CD22 mediated BCR regulation,0.016742851945039598,0,0,1,0.018668304458165988
1011,IGKC,CD22 mediated BCR regulation,0.01651036199072974,1,0,1,0.018409077818357624
1012,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.016742851945039598,0,0,1,0.018668304458165988
1013,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01651036199072974,1,0,1,0.018409077818357624
1014,IGKC,Cell surface interactions at the vascular wall,0.016742851945039598,0,0,1,0.018668304458165988
1015,IGKC,Cell surface interactions at the vascular wall,0.01651036199072974,1,0,1,0.018409077818357624
1016,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.016742851945039598,0,0,1,0.018668304458165988
1017,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01651036199072974,1,0,1,0.018409077818357624
1018,IGKC,Scavenging of heme from plasma,0.016742851945039598,0,0,1,0.018668304458165988
1019,IGKC,Scavenging of heme from plasma,0.01651036199072974,1,0,1,0.018409077818357624
1020,IGHM,Potential therapeutics for SARS,0.0012999410319915927,0,0,1,0.0014494361559513958
1021,IGHM,Potential therapeutics for SARS,0.0013318709491537226,1,0,1,0.001485038060385799
1022,IGHM,CD22 mediated BCR regulation,0.0012999410319915927,0,0,1,0.0014494361559513958
1023,IGHM,CD22 mediated BCR regulation,0.0013318709491537226,1,0,1,0.001485038060385799
1024,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0012999410319915927,0,0,1,0.0014494361559513958
1025,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0013318709491537226,1,0,1,0.001485038060385799
1026,IGHM,Cell surface interactions at the vascular wall,0.0012999410319915927,0,0,1,0.0014494361559513958
1027,IGHM,Cell surface interactions at the vascular wall,0.0013318709491537226,1,0,1,0.001485038060385799
1028,IGHD,Potential therapeutics for SARS,7.245578853238743e-05,0,0,1,8.078831040967562e-05
1029,IGHD,Potential therapeutics for SARS,8.290261530120326e-05,1,0,1,9.243653756847531e-05
1030,IGHD,CD22 mediated BCR regulation,7.245578853238743e-05,0,0,1,8.078831040967562e-05
1031,IGHD,CD22 mediated BCR regulation,8.290261530120326e-05,1,0,1,9.243653756847531e-05
1032,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,7.245578853238743e-05,0,0,1,8.078831040967562e-05
1033,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,8.290261530120326e-05,1,0,1,9.243653756847531e-05
1034,HBD,Factors involved in megakaryocyte development and platelet production,0.0022243932203713447,0,0,1,0.002480201700933954
1035,HBD,Factors involved in megakaryocyte development and platelet production,0.002181015821920277,1,0,1,0.002431835838084189
1036,APOA1,PPARA activates gene expression,0.020243181724642324,0,0,1,0.022571177292741138
1037,APOA1,PPARA activates gene expression,0.021726866566759477,1,0,1,0.024225488066289786
1038,APOA1,Defective ABCA1 causes TGD,0.020243181724642324,0,0,1,0.022571177292741138
1039,APOA1,Defective ABCA1 causes TGD,0.021726866566759477,1,0,1,0.024225488066289786
1040,APOA1,Platelet degranulation ,0.020243181724642324,0,0,1,0.022571177292741138
1041,APOA1,Platelet degranulation ,0.021726866566759477,1,0,1,0.024225488066289786
1042,APOA1,Chylomicron assembly,0.020243181724642324,0,0,1,0.022571177292741138
1043,APOA1,Chylomicron assembly,0.021726866566759477,1,0,1,0.024225488066289786
1044,APOA1,HDL assembly,0.020243181724642324,0,0,1,0.022571177292741138
1045,APOA1,HDL assembly,0.021726866566759477,1,0,1,0.024225488066289786
1046,APOA1,Chylomicron remodeling,0.020243181724642324,0,0,1,0.022571177292741138
1047,APOA1,Chylomicron remodeling,0.021726866566759477,1,0,1,0.024225488066289786
1048,APOA1,HDL remodeling,0.020243181724642324,0,0,1,0.022571177292741138
1049,APOA1,HDL remodeling,0.021726866566759477,1,0,1,0.024225488066289786
1050,APOA1,HDL clearance,0.020243181724642324,0,0,1,0.022571177292741138
1051,APOA1,HDL clearance,0.021726866566759477,1,0,1,0.024225488066289786
1052,APOA1,Scavenging of heme from plasma,0.020243181724642324,0,0,1,0.022571177292741138
1053,APOA1,Scavenging of heme from plasma,0.021726866566759477,1,0,1,0.024225488066289786
1054,APOA1,Scavenging by Class B Receptors,0.020243181724642324,0,0,1,0.022571177292741138
1055,APOA1,Scavenging by Class B Receptors,0.021726866566759477,1,0,1,0.024225488066289786
1056,APOA1,Scavenging by Class A Receptors,0.020243181724642324,0,0,1,0.022571177292741138
1057,APOA1,Scavenging by Class A Receptors,0.021726866566759477,1,0,1,0.024225488066289786
1058,APOA1,Retinoid metabolism and transport,0.020243181724642324,0,0,1,0.022571177292741138
1059,APOA1,Retinoid metabolism and transport,0.021726866566759477,1,0,1,0.024225488066289786
1060,APOA1,Heme signaling,0.020243181724642324,0,0,1,0.022571177292741138
1061,APOA1,Heme signaling,0.021726866566759477,1,0,1,0.024225488066289786
1062,APOA1,ABC transporters in lipid homeostasis,0.020243181724642324,0,0,1,0.022571177292741138
1063,APOA1,ABC transporters in lipid homeostasis,0.021726866566759477,1,0,1,0.024225488066289786
1064,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.020243181724642324,0,0,1,0.022571177292741138
1065,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.021726866566759477,1,0,1,0.024225488066289786
1066,APOA1,Amyloid fiber formation,0.020243181724642324,0,0,1,0.022571177292741138
1067,APOA1,Amyloid fiber formation,0.021726866566759477,1,0,1,0.024225488066289786
1068,APOA1,Post-translational protein phosphorylation,0.020243181724642324,0,0,1,0.022571177292741138
1069,APOA1,Post-translational protein phosphorylation,0.021726866566759477,1,0,1,0.024225488066289786
1070,APOE,Nuclear signaling by ERBB4,0.031885613646624976,0,0,1,0.035552505949680936
1071,APOE,Nuclear signaling by ERBB4,0.03412554045829697,1,0,1,0.03805002762768219
1072,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.031885613646624976,0,0,1,0.035552505949680936
1073,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.03412554045829697,1,0,1,0.03805002762768219
1074,APOE,Chylomicron assembly,0.031885613646624976,0,0,1,0.035552505949680936
1075,APOE,Chylomicron assembly,0.03412554045829697,1,0,1,0.03805002762768219
1076,APOE,Chylomicron remodeling,0.031885613646624976,0,0,1,0.035552505949680936
1077,APOE,Chylomicron remodeling,0.03412554045829697,1,0,1,0.03805002762768219
1078,APOE,HDL remodeling,0.031885613646624976,0,0,1,0.035552505949680936
1079,APOE,HDL remodeling,0.03412554045829697,1,0,1,0.03805002762768219
1080,APOE,Chylomicron clearance,0.031885613646624976,0,0,1,0.035552505949680936
1081,APOE,Chylomicron clearance,0.03412554045829697,1,0,1,0.03805002762768219
1082,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.031885613646624976,0,0,1,0.035552505949680936
1083,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.03412554045829697,1,0,1,0.03805002762768219
1084,APOE,Scavenging by Class A Receptors,0.031885613646624976,0,0,1,0.035552505949680936
1085,APOE,Scavenging by Class A Receptors,0.03412554045829697,1,0,1,0.03805002762768219
1086,APOE,Retinoid metabolism and transport,0.031885613646624976,0,0,1,0.035552505949680936
1087,APOE,Retinoid metabolism and transport,0.03412554045829697,1,0,1,0.03805002762768219
1088,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.031885613646624976,0,0,1,0.035552505949680936
1089,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03412554045829697,1,0,1,0.03805002762768219
1090,APOE,Amyloid fiber formation,0.031885613646624976,0,0,1,0.035552505949680936
1091,APOE,Amyloid fiber formation,0.03412554045829697,1,0,1,0.03805002762768219
1092,APOE,Post-translational protein phosphorylation,0.031885613646624976,0,0,1,0.035552505949680936
1093,APOE,Post-translational protein phosphorylation,0.03412554045829697,1,0,1,0.03805002762768219
1094,FIBA,Antigen processing-Cross presentation,0.03577532252529636,0,0,1,0.03988953705041776
1095,FIBA,Antigen processing-Cross presentation,0.04069738034847725,1,0,1,0.04537763873736255
1096,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.03577532252529636,0,0,1,0.03988953705041776
1097,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.04069738034847725,1,0,1,0.04537763873736255
1098,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.03577532252529636,0,0,1,0.03988953705041776
1099,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.04069738034847725,1,0,1,0.04537763873736255
1100,FIBA,Regulation of TLR by endogenous ligand,0.03577532252529636,0,0,1,0.03988953705041776
1101,FIBA,Regulation of TLR by endogenous ligand,0.04069738034847725,1,0,1,0.04537763873736255
1102,FIBA,MyD88 deficiency (TLR2/4),0.03577532252529636,0,0,1,0.03988953705041776
1103,FIBA,MyD88 deficiency (TLR2/4),0.04069738034847725,1,0,1,0.04537763873736255
1104,FIBA,IRAK4 deficiency (TLR2/4),0.03577532252529636,0,0,1,0.03988953705041776
1105,FIBA,IRAK4 deficiency (TLR2/4),0.04069738034847725,1,0,1,0.04537763873736255
1106,FIBA,RAF/MAP kinase cascade,0.03577532252529636,0,0,1,0.03988953705041776
1107,FIBA,RAF/MAP kinase cascade,0.04069738034847725,1,0,1,0.04537763873736255
1108,FIBA,Signaling by RAS mutants,0.03577532252529636,0,0,1,0.03988953705041776
1109,FIBA,Signaling by RAS mutants,0.04069738034847725,1,0,1,0.04537763873736255
1110,FIBA,Signaling by moderate kinase activity BRAF mutants,0.03577532252529636,0,0,1,0.03988953705041776
1111,FIBA,Signaling by moderate kinase activity BRAF mutants,0.04069738034847725,1,0,1,0.04537763873736255
1112,FIBA,Signaling by high-kinase activity BRAF mutants,0.03577532252529636,0,0,1,0.03988953705041776
1113,FIBA,Signaling by high-kinase activity BRAF mutants,0.04069738034847725,1,0,1,0.04537763873736255
1114,FIBA,Signaling by BRAF and RAF1 fusions,0.03577532252529636,0,0,1,0.03988953705041776
1115,FIBA,Signaling by BRAF and RAF1 fusions,0.04069738034847725,1,0,1,0.04537763873736255
1116,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.03577532252529636,0,0,1,0.03988953705041776
1117,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.04069738034847725,1,0,1,0.04537763873736255
1118,FIBA,Signaling by RAF1 mutants,0.03577532252529636,0,0,1,0.03988953705041776
1119,FIBA,Signaling by RAF1 mutants,0.04069738034847725,1,0,1,0.04537763873736255
1120,FIBA,Platelet degranulation ,0.03577532252529636,0,0,1,0.03988953705041776
1121,FIBA,Platelet degranulation ,0.04069738034847725,1,0,1,0.04537763873736255
1122,FIBA,Common Pathway of Fibrin Clot Formation,0.03577532252529636,0,0,1,0.03988953705041776
1123,FIBA,Common Pathway of Fibrin Clot Formation,0.04069738034847725,1,0,1,0.04537763873736255
1124,FIBA,Integrin cell surface interactions,0.03577532252529636,0,0,1,0.03988953705041776
1125,FIBA,Integrin cell surface interactions,0.04069738034847725,1,0,1,0.04537763873736255
1126,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.03577532252529636,0,0,1,0.03988953705041776
1127,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.04069738034847725,1,0,1,0.04537763873736255
1128,FIBA,p130Cas linkage to MAPK signaling for integrins,0.03577532252529636,0,0,1,0.03988953705041776
1129,FIBA,p130Cas linkage to MAPK signaling for integrins,0.04069738034847725,1,0,1,0.04537763873736255
1130,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03577532252529636,0,0,1,0.03988953705041776
1131,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.04069738034847725,1,0,1,0.04537763873736255
1132,FIBA,Amyloid fiber formation,0.03577532252529636,0,0,1,0.03988953705041776
1133,FIBA,Amyloid fiber formation,0.04069738034847725,1,0,1,0.04537763873736255
1134,FIBA,Post-translational protein phosphorylation,0.03577532252529636,0,0,1,0.03988953705041776
1135,FIBA,Post-translational protein phosphorylation,0.04069738034847725,1,0,1,0.04537763873736255
1136,FIBB,Antigen processing-Cross presentation,0.025196572754142693,0,0,1,0.02809421555065619
1137,FIBB,Antigen processing-Cross presentation,0.030730637158574655,1,0,1,0.034264705472693814
1138,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.025196572754142693,0,0,1,0.02809421555065619
1139,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.030730637158574655,1,0,1,0.034264705472693814
1140,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.025196572754142693,0,0,1,0.02809421555065619
1141,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.030730637158574655,1,0,1,0.034264705472693814
1142,FIBB,Regulation of TLR by endogenous ligand,0.025196572754142693,0,0,1,0.02809421555065619
1143,FIBB,Regulation of TLR by endogenous ligand,0.030730637158574655,1,0,1,0.034264705472693814
1144,FIBB,MyD88 deficiency (TLR2/4),0.025196572754142693,0,0,1,0.02809421555065619
1145,FIBB,MyD88 deficiency (TLR2/4),0.030730637158574655,1,0,1,0.034264705472693814
1146,FIBB,IRAK4 deficiency (TLR2/4),0.025196572754142693,0,0,1,0.02809421555065619
1147,FIBB,IRAK4 deficiency (TLR2/4),0.030730637158574655,1,0,1,0.034264705472693814
1148,FIBB,RAF/MAP kinase cascade,0.025196572754142693,0,0,1,0.02809421555065619
1149,FIBB,RAF/MAP kinase cascade,0.030730637158574655,1,0,1,0.034264705472693814
1150,FIBB,Signaling by RAS mutants,0.025196572754142693,0,0,1,0.02809421555065619
1151,FIBB,Signaling by RAS mutants,0.030730637158574655,1,0,1,0.034264705472693814
1152,FIBB,Signaling by moderate kinase activity BRAF mutants,0.025196572754142693,0,0,1,0.02809421555065619
1153,FIBB,Signaling by moderate kinase activity BRAF mutants,0.030730637158574655,1,0,1,0.034264705472693814
1154,FIBB,Signaling by high-kinase activity BRAF mutants,0.025196572754142693,0,0,1,0.02809421555065619
1155,FIBB,Signaling by high-kinase activity BRAF mutants,0.030730637158574655,1,0,1,0.034264705472693814
1156,FIBB,Signaling by BRAF and RAF1 fusions,0.025196572754142693,0,0,1,0.02809421555065619
1157,FIBB,Signaling by BRAF and RAF1 fusions,0.030730637158574655,1,0,1,0.034264705472693814
1158,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.025196572754142693,0,0,1,0.02809421555065619
1159,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.030730637158574655,1,0,1,0.034264705472693814
1160,FIBB,Signaling by RAF1 mutants,0.025196572754142693,0,0,1,0.02809421555065619
1161,FIBB,Signaling by RAF1 mutants,0.030730637158574655,1,0,1,0.034264705472693814
1162,FIBB,Platelet degranulation ,0.025196572754142693,0,0,1,0.02809421555065619
1163,FIBB,Platelet degranulation ,0.030730637158574655,1,0,1,0.034264705472693814
1164,FIBB,Common Pathway of Fibrin Clot Formation,0.025196572754142693,0,0,1,0.02809421555065619
1165,FIBB,Common Pathway of Fibrin Clot Formation,0.030730637158574655,1,0,1,0.034264705472693814
1166,FIBB,Integrin cell surface interactions,0.025196572754142693,0,0,1,0.02809421555065619
1167,FIBB,Integrin cell surface interactions,0.030730637158574655,1,0,1,0.034264705472693814
1168,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.025196572754142693,0,0,1,0.02809421555065619
1169,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.030730637158574655,1,0,1,0.034264705472693814
1170,FIBB,p130Cas linkage to MAPK signaling for integrins,0.025196572754142693,0,0,1,0.02809421555065619
1171,FIBB,p130Cas linkage to MAPK signaling for integrins,0.030730637158574655,1,0,1,0.034264705472693814
1172,CRP,Initial triggering of complement,0.0002490630745007784,0,0,1,0.0002777056931119158
1173,CRP,Initial triggering of complement,0.0002614681806535684,1,0,1,0.00029153740465403226
1174,SAMP,Amyloid fiber formation,0.0066684590559130804,0,0,1,0.007435341621083964
1175,SAMP,Amyloid fiber formation,0.00620023654250852,1,0,1,0.006913272832379557
1176,C1QA,Initial triggering of complement,0.002315468735637435,0,0,1,0.002581751033942029
1177,C1QA,Initial triggering of complement,0.002498159682782492,1,0,1,0.0027854517077728733
1178,C1QA,Regulation of Complement cascade,0.002315468735637435,0,0,1,0.002581751033942029
1179,C1QA,Regulation of Complement cascade,0.002498159682782492,1,0,1,0.0027854517077728733
1180,C1QC,Initial triggering of complement,0.0036662596867556266,0,0,1,0.004087884924248634
1181,C1QC,Initial triggering of complement,0.003940951860724038,1,0,1,0.0043941671008306885
1182,C1QC,Regulation of Complement cascade,0.0036662596867556266,0,0,1,0.004087884924248634
1183,C1QC,Regulation of Complement cascade,0.003940951860724038,1,0,1,0.0043941671008306885
1184,CO9,Terminal pathway of complement,0.010226327307201303,0,0,1,0.011402369935920684
1185,CO9,Terminal pathway of complement,0.01233764725040847,1,0,1,0.013756494767088802
1186,CO9,Regulation of Complement cascade,0.010226327307201303,0,0,1,0.011402369935920684
1187,CO9,Regulation of Complement cascade,0.01233764725040847,1,0,1,0.013756494767088802
1188,APOH,Platelet degranulation ,0.004053160678622682,0,0,1,0.004519280097248446
1189,APOH,Platelet degranulation ,0.0038692033076427224,1,0,1,0.0043141673589855295
1190,A2GL,Neutrophil degranulation,0.00346606516200452,0,0,1,0.003864667735732627
1191,A2GL,Neutrophil degranulation,0.0036956838242750475,1,0,1,0.004120692880708778
1192,AMBP,Scavenging of heme from plasma,0.008759810932384277,0,0,1,0.009767202028574935
1193,AMBP,Scavenging of heme from plasma,0.005993320231984102,1,0,1,0.006682560842874407
1194,A1AG1,Platelet degranulation ,0.0001193082220368307,0,0,1,0.00013302884243719903
1195,A1AG1,Platelet degranulation ,9.584785309576178e-05,1,0,1,0.00010687049668281686
1196,A1AG1,Neutrophil degranulation,0.0001193082220368307,0,0,1,0.00013302884243719903
1197,A1AG1,Neutrophil degranulation,9.584785309576178e-05,1,0,1,0.00010687049668281686
1198,FETUA,Platelet degranulation ,0.008013828208381703,0,0,1,0.008935430197949748
1199,FETUA,Platelet degranulation ,0.008108466027568607,1,0,1,0.009040951505050682
1200,FETUA,Neutrophil degranulation,0.008013828208381703,0,0,1,0.008935430197949748
1201,FETUA,Neutrophil degranulation,0.008108466027568607,1,0,1,0.009040951505050682
1202,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.008013828208381703,0,0,1,0.008935430197949748
1203,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.008108466027568607,1,0,1,0.009040951505050682
1204,FETUA,Post-translational protein phosphorylation,0.008013828208381703,0,0,1,0.008935430197949748
1205,FETUA,Post-translational protein phosphorylation,0.008108466027568607,1,0,1,0.009040951505050682
1206,CXCL7,Class A/1 (Rhodopsin-like receptors),0.013854314096520687,0,0,1,0.015447580523432583
1207,CXCL7,Class A/1 (Rhodopsin-like receptors),0.01509556283661744,1,0,1,0.016831574687897873
1208,CXCL7,G alpha (i) signalling events,0.013854314096520687,0,0,1,0.015447580523432583
1209,CXCL7,G alpha (i) signalling events,0.01509556283661744,1,0,1,0.016831574687897873
1210,CXCL7,Platelet degranulation ,0.013854314096520687,0,0,1,0.015447580523432583
1211,CXCL7,Platelet degranulation ,0.01509556283661744,1,0,1,0.016831574687897873
1212,CXCL7,Neutrophil degranulation,0.013854314096520687,0,0,1,0.015447580523432583
1213,CXCL7,Neutrophil degranulation,0.01509556283661744,1,0,1,0.016831574687897873
1214,PLF4,Transcriptional regulation by RUNX1,0.03474959513022371,0,0,1,0.03874584950153688
1215,PLF4,Transcriptional regulation by RUNX1,0.03565714107102781,1,0,1,0.039757764555693666
1216,PLF4,Class A/1 (Rhodopsin-like receptors),0.03474959513022371,0,0,1,0.03874584950153688
1217,PLF4,Class A/1 (Rhodopsin-like receptors),0.03565714107102781,1,0,1,0.039757764555693666
1218,PLF4,G alpha (i) signalling events,0.03474959513022371,0,0,1,0.03874584950153688
1219,PLF4,G alpha (i) signalling events,0.03565714107102781,1,0,1,0.039757764555693666
1220,PLF4,Platelet degranulation ,0.03474959513022371,0,0,1,0.03874584950153688
1221,PLF4,Platelet degranulation ,0.03565714107102781,1,0,1,0.039757764555693666
1222,PLF4,Cell surface interactions at the vascular wall,0.03474959513022371,0,0,1,0.03874584950153688
1223,PLF4,Cell surface interactions at the vascular wall,0.03565714107102781,1,0,1,0.039757764555693666
1224,PLF4,Common Pathway of Fibrin Clot Formation,0.03474959513022371,0,0,1,0.03874584950153688
1225,PLF4,Common Pathway of Fibrin Clot Formation,0.03565714107102781,1,0,1,0.039757764555693666
1226,TRFE,Platelet degranulation ,0.00401987027173638,0,0,1,0.004482161244777566
1227,TRFE,Platelet degranulation ,0.0038105162158159436,1,0,1,0.004248731165582933
1228,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.00401987027173638,0,0,1,0.004482161244777566
1229,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.0038105162158159436,1,0,1,0.004248731165582933
1230,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00401987027173638,0,0,1,0.004482161244777566
1231,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0038105162158159436,1,0,1,0.004248731165582933
1232,TRFE,Post-translational protein phosphorylation,0.00401987027173638,0,0,1,0.004482161244777566
1233,TRFE,Post-translational protein phosphorylation,0.0038105162158159436,1,0,1,0.004248731165582933
1234,TRFE,Transferrin endocytosis and recycling,0.00401987027173638,0,0,1,0.004482161244777566
1235,TRFE,Transferrin endocytosis and recycling,0.0038105162158159436,1,0,1,0.004248731165582933
1236,HEMO,Scavenging of heme from plasma,0.003228021403843566,0,0,1,0.0035992485964902645
1237,HEMO,Scavenging of heme from plasma,0.0022019231049566312,1,0,1,0.0024551474893128402
1238,ANGI,Adherens junctions interactions,0.0005982916933622312,0,0,1,0.0006670961149953239
1239,ANGI,Adherens junctions interactions,0.0004943624685365595,1,0,1,0.0005512148769890571
1240,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0005982916933622312,0,0,1,0.0006670961149953239
1241,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0004943624685365595,1,0,1,0.0005512148769890571
1242,C4BPA,Regulation of Complement cascade,0.0067348735893538745,0,0,1,0.007509393923212043
1243,C4BPA,Regulation of Complement cascade,0.007257003012902047,1,0,1,0.00809156899573616
1244,VTNC,Regulation of Complement cascade,0.015163658629616633,0,0,1,0.016907501596897734
1245,VTNC,Regulation of Complement cascade,0.01619940826325152,1,0,1,0.01806236395646477
1246,VTNC,Integrin cell surface interactions,0.015163658629616633,0,0,1,0.016907501596897734
1247,VTNC,Integrin cell surface interactions,0.01619940826325152,1,0,1,0.01806236395646477
1248,VTNC,ECM proteoglycans,0.015163658629616633,0,0,1,0.016907501596897734
1249,VTNC,ECM proteoglycans,0.01619940826325152,1,0,1,0.01806236395646477
1250,VTNC,Molecules associated with elastic fibres,0.015163658629616633,0,0,1,0.016907501596897734
1251,VTNC,Molecules associated with elastic fibres,0.01619940826325152,1,0,1,0.01806236395646477
1252,VTNC,Syndecan interactions,0.015163658629616633,0,0,1,0.016907501596897734
1253,VTNC,Syndecan interactions,0.01619940826325152,1,0,1,0.01806236395646477
1254,CATA,FOXO-mediated transcription,0.0015039914692623279,0,0,1,0.0016769526925782732
1255,CATA,FOXO-mediated transcription,0.00100959817762995,1,0,1,0.0011257034477922022
1256,CATA,Detoxification of Reactive Oxygen Species,0.0015039914692623279,0,0,1,0.0016769526925782732
1257,CATA,Detoxification of Reactive Oxygen Species,0.00100959817762995,1,0,1,0.0011257034477922022
1258,CATA,Neutrophil degranulation,0.0015039914692623279,0,0,1,0.0016769526925782732
1259,CATA,Neutrophil degranulation,0.00100959817762995,1,0,1,0.0011257034477922022
1260,CATA,Peroxisomal protein import,0.0015039914692623279,0,0,1,0.0016769526925782732
1261,CATA,Peroxisomal protein import,0.00100959817762995,1,0,1,0.0011257034477922022
1262,APOB,Regulation of TLR by endogenous ligand,0.0068183786917481535,0,0,1,0.0076025022347723445
1263,APOB,Regulation of TLR by endogenous ligand,0.006892309293199917,1,0,1,0.0076849349637487085
1264,APOB,Cargo recognition for clathrin-mediated endocytosis,0.0068183786917481535,0,0,1,0.0076025022347723445
1265,APOB,Cargo recognition for clathrin-mediated endocytosis,0.006892309293199917,1,0,1,0.0076849349637487085
1266,APOB,VLDL assembly,0.0068183786917481535,0,0,1,0.0076025022347723445
1267,APOB,VLDL assembly,0.006892309293199917,1,0,1,0.0076849349637487085
1268,APOB,Chylomicron assembly,0.0068183786917481535,0,0,1,0.0076025022347723445
1269,APOB,Chylomicron assembly,0.006892309293199917,1,0,1,0.0076849349637487085
1270,APOB,Chylomicron remodeling,0.0068183786917481535,0,0,1,0.0076025022347723445
1271,APOB,Chylomicron remodeling,0.006892309293199917,1,0,1,0.0076849349637487085
1272,APOB,LDL remodeling,0.0068183786917481535,0,0,1,0.0076025022347723445
1273,APOB,LDL remodeling,0.006892309293199917,1,0,1,0.0076849349637487085
1274,APOB,Chylomicron clearance,0.0068183786917481535,0,0,1,0.0076025022347723445
1275,APOB,Chylomicron clearance,0.006892309293199917,1,0,1,0.0076849349637487085
1276,APOB,LDL clearance,0.0068183786917481535,0,0,1,0.0076025022347723445
1277,APOB,LDL clearance,0.006892309293199917,1,0,1,0.0076849349637487085
1278,APOB,VLDL clearance,0.0068183786917481535,0,0,1,0.0076025022347723445
1279,APOB,VLDL clearance,0.006892309293199917,1,0,1,0.0076849349637487085
1280,APOB,Cell surface interactions at the vascular wall,0.0068183786917481535,0,0,1,0.0076025022347723445
1281,APOB,Cell surface interactions at the vascular wall,0.006892309293199917,1,0,1,0.0076849349637487085
1282,APOB,Scavenging by Class B Receptors,0.0068183786917481535,0,0,1,0.0076025022347723445
1283,APOB,Scavenging by Class B Receptors,0.006892309293199917,1,0,1,0.0076849349637487085
1284,APOB,Scavenging by Class A Receptors,0.0068183786917481535,0,0,1,0.0076025022347723445
1285,APOB,Scavenging by Class A Receptors,0.006892309293199917,1,0,1,0.0076849349637487085
1286,APOB,Scavenging by Class F Receptors,0.0068183786917481535,0,0,1,0.0076025022347723445
1287,APOB,Scavenging by Class F Receptors,0.006892309293199917,1,0,1,0.0076849349637487085
1288,APOB,Scavenging by Class H Receptors,0.0068183786917481535,0,0,1,0.0076025022347723445
1289,APOB,Scavenging by Class H Receptors,0.006892309293199917,1,0,1,0.0076849349637487085
1290,APOB,Retinoid metabolism and transport,0.0068183786917481535,0,0,1,0.0076025022347723445
1291,APOB,Retinoid metabolism and transport,0.006892309293199917,1,0,1,0.0076849349637487085
1292,APOB,Heme signaling,0.0068183786917481535,0,0,1,0.0076025022347723445
1293,APOB,Heme signaling,0.006892309293199917,1,0,1,0.0076849349637487085
1294,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0068183786917481535,0,0,1,0.0076025022347723445
1295,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006892309293199917,1,0,1,0.0076849349637487085
1296,APOB,Platelet sensitization by LDL,0.0068183786917481535,0,0,1,0.0076025022347723445
1297,APOB,Platelet sensitization by LDL,0.006892309293199917,1,0,1,0.0076849349637487085
1298,APOB,Post-translational protein phosphorylation,0.0068183786917481535,0,0,1,0.0076025022347723445
1299,APOB,Post-translational protein phosphorylation,0.006892309293199917,1,0,1,0.0076849349637487085
1300,LCAT,HDL remodeling,0.003894762754316484,0,0,1,0.004342666179488413
1301,LCAT,HDL remodeling,0.004093085968107216,1,0,1,0.004563796853540884
1302,HRG,Platelet degranulation ,0.0003063579686229261,0,0,1,0.0003415895840333504
1303,HRG,Platelet degranulation ,0.0009882629346278907,1,0,1,0.0011019146205745428
1304,HRG,Dissolution of Fibrin Clot,0.0003063579686229261,0,0,1,0.0003415895840333504
1305,HRG,Dissolution of Fibrin Clot,0.0009882629346278907,1,0,1,0.0011019146205745428
1306,LV743,Initial triggering of complement,0.007618935810594536,0,0,1,0.008495124595636271
1307,LV743,Initial triggering of complement,0.007726613861228051,1,0,1,0.008615185779912814
1308,LV743,Regulation of Complement cascade,0.007618935810594536,0,0,1,0.008495124595636271
1309,LV743,Regulation of Complement cascade,0.007726613861228051,1,0,1,0.008615185779912814
1310,LV743,FCGR activation,0.007618935810594536,0,0,1,0.008495124595636271
1311,LV743,FCGR activation,0.007726613861228051,1,0,1,0.008615185779912814
1312,LV743,Regulation of actin dynamics for phagocytic cup formation,0.007618935810594536,0,0,1,0.008495124595636271
1313,LV743,Regulation of actin dynamics for phagocytic cup formation,0.007726613861228051,1,0,1,0.008615185779912814
1314,LV743,Role of phospholipids in phagocytosis,0.007618935810594536,0,0,1,0.008495124595636271
1315,LV743,Role of phospholipids in phagocytosis,0.007726613861228051,1,0,1,0.008615185779912814
1316,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.007618935810594536,0,0,1,0.008495124595636271
1317,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.007726613861228051,1,0,1,0.008615185779912814
1318,LV743,FCERI mediated MAPK activation,0.007618935810594536,0,0,1,0.008495124595636271
1319,LV743,FCERI mediated MAPK activation,0.007726613861228051,1,0,1,0.008615185779912814
1320,LV743,FCERI mediated Ca+2 mobilization,0.007618935810594536,0,0,1,0.008495124595636271
1321,LV743,FCERI mediated Ca+2 mobilization,0.007726613861228051,1,0,1,0.008615185779912814
1322,LV743,FCERI mediated NF-kB activation,0.007618935810594536,0,0,1,0.008495124595636271
1323,LV743,FCERI mediated NF-kB activation,0.007726613861228051,1,0,1,0.008615185779912814
1324,LV743,Parasite infection,0.007618935810594536,0,0,1,0.008495124595636271
1325,LV743,Parasite infection,0.007726613861228051,1,0,1,0.008615185779912814
1326,LV743,Leishmania parasite growth and survival,0.007618935810594536,0,0,1,0.008495124595636271
1327,LV743,Leishmania parasite growth and survival,0.007726613861228051,1,0,1,0.008615185779912814
1328,LV743,Potential therapeutics for SARS,0.007618935810594536,0,0,1,0.008495124595636271
1329,LV743,Potential therapeutics for SARS,0.007726613861228051,1,0,1,0.008615185779912814
1330,LV743,CD22 mediated BCR regulation,0.007618935810594536,0,0,1,0.008495124595636271
1331,LV743,CD22 mediated BCR regulation,0.007726613861228051,1,0,1,0.008615185779912814
1332,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007618935810594536,0,0,1,0.008495124595636271
1333,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007726613861228051,1,0,1,0.008615185779912814
1334,LV743,Cell surface interactions at the vascular wall,0.007618935810594536,0,0,1,0.008495124595636271
1335,LV743,Cell surface interactions at the vascular wall,0.007726613861228051,1,0,1,0.008615185779912814
1336,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007618935810594536,0,0,1,0.008495124595636271
1337,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007726613861228051,1,0,1,0.008615185779912814
1338,LV743,Scavenging of heme from plasma,0.007618935810594536,0,0,1,0.008495124595636271
1339,LV743,Scavenging of heme from plasma,0.007726613861228051,1,0,1,0.008615185779912814
1340,K2C1,Neutrophil degranulation,6.949079310374042e-05,0,0,1,7.748233616103804e-05
1341,K2C1,Neutrophil degranulation,8.472233347139601e-05,1,0,1,9.446552599534123e-05
1342,K2C1,Formation of the cornified envelope,6.949079310374042e-05,0,0,1,7.748233616103804e-05
1343,K2C1,Formation of the cornified envelope,8.472233347139601e-05,1,0,1,9.446552599534123e-05
1344,VWF,RAF/MAP kinase cascade,0.007388195049392022,0,0,1,0.008237848308706332
1345,VWF,RAF/MAP kinase cascade,0.008293373175501124,1,0,1,0.009247123246007755
1346,VWF,Signaling by RAS mutants,0.007388195049392022,0,0,1,0.008237848308706332
1347,VWF,Signaling by RAS mutants,0.008293373175501124,1,0,1,0.009247123246007755
1348,VWF,Signaling by moderate kinase activity BRAF mutants,0.007388195049392022,0,0,1,0.008237848308706332
1349,VWF,Signaling by moderate kinase activity BRAF mutants,0.008293373175501124,1,0,1,0.009247123246007755
1350,VWF,Signaling by high-kinase activity BRAF mutants,0.007388195049392022,0,0,1,0.008237848308706332
1351,VWF,Signaling by high-kinase activity BRAF mutants,0.008293373175501124,1,0,1,0.009247123246007755
1352,VWF,Signaling by BRAF and RAF1 fusions,0.007388195049392022,0,0,1,0.008237848308706332
1353,VWF,Signaling by BRAF and RAF1 fusions,0.008293373175501124,1,0,1,0.009247123246007755
1354,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.007388195049392022,0,0,1,0.008237848308706332
1355,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.008293373175501124,1,0,1,0.009247123246007755
1356,VWF,Signaling by RAF1 mutants,0.007388195049392022,0,0,1,0.008237848308706332
1357,VWF,Signaling by RAF1 mutants,0.008293373175501124,1,0,1,0.009247123246007755
1358,VWF,Platelet degranulation ,0.007388195049392022,0,0,1,0.008237848308706332
1359,VWF,Platelet degranulation ,0.008293373175501124,1,0,1,0.009247123246007755
1360,VWF,Defective factor VIII causes hemophilia A,0.007388195049392022,0,0,1,0.008237848308706332
1361,VWF,Defective factor VIII causes hemophilia A,0.008293373175501124,1,0,1,0.009247123246007755
1362,VWF,Platelet Adhesion to exposed collagen,0.007388195049392022,0,0,1,0.008237848308706332
1363,VWF,Platelet Adhesion to exposed collagen,0.008293373175501124,1,0,1,0.009247123246007755
1364,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.007388195049392022,0,0,1,0.008237848308706332
1365,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.008293373175501124,1,0,1,0.009247123246007755
1366,VWF,Integrin cell surface interactions,0.007388195049392022,0,0,1,0.008237848308706332
1367,VWF,Integrin cell surface interactions,0.008293373175501124,1,0,1,0.009247123246007755
1368,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.007388195049392022,0,0,1,0.008237848308706332
1369,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.008293373175501124,1,0,1,0.009247123246007755
1370,VWF,p130Cas linkage to MAPK signaling for integrins,0.007388195049392022,0,0,1,0.008237848308706332
1371,VWF,p130Cas linkage to MAPK signaling for integrins,0.008293373175501124,1,0,1,0.009247123246007755
1372,VWF,GP1b-IX-V activation signalling,0.007388195049392022,0,0,1,0.008237848308706332
1373,VWF,GP1b-IX-V activation signalling,0.008293373175501124,1,0,1,0.009247123246007755
1374,KV116,Initial triggering of complement,0.008333380952391362,0,0,1,0.009291731975878454
1375,KV116,Initial triggering of complement,0.008256967622979663,1,0,1,0.009206531001587907
1376,KV116,Regulation of Complement cascade,0.008333380952391362,0,0,1,0.009291731975878454
1377,KV116,Regulation of Complement cascade,0.008256967622979663,1,0,1,0.009206531001587907
1378,KV116,FCGR activation,0.008333380952391362,0,0,1,0.009291731975878454
1379,KV116,FCGR activation,0.008256967622979663,1,0,1,0.009206531001587907
1380,KV116,Regulation of actin dynamics for phagocytic cup formation,0.008333380952391362,0,0,1,0.009291731975878454
1381,KV116,Regulation of actin dynamics for phagocytic cup formation,0.008256967622979663,1,0,1,0.009206531001587907
1382,KV116,Role of phospholipids in phagocytosis,0.008333380952391362,0,0,1,0.009291731975878454
1383,KV116,Role of phospholipids in phagocytosis,0.008256967622979663,1,0,1,0.009206531001587907
1384,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.008333380952391362,0,0,1,0.009291731975878454
1385,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.008256967622979663,1,0,1,0.009206531001587907
1386,KV116,FCERI mediated MAPK activation,0.008333380952391362,0,0,1,0.009291731975878454
1387,KV116,FCERI mediated MAPK activation,0.008256967622979663,1,0,1,0.009206531001587907
1388,KV116,FCERI mediated Ca+2 mobilization,0.008333380952391362,0,0,1,0.009291731975878454
1389,KV116,FCERI mediated Ca+2 mobilization,0.008256967622979663,1,0,1,0.009206531001587907
1390,KV116,FCERI mediated NF-kB activation,0.008333380952391362,0,0,1,0.009291731975878454
1391,KV116,FCERI mediated NF-kB activation,0.008256967622979663,1,0,1,0.009206531001587907
1392,KV116,Parasite infection,0.008333380952391362,0,0,1,0.009291731975878454
1393,KV116,Parasite infection,0.008256967622979663,1,0,1,0.009206531001587907
1394,KV116,Leishmania parasite growth and survival,0.008333380952391362,0,0,1,0.009291731975878454
1395,KV116,Leishmania parasite growth and survival,0.008256967622979663,1,0,1,0.009206531001587907
1396,KV116,Potential therapeutics for SARS,0.008333380952391362,0,0,1,0.009291731975878454
1397,KV116,Potential therapeutics for SARS,0.008256967622979663,1,0,1,0.009206531001587907
1398,KV116,CD22 mediated BCR regulation,0.008333380952391362,0,0,1,0.009291731975878454
1399,KV116,CD22 mediated BCR regulation,0.008256967622979663,1,0,1,0.009206531001587907
1400,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.008333380952391362,0,0,1,0.009291731975878454
1401,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.008256967622979663,1,0,1,0.009206531001587907
1402,KV116,Cell surface interactions at the vascular wall,0.008333380952391362,0,0,1,0.009291731975878454
1403,KV116,Cell surface interactions at the vascular wall,0.008256967622979663,1,0,1,0.009206531001587907
1404,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.008333380952391362,0,0,1,0.009291731975878454
1405,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.008256967622979663,1,0,1,0.009206531001587907
1406,KV116,Scavenging of heme from plasma,0.008333380952391362,0,0,1,0.009291731975878454
1407,KV116,Scavenging of heme from plasma,0.008256967622979663,1,0,1,0.009206531001587907
1408,S10A8,Antigen processing-Cross presentation,0.03470939282328568,0,0,1,0.038701023870377785
1409,S10A8,Antigen processing-Cross presentation,0.034553205457151605,1,0,1,0.038526874728219605
1410,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.03470939282328568,0,0,1,0.038701023870377785
1411,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.034553205457151605,1,0,1,0.038526874728219605
1412,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.03470939282328568,0,0,1,0.038701023870377785
1413,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.034553205457151605,1,0,1,0.038526874728219605
1414,S10A8,Regulation of TLR by endogenous ligand,0.03470939282328568,0,0,1,0.038701023870377785
1415,S10A8,Regulation of TLR by endogenous ligand,0.034553205457151605,1,0,1,0.038526874728219605
1416,S10A8,RHO GTPase Effectors,0.03470939282328568,0,0,1,0.038701023870377785
1417,S10A8,RHO GTPase Effectors,0.034553205457151605,1,0,1,0.038526874728219605
1418,S10A8,MyD88 deficiency (TLR2/4),0.03470939282328568,0,0,1,0.038701023870377785
1419,S10A8,MyD88 deficiency (TLR2/4),0.034553205457151605,1,0,1,0.038526874728219605
1420,S10A8,IRAK4 deficiency (TLR2/4),0.03470939282328568,0,0,1,0.038701023870377785
1421,S10A8,IRAK4 deficiency (TLR2/4),0.034553205457151605,1,0,1,0.038526874728219605
1422,S10A8,Metal sequestration by antimicrobial proteins,0.03470939282328568,0,0,1,0.038701023870377785
1423,S10A8,Metal sequestration by antimicrobial proteins,0.034553205457151605,1,0,1,0.038526874728219605
1424,S10A8,Neutrophil degranulation,0.03470939282328568,0,0,1,0.038701023870377785
1425,S10A8,Neutrophil degranulation,0.034553205457151605,1,0,1,0.038526874728219605
1426,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.0026325280605901773,0,0,1,0.00293527264596775
1427,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.002537834014399743,1,0,1,0.00282968864567547
1428,IPSP,Common Pathway of Fibrin Clot Formation,0.0026325280605901773,0,0,1,0.00293527264596775
1429,IPSP,Common Pathway of Fibrin Clot Formation,0.002537834014399743,1,0,1,0.00282968864567547
1430,F13B,Common Pathway of Fibrin Clot Formation,0.0015825805513612985,0,0,1,0.0017645796343040553
1431,F13B,Common Pathway of Fibrin Clot Formation,0.0014514164276058941,1,0,1,0.0016183314440738417
1432,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.005280383433721325,0,0,1,0.005887635267883419
1433,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.0053374409579236715,1,0,1,0.00595125449099637
1434,HEP2,Common Pathway of Fibrin Clot Formation,0.005280383433721325,0,0,1,0.005887635267883419
1435,HEP2,Common Pathway of Fibrin Clot Formation,0.0053374409579236715,1,0,1,0.00595125449099637
1436,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005280383433721325,0,0,1,0.005887635267883419
1437,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0053374409579236715,1,0,1,0.00595125449099637
1438,HEP2,Post-translational protein phosphorylation,0.005280383433721325,0,0,1,0.005887635267883419
1439,HEP2,Post-translational protein phosphorylation,0.0053374409579236715,1,0,1,0.00595125449099637
1440,KV230,Initial triggering of complement,0.010755167799905678,0,0,1,0.01199202786039016
1441,KV230,Initial triggering of complement,0.010801151131352717,1,0,1,0.012043299342349864
1442,KV230,Regulation of Complement cascade,0.010755167799905678,0,0,1,0.01199202786039016
1443,KV230,Regulation of Complement cascade,0.010801151131352717,1,0,1,0.012043299342349864
1444,KV230,FCGR activation,0.010755167799905678,0,0,1,0.01199202786039016
1445,KV230,FCGR activation,0.010801151131352717,1,0,1,0.012043299342349864
1446,KV230,Regulation of actin dynamics for phagocytic cup formation,0.010755167799905678,0,0,1,0.01199202786039016
1447,KV230,Regulation of actin dynamics for phagocytic cup formation,0.010801151131352717,1,0,1,0.012043299342349864
1448,KV230,Role of phospholipids in phagocytosis,0.010755167799905678,0,0,1,0.01199202786039016
1449,KV230,Role of phospholipids in phagocytosis,0.010801151131352717,1,0,1,0.012043299342349864
1450,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.010755167799905678,0,0,1,0.01199202786039016
1451,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.010801151131352717,1,0,1,0.012043299342349864
1452,KV230,FCERI mediated MAPK activation,0.010755167799905678,0,0,1,0.01199202786039016
1453,KV230,FCERI mediated MAPK activation,0.010801151131352717,1,0,1,0.012043299342349864
1454,KV230,FCERI mediated Ca+2 mobilization,0.010755167799905678,0,0,1,0.01199202786039016
1455,KV230,FCERI mediated Ca+2 mobilization,0.010801151131352717,1,0,1,0.012043299342349864
1456,KV230,FCERI mediated NF-kB activation,0.010755167799905678,0,0,1,0.01199202786039016
1457,KV230,FCERI mediated NF-kB activation,0.010801151131352717,1,0,1,0.012043299342349864
1458,KV230,Parasite infection,0.010755167799905678,0,0,1,0.01199202786039016
1459,KV230,Parasite infection,0.010801151131352717,1,0,1,0.012043299342349864
1460,KV230,Leishmania parasite growth and survival,0.010755167799905678,0,0,1,0.01199202786039016
1461,KV230,Leishmania parasite growth and survival,0.010801151131352717,1,0,1,0.012043299342349864
1462,KV230,Potential therapeutics for SARS,0.010755167799905678,0,0,1,0.01199202786039016
1463,KV230,Potential therapeutics for SARS,0.010801151131352717,1,0,1,0.012043299342349864
1464,KV230,CD22 mediated BCR regulation,0.010755167799905678,0,0,1,0.01199202786039016
1465,KV230,CD22 mediated BCR regulation,0.010801151131352717,1,0,1,0.012043299342349864
1466,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.010755167799905678,0,0,1,0.01199202786039016
1467,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.010801151131352717,1,0,1,0.012043299342349864
1468,KV230,Cell surface interactions at the vascular wall,0.010755167799905678,0,0,1,0.01199202786039016
1469,KV230,Cell surface interactions at the vascular wall,0.010801151131352717,1,0,1,0.012043299342349864
1470,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010755167799905678,0,0,1,0.01199202786039016
1471,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010801151131352717,1,0,1,0.012043299342349864
1472,KV230,Scavenging of heme from plasma,0.010755167799905678,0,0,1,0.01199202786039016
1473,KV230,Scavenging of heme from plasma,0.010801151131352717,1,0,1,0.012043299342349864
1474,KV401,Initial triggering of complement,0.010370710279597229,0,0,1,0.011563357161759512
1475,KV401,Initial triggering of complement,0.010744562872976668,1,0,1,0.011980203351321023
1476,KV401,Regulation of Complement cascade,0.010370710279597229,0,0,1,0.011563357161759512
1477,KV401,Regulation of Complement cascade,0.010744562872976668,1,0,1,0.011980203351321023
1478,KV401,FCGR activation,0.010370710279597229,0,0,1,0.011563357161759512
1479,KV401,FCGR activation,0.010744562872976668,1,0,1,0.011980203351321023
1480,KV401,Regulation of actin dynamics for phagocytic cup formation,0.010370710279597229,0,0,1,0.011563357161759512
1481,KV401,Regulation of actin dynamics for phagocytic cup formation,0.010744562872976668,1,0,1,0.011980203351321023
1482,KV401,Role of phospholipids in phagocytosis,0.010370710279597229,0,0,1,0.011563357161759512
1483,KV401,Role of phospholipids in phagocytosis,0.010744562872976668,1,0,1,0.011980203351321023
1484,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.010370710279597229,0,0,1,0.011563357161759512
1485,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.010744562872976668,1,0,1,0.011980203351321023
1486,KV401,FCERI mediated MAPK activation,0.010370710279597229,0,0,1,0.011563357161759512
1487,KV401,FCERI mediated MAPK activation,0.010744562872976668,1,0,1,0.011980203351321023
1488,KV401,FCERI mediated Ca+2 mobilization,0.010370710279597229,0,0,1,0.011563357161759512
1489,KV401,FCERI mediated Ca+2 mobilization,0.010744562872976668,1,0,1,0.011980203351321023
1490,KV401,FCERI mediated NF-kB activation,0.010370710279597229,0,0,1,0.011563357161759512
1491,KV401,FCERI mediated NF-kB activation,0.010744562872976668,1,0,1,0.011980203351321023
1492,KV401,Parasite infection,0.010370710279597229,0,0,1,0.011563357161759512
1493,KV401,Parasite infection,0.010744562872976668,1,0,1,0.011980203351321023
1494,KV401,Leishmania parasite growth and survival,0.010370710279597229,0,0,1,0.011563357161759512
1495,KV401,Leishmania parasite growth and survival,0.010744562872976668,1,0,1,0.011980203351321023
1496,KV401,Potential therapeutics for SARS,0.010370710279597229,0,0,1,0.011563357161759512
1497,KV401,Potential therapeutics for SARS,0.010744562872976668,1,0,1,0.011980203351321023
1498,KV401,CD22 mediated BCR regulation,0.010370710279597229,0,0,1,0.011563357161759512
1499,KV401,CD22 mediated BCR regulation,0.010744562872976668,1,0,1,0.011980203351321023
1500,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.010370710279597229,0,0,1,0.011563357161759512
1501,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.010744562872976668,1,0,1,0.011980203351321023
1502,KV401,Cell surface interactions at the vascular wall,0.010370710279597229,0,0,1,0.011563357161759512
1503,KV401,Cell surface interactions at the vascular wall,0.010744562872976668,1,0,1,0.011980203351321023
1504,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010370710279597229,0,0,1,0.011563357161759512
1505,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010744562872976668,1,0,1,0.011980203351321023
1506,KV401,Scavenging of heme from plasma,0.010370710279597229,0,0,1,0.011563357161759512
1507,KV401,Scavenging of heme from plasma,0.010744562872976668,1,0,1,0.011980203351321023
1508,HV434,Initial triggering of complement,0.002691587195643583,0,0,1,0.003001123668113327
1509,HV434,Initial triggering of complement,0.0019747116295397117,1,0,1,0.0022018063612065965
1510,HV434,Regulation of Complement cascade,0.002691587195643583,0,0,1,0.003001123668113327
1511,HV434,Regulation of Complement cascade,0.0019747116295397117,1,0,1,0.0022018063612065965
1512,HV434,FCGR activation,0.002691587195643583,0,0,1,0.003001123668113327
1513,HV434,FCGR activation,0.0019747116295397117,1,0,1,0.0022018063612065965
1514,HV434,Regulation of actin dynamics for phagocytic cup formation,0.002691587195643583,0,0,1,0.003001123668113327
1515,HV434,Regulation of actin dynamics for phagocytic cup formation,0.0019747116295397117,1,0,1,0.0022018063612065965
1516,HV434,Role of phospholipids in phagocytosis,0.002691587195643583,0,0,1,0.003001123668113327
1517,HV434,Role of phospholipids in phagocytosis,0.0019747116295397117,1,0,1,0.0022018063612065965
1518,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.002691587195643583,0,0,1,0.003001123668113327
1519,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.0019747116295397117,1,0,1,0.0022018063612065965
1520,HV434,FCERI mediated MAPK activation,0.002691587195643583,0,0,1,0.003001123668113327
1521,HV434,FCERI mediated MAPK activation,0.0019747116295397117,1,0,1,0.0022018063612065965
1522,HV434,FCERI mediated Ca+2 mobilization,0.002691587195643583,0,0,1,0.003001123668113327
1523,HV434,FCERI mediated Ca+2 mobilization,0.0019747116295397117,1,0,1,0.0022018063612065965
1524,HV434,FCERI mediated NF-kB activation,0.002691587195643583,0,0,1,0.003001123668113327
1525,HV434,FCERI mediated NF-kB activation,0.0019747116295397117,1,0,1,0.0022018063612065965
1526,HV434,Parasite infection,0.002691587195643583,0,0,1,0.003001123668113327
1527,HV434,Parasite infection,0.0019747116295397117,1,0,1,0.0022018063612065965
1528,HV434,Leishmania parasite growth and survival,0.002691587195643583,0,0,1,0.003001123668113327
1529,HV434,Leishmania parasite growth and survival,0.0019747116295397117,1,0,1,0.0022018063612065965
1530,HV434,Potential therapeutics for SARS,0.002691587195643583,0,0,1,0.003001123668113327
1531,HV434,Potential therapeutics for SARS,0.0019747116295397117,1,0,1,0.0022018063612065965
1532,HV434,CD22 mediated BCR regulation,0.002691587195643583,0,0,1,0.003001123668113327
1533,HV434,CD22 mediated BCR regulation,0.0019747116295397117,1,0,1,0.0022018063612065965
1534,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002691587195643583,0,0,1,0.003001123668113327
1535,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0019747116295397117,1,0,1,0.0022018063612065965
1536,HV434,Cell surface interactions at the vascular wall,0.002691587195643583,0,0,1,0.003001123668113327
1537,HV434,Cell surface interactions at the vascular wall,0.0019747116295397117,1,0,1,0.0022018063612065965
1538,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002691587195643583,0,0,1,0.003001123668113327
1539,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0019747116295397117,1,0,1,0.0022018063612065965
1540,HV434,Scavenging of heme from plasma,0.002691587195643583,0,0,1,0.003001123668113327
1541,HV434,Scavenging of heme from plasma,0.0019747116295397117,1,0,1,0.0022018063612065965
1542,GELS,Apoptotic cleavage of cellular proteins,0.052864644085325666,0,0,1,0.05894415563710638
1543,GELS,Apoptotic cleavage of cellular proteins,0.04879645482726206,1,0,1,0.05440811865175441
1544,GELS,Neutrophil degranulation,0.052864644085325666,0,0,1,0.05894415563710638
1545,GELS,Neutrophil degranulation,0.04879645482726206,1,0,1,0.05440811865175441
1546,GELS,Amyloid fiber formation,0.052864644085325666,0,0,1,0.05894415563710638
1547,GELS,Amyloid fiber formation,0.04879645482726206,1,0,1,0.05440811865175441
1548,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.052864644085325666,0,0,1,0.05894415563710638
1549,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.04879645482726206,1,0,1,0.05440811865175441
1550,S10A9,Antigen processing-Cross presentation,0.003887954045250485,0,0,1,0.004335074458900524
1551,S10A9,Antigen processing-Cross presentation,0.00373718740177483,1,0,1,0.004166969430451463
1552,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.003887954045250485,0,0,1,0.004335074458900524
1553,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.00373718740177483,1,0,1,0.004166969430451463
1554,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.003887954045250485,0,0,1,0.004335074458900524
1555,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.00373718740177483,1,0,1,0.004166969430451463
1556,S10A9,Regulation of TLR by endogenous ligand,0.003887954045250485,0,0,1,0.004335074458900524
1557,S10A9,Regulation of TLR by endogenous ligand,0.00373718740177483,1,0,1,0.004166969430451463
1558,S10A9,RHO GTPase Effectors,0.003887954045250485,0,0,1,0.004335074458900524
1559,S10A9,RHO GTPase Effectors,0.00373718740177483,1,0,1,0.004166969430451463
1560,S10A9,MyD88 deficiency (TLR2/4),0.003887954045250485,0,0,1,0.004335074458900524
1561,S10A9,MyD88 deficiency (TLR2/4),0.00373718740177483,1,0,1,0.004166969430451463
1562,S10A9,IRAK4 deficiency (TLR2/4),0.003887954045250485,0,0,1,0.004335074458900524
1563,S10A9,IRAK4 deficiency (TLR2/4),0.00373718740177483,1,0,1,0.004166969430451463
1564,S10A9,Metal sequestration by antimicrobial proteins,0.003887954045250485,0,0,1,0.004335074458900524
1565,S10A9,Metal sequestration by antimicrobial proteins,0.00373718740177483,1,0,1,0.004166969430451463
1566,S10A9,Neutrophil degranulation,0.003887954045250485,0,0,1,0.004335074458900524
1567,S10A9,Neutrophil degranulation,0.00373718740177483,1,0,1,0.004166969430451463
1568,APOA4,Chylomicron assembly,0.03099439435038957,0,0,1,0.034558795128147676
1569,APOA4,Chylomicron assembly,0.0319649305332743,1,0,1,0.03564094439454708
1570,APOA4,Assembly of active LPL and LIPC lipase complexes,0.03099439435038957,0,0,1,0.034558795128147676
1571,APOA4,Assembly of active LPL and LIPC lipase complexes,0.0319649305332743,1,0,1,0.03564094439454708
1572,APOA4,Chylomicron remodeling,0.03099439435038957,0,0,1,0.034558795128147676
1573,APOA4,Chylomicron remodeling,0.0319649305332743,1,0,1,0.03564094439454708
1574,APOA4,Retinoid metabolism and transport,0.03099439435038957,0,0,1,0.034558795128147676
1575,APOA4,Retinoid metabolism and transport,0.0319649305332743,1,0,1,0.03564094439454708
1576,APOA4,Amyloid fiber formation,0.03099439435038957,0,0,1,0.034558795128147676
1577,APOA4,Amyloid fiber formation,0.0319649305332743,1,0,1,0.03564094439454708
1578,LDHB,Pyruvate metabolism,0.0002637918979632799,0,0,1,0.00029412835286015657
1579,LDHB,Pyruvate metabolism,0.00032051365030755756,1,0,1,0.000357373189859231
1580,CO8A,Terminal pathway of complement,0.0013296124682309004,0,0,1,0.001482519850846671
1581,CO8A,Terminal pathway of complement,0.0012092967055784372,1,0,1,0.0013483675991463227
1582,CO8A,Regulation of Complement cascade,0.0013296124682309004,0,0,1,0.001482519850846671
1583,CO8A,Regulation of Complement cascade,0.0012092967055784372,1,0,1,0.0013483675991463227
1584,CO8G,Terminal pathway of complement,0.01160444475896019,0,0,1,0.012938972914493219
1585,CO8G,Terminal pathway of complement,0.013745354901491305,1,0,1,0.015326090861276917
1586,CO8G,Regulation of Complement cascade,0.01160444475896019,0,0,1,0.012938972914493219
1587,CO8G,Regulation of Complement cascade,0.013745354901491305,1,0,1,0.015326090861276917
1588,TSP1,Transcriptional regulation by RUNX1,0.026897760158213605,0,0,1,0.029991041999569625
1589,TSP1,Transcriptional regulation by RUNX1,0.02631934109789789,1,0,1,0.02934610389954783
1590,TSP1,Diseases associated with O-glycosylation of proteins,0.026897760158213605,0,0,1,0.029991041999569625
1591,TSP1,Diseases associated with O-glycosylation of proteins,0.02631934109789789,1,0,1,0.02934610389954783
1592,TSP1,O-glycosylation of TSR domain-containing proteins,0.026897760158213605,0,0,1,0.029991041999569625
1593,TSP1,O-glycosylation of TSR domain-containing proteins,0.02631934109789789,1,0,1,0.02934610389954783
1594,TSP1,Platelet degranulation ,0.026897760158213605,0,0,1,0.029991041999569625
1595,TSP1,Platelet degranulation ,0.02631934109789789,1,0,1,0.02934610389954783
1596,TSP1,Integrin cell surface interactions,0.026897760158213605,0,0,1,0.029991041999569625
1597,TSP1,Integrin cell surface interactions,0.02631934109789789,1,0,1,0.02934610389954783
1598,TSP1,Syndecan interactions,0.026897760158213605,0,0,1,0.029991041999569625
1599,TSP1,Syndecan interactions,0.02631934109789789,1,0,1,0.02934610389954783
1600,TSP1,Signaling by PDGF,0.026897760158213605,0,0,1,0.029991041999569625
1601,TSP1,Signaling by PDGF,0.02631934109789789,1,0,1,0.02934610389954783
1602,RNAS1,Chaperone Mediated Autophagy,0.018429011833875034,0,0,1,0.020548375205566533
1603,RNAS1,Chaperone Mediated Autophagy,0.011761884777058557,1,0,1,0.013114518765427546
1604,RNAS1,Late endosomal microautophagy,0.018429011833875034,0,0,1,0.020548375205566533
1605,RNAS1,Late endosomal microautophagy,0.011761884777058557,1,0,1,0.013114518765427546
1606,CBG,Metabolism of steroid hormones,8.764338907329066e-05,0,0,1,9.772250727274879e-05
1607,CBG,Metabolism of steroid hormones,0.0007152082447443984,1,0,1,0.0007974582411471803
1608,APOA,LDL remodeling,5.2022608660994264e-05,0,0,1,5.800528490483327e-05
1609,APOA,LDL remodeling,4.862033969520205e-05,1,0,1,5.4211750021381346e-05
1610,CD14,Antigen processing-Cross presentation,0.023177005426595444,0,0,1,0.02584239502042767
1611,CD14,Antigen processing-Cross presentation,0.02228820347465187,1,0,1,0.024851379541322827
1612,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.023177005426595444,0,0,1,0.02584239502042767
1613,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.02228820347465187,1,0,1,0.024851379541322827
1614,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.023177005426595444,0,0,1,0.02584239502042767
1615,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.02228820347465187,1,0,1,0.024851379541322827
1616,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.023177005426595444,0,0,1,0.02584239502042767
1617,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.02228820347465187,1,0,1,0.024851379541322827
1618,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.023177005426595444,0,0,1,0.02584239502042767
1619,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.02228820347465187,1,0,1,0.024851379541322827
1620,CD14,Regulation of TLR by endogenous ligand,0.023177005426595444,0,0,1,0.02584239502042767
1621,CD14,Regulation of TLR by endogenous ligand,0.02228820347465187,1,0,1,0.024851379541322827
1622,CD14,Caspase activation via Death Receptors in the presence of ligand,0.023177005426595444,0,0,1,0.02584239502042767
1623,CD14,Caspase activation via Death Receptors in the presence of ligand,0.02228820347465187,1,0,1,0.024851379541322827
1624,CD14,MyD88 deficiency (TLR2/4),0.023177005426595444,0,0,1,0.02584239502042767
1625,CD14,MyD88 deficiency (TLR2/4),0.02228820347465187,1,0,1,0.024851379541322827
1626,CD14,IRAK4 deficiency (TLR2/4),0.023177005426595444,0,0,1,0.02584239502042767
1627,CD14,IRAK4 deficiency (TLR2/4),0.02228820347465187,1,0,1,0.024851379541322827
1628,CD14,Neutrophil degranulation,0.023177005426595444,0,0,1,0.02584239502042767
1629,CD14,Neutrophil degranulation,0.02228820347465187,1,0,1,0.024851379541322827
1630,CFAH,Regulation of Complement cascade,0.00894125902097818,0,0,1,0.009969516913299626
1631,CFAH,Regulation of Complement cascade,0.009646414767466959,1,0,1,0.010755766604158175
1632,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.012133440649631136,0,0,1,0.013528804107923183
1633,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.014060399789995678,1,0,1,0.015677366373710214
1634,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.012133440649631136,0,0,1,0.013528804107923183
1635,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.014060399789995678,1,0,1,0.015677366373710214
1636,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.012133440649631136,0,0,1,0.013528804107923183
1637,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.014060399789995678,1,0,1,0.015677366373710214
1638,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.012133440649631136,0,0,1,0.013528804107923183
1639,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.014060399789995678,1,0,1,0.015677366373710214
1640,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.012133440649631136,0,0,1,0.013528804107923183
1641,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.014060399789995678,1,0,1,0.015677366373710214
1642,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.012133440649631136,0,0,1,0.013528804107923183
1643,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.014060399789995678,1,0,1,0.015677366373710214
1644,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.012133440649631136,0,0,1,0.013528804107923183
1645,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.014060399789995678,1,0,1,0.015677366373710214
1646,SAA1,TRAF6 mediated NF-kB activation,0.012133440649631136,0,0,1,0.013528804107923183
1647,SAA1,TRAF6 mediated NF-kB activation,0.014060399789995678,1,0,1,0.015677366373710214
1648,SAA1,Class A/1 (Rhodopsin-like receptors),0.012133440649631136,0,0,1,0.013528804107923183
1649,SAA1,Class A/1 (Rhodopsin-like receptors),0.014060399789995678,1,0,1,0.015677366373710214
1650,SAA1,G alpha (q) signalling events,0.012133440649631136,0,0,1,0.013528804107923183
1651,SAA1,G alpha (q) signalling events,0.014060399789995678,1,0,1,0.015677366373710214
1652,SAA1,G alpha (i) signalling events,0.012133440649631136,0,0,1,0.013528804107923183
1653,SAA1,G alpha (i) signalling events,0.014060399789995678,1,0,1,0.015677366373710214
1654,SAA1,Interleukin-1 family signaling,0.012133440649631136,0,0,1,0.013528804107923183
1655,SAA1,Interleukin-1 family signaling,0.014060399789995678,1,0,1,0.015677366373710214
1656,SAA1,Interleukin-4 and Interleukin-13 signaling,0.012133440649631136,0,0,1,0.013528804107923183
1657,SAA1,Interleukin-4 and Interleukin-13 signaling,0.014060399789995678,1,0,1,0.015677366373710214
1658,SAA1,Advanced glycosylation endproduct receptor signaling,0.012133440649631136,0,0,1,0.013528804107923183
1659,SAA1,Advanced glycosylation endproduct receptor signaling,0.014060399789995678,1,0,1,0.015677366373710214
1660,SAA1,Scavenging by Class B Receptors,0.012133440649631136,0,0,1,0.013528804107923183
1661,SAA1,Scavenging by Class B Receptors,0.014060399789995678,1,0,1,0.015677366373710214
1662,SAA1,Amyloid fiber formation,0.012133440649631136,0,0,1,0.013528804107923183
1663,SAA1,Amyloid fiber formation,0.014060399789995678,1,0,1,0.015677366373710214
1664,CO7,Terminal pathway of complement,0.007642260515219014,0,0,1,0.008521131675478815
1665,CO7,Terminal pathway of complement,0.008572378145078524,1,0,1,0.009558214196014955
1666,CO7,Regulation of Complement cascade,0.007642260515219014,0,0,1,0.008521131675478815
1667,CO7,Regulation of Complement cascade,0.008572378145078524,1,0,1,0.009558214196014955
1668,MBL2,Initial triggering of complement,0.0009502109579755411,0,0,1,0.0010594866108356437
1669,MBL2,Initial triggering of complement,0.001123592013184281,1,0,1,0.0012528067415122925
1670,MBL2,SARS-CoV-2 Infection,0.0009502109579755411,0,0,1,0.0010594866108356437
1671,MBL2,SARS-CoV-2 Infection,0.001123592013184281,1,0,1,0.0012528067415122925
1672,CO6,Terminal pathway of complement,0.0021730416281940156,0,0,1,0.0024229446003918944
1673,CO6,Terminal pathway of complement,0.002413846550196208,1,0,1,0.0026914424413641844
1674,CO6,Regulation of Complement cascade,0.0021730416281940156,0,0,1,0.0024229446003918944
1675,CO6,Regulation of Complement cascade,0.002413846550196208,1,0,1,0.0026914424413641844
1676,CBPN,Regulation of Complement cascade,0.002492633659429854,0,0,1,0.002779290183635372
1677,CBPN,Regulation of Complement cascade,0.002693103538595917,1,0,1,0.0030028143927276333
1678,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.01147975714834164,0,0,1,0.012799946045903008
1679,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.011440218104608033,1,0,1,0.012755859954188962
1680,LBP,Regulation of TLR by endogenous ligand,0.01147975714834164,0,0,1,0.012799946045903008
1681,LBP,Regulation of TLR by endogenous ligand,0.011440218104608033,1,0,1,0.012755859954188962
1682,LBP,Interleukin-4 and Interleukin-13 signaling,0.01147975714834164,0,0,1,0.012799946045903008
1683,LBP,Interleukin-4 and Interleukin-13 signaling,0.011440218104608033,1,0,1,0.012755859954188962
1684,A1AG2,Platelet degranulation ,0.009192186870048852,0,0,1,0.010249301832790112
1685,A1AG2,Platelet degranulation ,0.009546343950131346,1,0,1,0.010644187496158464
1686,A1AG2,Neutrophil degranulation,0.009192186870048852,0,0,1,0.010249301832790112
1687,A1AG2,Neutrophil degranulation,0.009546343950131346,1,0,1,0.010644187496158464
1688,CPN2,Regulation of Complement cascade,0.0041897235877370615,0,0,1,0.004671547941066739
1689,CPN2,Regulation of Complement cascade,0.0045185736271060395,1,0,1,0.005038216216947825
1690,HV102,Initial triggering of complement,0.016265476674373145,0,0,1,0.018136030331699676
1691,HV102,Initial triggering of complement,0.016367484181377793,1,0,1,0.018249768851518904
1692,HV102,Regulation of Complement cascade,0.016265476674373145,0,0,1,0.018136030331699676
1693,HV102,Regulation of Complement cascade,0.016367484181377793,1,0,1,0.018249768851518904
1694,HV102,FCGR activation,0.016265476674373145,0,0,1,0.018136030331699676
1695,HV102,FCGR activation,0.016367484181377793,1,0,1,0.018249768851518904
1696,HV102,Regulation of actin dynamics for phagocytic cup formation,0.016265476674373145,0,0,1,0.018136030331699676
1697,HV102,Regulation of actin dynamics for phagocytic cup formation,0.016367484181377793,1,0,1,0.018249768851518904
1698,HV102,Role of phospholipids in phagocytosis,0.016265476674373145,0,0,1,0.018136030331699676
1699,HV102,Role of phospholipids in phagocytosis,0.016367484181377793,1,0,1,0.018249768851518904
1700,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.016265476674373145,0,0,1,0.018136030331699676
1701,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.016367484181377793,1,0,1,0.018249768851518904
1702,HV102,FCERI mediated MAPK activation,0.016265476674373145,0,0,1,0.018136030331699676
1703,HV102,FCERI mediated MAPK activation,0.016367484181377793,1,0,1,0.018249768851518904
1704,HV102,FCERI mediated Ca+2 mobilization,0.016265476674373145,0,0,1,0.018136030331699676
1705,HV102,FCERI mediated Ca+2 mobilization,0.016367484181377793,1,0,1,0.018249768851518904
1706,HV102,FCERI mediated NF-kB activation,0.016265476674373145,0,0,1,0.018136030331699676
1707,HV102,FCERI mediated NF-kB activation,0.016367484181377793,1,0,1,0.018249768851518904
1708,HV102,Parasite infection,0.016265476674373145,0,0,1,0.018136030331699676
1709,HV102,Parasite infection,0.016367484181377793,1,0,1,0.018249768851518904
1710,HV102,Leishmania parasite growth and survival,0.016265476674373145,0,0,1,0.018136030331699676
1711,HV102,Leishmania parasite growth and survival,0.016367484181377793,1,0,1,0.018249768851518904
1712,HV102,Potential therapeutics for SARS,0.016265476674373145,0,0,1,0.018136030331699676
1713,HV102,Potential therapeutics for SARS,0.016367484181377793,1,0,1,0.018249768851518904
1714,HV102,CD22 mediated BCR regulation,0.016265476674373145,0,0,1,0.018136030331699676
1715,HV102,CD22 mediated BCR regulation,0.016367484181377793,1,0,1,0.018249768851518904
1716,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.016265476674373145,0,0,1,0.018136030331699676
1717,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.016367484181377793,1,0,1,0.018249768851518904
1718,HV102,Cell surface interactions at the vascular wall,0.016265476674373145,0,0,1,0.018136030331699676
1719,HV102,Cell surface interactions at the vascular wall,0.016367484181377793,1,0,1,0.018249768851518904
1720,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.016265476674373145,0,0,1,0.018136030331699676
1721,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.016367484181377793,1,0,1,0.018249768851518904
1722,HV102,Scavenging of heme from plasma,0.016265476674373145,0,0,1,0.018136030331699676
1723,HV102,Scavenging of heme from plasma,0.016367484181377793,1,0,1,0.018249768851518904
1724,FBLN1,Molecules associated with elastic fibres,0.0011180464776033867,0,0,1,0.0012466234612116866
1725,FBLN1,Molecules associated with elastic fibres,0.0014524569054676284,1,0,1,0.0016194915784146697
1726,ZA2G,Miscellaneous transport and binding events,0.026713051658366984,0,0,1,0.029785091751519475
1727,ZA2G,Miscellaneous transport and binding events,0.027547706292240286,1,0,1,0.030715732891614018
1728,PON1,Arachidonic acid metabolism,0.0002073944962465644,0,0,1,0.00023124516728620395
1729,PON1,Arachidonic acid metabolism,0.00030951692831682214,1,0,1,0.0003451118287220277
1730,PON1,Atorvastatin ADME,0.0002073944962465644,0,0,1,0.00023124516728620395
1731,PON1,Atorvastatin ADME,0.00030951692831682214,1,0,1,0.0003451118287220277
1732,PROP,Initial triggering of complement,0.01088231828970224,0,0,1,0.012133800842873615
1733,PROP,Initial triggering of complement,0.01097357594836815,1,0,1,0.012235553266039449
1734,PROP,Activation of C3 and C5,0.01088231828970224,0,0,1,0.012133800842873615
1735,PROP,Activation of C3 and C5,0.01097357594836815,1,0,1,0.012235553266039449
1736,PROP,Regulation of Complement cascade,0.01088231828970224,0,0,1,0.012133800842873615
1737,PROP,Regulation of Complement cascade,0.01097357594836815,1,0,1,0.012235553266039449
1738,PROP,Diseases associated with O-glycosylation of proteins,0.01088231828970224,0,0,1,0.012133800842873615
1739,PROP,Diseases associated with O-glycosylation of proteins,0.01097357594836815,1,0,1,0.012235553266039449
1740,PROP,O-glycosylation of TSR domain-containing proteins,0.01088231828970224,0,0,1,0.012133800842873615
1741,PROP,O-glycosylation of TSR domain-containing proteins,0.01097357594836815,1,0,1,0.012235553266039449
1742,PROP,Neutrophil degranulation,0.01088231828970224,0,0,1,0.012133800842873615
1743,PROP,Neutrophil degranulation,0.01097357594836815,1,0,1,0.012235553266039449
1744,KAIN,Platelet degranulation ,0.0002518550537239264,0,0,1,0.0002808187540378378
1745,KAIN,Platelet degranulation ,0.00024072083514340068,1,0,1,0.0002684040840014941
1746,BLVRB,Cytoprotection by HMOX1,3.721721458694068e-05,0,0,1,4.14972488124849e-05
1747,BLVRB,Cytoprotection by HMOX1,3.950711077557907e-05,1,0,1,4.405048641904216e-05
1748,BLVRB,Heme degradation,3.721721458694068e-05,0,0,1,4.14972488124849e-05
1749,BLVRB,Heme degradation,3.950711077557907e-05,1,0,1,4.405048641904216e-05
1750,PRDX2,Transcriptional Regulation by TP53,0.0037191495595207055,0,0,1,0.004146857209900643
1751,PRDX2,Transcriptional Regulation by TP53,0.002857376731189274,1,0,1,0.003185979243239036
1752,PRDX2,Neurodegenerative Diseases,0.0037191495595207055,0,0,1,0.004146857209900643
1753,PRDX2,Neurodegenerative Diseases,0.002857376731189274,1,0,1,0.003185979243239036
1754,PRDX2,Detoxification of Reactive Oxygen Species,0.0037191495595207055,0,0,1,0.004146857209900643
1755,PRDX2,Detoxification of Reactive Oxygen Species,0.002857376731189274,1,0,1,0.003185979243239036
1756,MASP1,Initial triggering of complement,0.005283107255142199,0,0,1,0.005890672332759909
1757,MASP1,Initial triggering of complement,0.005295793132400994,1,0,1,0.005904817104496738
1758,MASP1,SARS-CoV-2 Infection,0.005283107255142199,0,0,1,0.005890672332759909
1759,MASP1,SARS-CoV-2 Infection,0.005295793132400994,1,0,1,0.005904817104496738
1760,MASP1,Scavenging by Class A Receptors,0.005283107255142199,0,0,1,0.005890672332759909
1761,MASP1,Scavenging by Class A Receptors,0.005295793132400994,1,0,1,0.005904817104496738
1762,LUM,Keratan sulfate/keratin metabolism,0.0077471456208309825,0,0,1,0.008638078721962808
1763,LUM,Keratan sulfate/keratin metabolism,0.006974815996732852,1,0,1,0.00777693005911529
1764,LUM,Diseases associated with glycosaminoglycan metabolism,0.0077471456208309825,0,0,1,0.008638078721962808
1765,LUM,Diseases associated with glycosaminoglycan metabolism,0.006974815996732852,1,0,1,0.00777693005911529
1766,LUM,Integrin cell surface interactions,0.0077471456208309825,0,0,1,0.008638078721962808
1767,LUM,Integrin cell surface interactions,0.006974815996732852,1,0,1,0.00777693005911529
1768,LUM,ECM proteoglycans,0.0077471456208309825,0,0,1,0.008638078721962808
1769,LUM,ECM proteoglycans,0.006974815996732852,1,0,1,0.00777693005911529
1770,APOC4,VLDL assembly,0.0003266854345227547,0,0,1,0.0003642547383049567
1771,APOC4,VLDL assembly,0.000465381725591143,1,0,1,0.0005189013061287969
1772,APOC4,VLDL clearance,0.0003266854345227547,0,0,1,0.0003642547383049567
1773,APOC4,VLDL clearance,0.000465381725591143,1,0,1,0.0005189013061287969
1774,APOC4,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0003266854345227547,0,0,1,0.0003642547383049567
1775,APOC4,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.000465381725591143,1,0,1,0.0005189013061287969
1776,TYB4,Platelet degranulation ,0.0008003155918420954,0,0,1,0.000892353057900149
1777,TYB4,Platelet degranulation ,0.0007668334295848802,1,0,1,0.0008550203979096511
1778,HBB,Cytoprotection by HMOX1,0.002507623653693089,0,0,1,0.0027960040492092195
1779,HBB,Cytoprotection by HMOX1,0.0017876721432066797,1,0,1,0.0019932570598076493
1780,HBB,Factors involved in megakaryocyte development and platelet production,0.002507623653693089,0,0,1,0.0027960040492092195
1781,HBB,Factors involved in megakaryocyte development and platelet production,0.0017876721432066797,1,0,1,0.0019932570598076493
1782,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.002507623653693089,0,0,1,0.0027960040492092195
1783,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.0017876721432066797,1,0,1,0.0019932570598076493
1784,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.002507623653693089,0,0,1,0.0027960040492092195
1785,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.0017876721432066797,1,0,1,0.0019932570598076493
1786,HBB,Neutrophil degranulation,0.002507623653693089,0,0,1,0.0027960040492092195
1787,HBB,Neutrophil degranulation,0.0017876721432066797,1,0,1,0.0019932570598076493
1788,HBB,Scavenging of heme from plasma,0.002507623653693089,0,0,1,0.0027960040492092195
1789,HBB,Scavenging of heme from plasma,0.0017876721432066797,1,0,1,0.0019932570598076493
1790,HBB,Heme signaling,0.002507623653693089,0,0,1,0.0027960040492092195
1791,HBB,Heme signaling,0.0017876721432066797,1,0,1,0.0019932570598076493
1792,HBB,Chaperone Mediated Autophagy,0.002507623653693089,0,0,1,0.0027960040492092195
1793,HBB,Chaperone Mediated Autophagy,0.0017876721432066797,1,0,1,0.0019932570598076493
1794,HBB,Late endosomal microautophagy,0.002507623653693089,0,0,1,0.0027960040492092195
1795,HBB,Late endosomal microautophagy,0.0017876721432066797,1,0,1,0.0019932570598076493
1796,HBA,Cytoprotection by HMOX1,0.009593541441709326,0,0,1,0.010696812768443722
1797,HBA,Cytoprotection by HMOX1,0.008158622452723833,1,0,1,0.009096875992611381
1798,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.009593541441709326,0,0,1,0.010696812768443722
1799,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.008158622452723833,1,0,1,0.009096875992611381
1800,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.009593541441709326,0,0,1,0.010696812768443722
1801,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.008158622452723833,1,0,1,0.009096875992611381
1802,HBA,Scavenging of heme from plasma,0.009593541441709326,0,0,1,0.010696812768443722
1803,HBA,Scavenging of heme from plasma,0.008158622452723833,1,0,1,0.009096875992611381
1804,HBA,Heme signaling,0.009593541441709326,0,0,1,0.010696812768443722
1805,HBA,Heme signaling,0.008158622452723833,1,0,1,0.009096875992611381
1806,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,3.491066581113734e-05,0,0,1,3.892544354683158e-05
1807,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.00016438622858071754,1,0,1,0.00018329088580298285
1808,LV321,Initial triggering of complement,0.004504087951247905,0,0,1,0.005022064667134826
1809,LV321,Initial triggering of complement,0.003992831795520647,1,0,1,0.00445201330416762
1810,LV321,Regulation of Complement cascade,0.004504087951247905,0,0,1,0.005022064667134826
1811,LV321,Regulation of Complement cascade,0.003992831795520647,1,0,1,0.00445201330416762
1812,LV321,FCGR activation,0.004504087951247905,0,0,1,0.005022064667134826
1813,LV321,FCGR activation,0.003992831795520647,1,0,1,0.00445201330416762
1814,LV321,Regulation of actin dynamics for phagocytic cup formation,0.004504087951247905,0,0,1,0.005022064667134826
1815,LV321,Regulation of actin dynamics for phagocytic cup formation,0.003992831795520647,1,0,1,0.00445201330416762
1816,LV321,Role of phospholipids in phagocytosis,0.004504087951247905,0,0,1,0.005022064667134826
1817,LV321,Role of phospholipids in phagocytosis,0.003992831795520647,1,0,1,0.00445201330416762
1818,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.004504087951247905,0,0,1,0.005022064667134826
1819,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.003992831795520647,1,0,1,0.00445201330416762
1820,LV321,FCERI mediated MAPK activation,0.004504087951247905,0,0,1,0.005022064667134826
1821,LV321,FCERI mediated MAPK activation,0.003992831795520647,1,0,1,0.00445201330416762
1822,LV321,FCERI mediated Ca+2 mobilization,0.004504087951247905,0,0,1,0.005022064667134826
1823,LV321,FCERI mediated Ca+2 mobilization,0.003992831795520647,1,0,1,0.00445201330416762
1824,LV321,FCERI mediated NF-kB activation,0.004504087951247905,0,0,1,0.005022064667134826
1825,LV321,FCERI mediated NF-kB activation,0.003992831795520647,1,0,1,0.00445201330416762
1826,LV321,Parasite infection,0.004504087951247905,0,0,1,0.005022064667134826
1827,LV321,Parasite infection,0.003992831795520647,1,0,1,0.00445201330416762
1828,LV321,Leishmania parasite growth and survival,0.004504087951247905,0,0,1,0.005022064667134826
1829,LV321,Leishmania parasite growth and survival,0.003992831795520647,1,0,1,0.00445201330416762
1830,LV321,Potential therapeutics for SARS,0.004504087951247905,0,0,1,0.005022064667134826
1831,LV321,Potential therapeutics for SARS,0.003992831795520647,1,0,1,0.00445201330416762
1832,LV321,CD22 mediated BCR regulation,0.004504087951247905,0,0,1,0.005022064667134826
1833,LV321,CD22 mediated BCR regulation,0.003992831795520647,1,0,1,0.00445201330416762
1834,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004504087951247905,0,0,1,0.005022064667134826
1835,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003992831795520647,1,0,1,0.00445201330416762
1836,LV321,Cell surface interactions at the vascular wall,0.004504087951247905,0,0,1,0.005022064667134826
1837,LV321,Cell surface interactions at the vascular wall,0.003992831795520647,1,0,1,0.00445201330416762
1838,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004504087951247905,0,0,1,0.005022064667134826
1839,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003992831795520647,1,0,1,0.00445201330416762
1840,LV321,Scavenging of heme from plasma,0.004504087951247905,0,0,1,0.005022064667134826
1841,LV321,Scavenging of heme from plasma,0.003992831795520647,1,0,1,0.00445201330416762
1842,FHR1,Regulation of Complement cascade,0.00011426877108839661,0,0,1,0.00012740984724353768
1843,FHR1,Regulation of Complement cascade,0.00012347659224058038,1,0,1,0.0001376765813238229
1844,LG3BP,Platelet degranulation ,0.0015595856823138702,0,0,1,0.0017389403216133503
1845,LG3BP,Platelet degranulation ,0.0014885923309056863,1,0,1,0.0016597826307406076
1846,APOF,LDL remodeling,8.117082589396083e-05,0,0,1,9.050558984117329e-05
1847,APOF,LDL remodeling,7.632138061425611e-05,1,0,1,8.509845124663025e-05
1848,ITIH4,Platelet degranulation ,0.0005217183096643233,0,0,1,0.0005817166799410693
1849,ITIH4,Platelet degranulation ,0.0004977778085211241,1,0,1,0.0005550229860775979
1850,PCOC1,Crosslinking of collagen fibrils,0.00034586459352644,0,0,1,0.0003856395287043277
1851,PCOC1,Crosslinking of collagen fibrils,0.0004205596799003279,1,0,1,0.0004689246594893415
1852,PCOC1,Collagen biosynthesis and modifying enzymes,0.00034586459352644,0,0,1,0.0003856395287043277
1853,PCOC1,Collagen biosynthesis and modifying enzymes,0.0004205596799003279,1,0,1,0.0004689246594893415
1854,PON3,Arachidonic acid metabolism,0.0026353930942971783,0,0,1,0.0029384671627502414
1855,PON3,Arachidonic acid metabolism,0.0014498774690066872,1,0,1,0.0016166155029801253
1856,PON3,Atorvastatin ADME,0.0026353930942971783,0,0,1,0.0029384671627502414
1857,PON3,Atorvastatin ADME,0.0014498774690066872,1,0,1,0.0016166155029801253
1858,FCN2,Initial triggering of complement,0.00027268958336716377,0,0,1,0.0003040492851265316
1859,FCN2,Initial triggering of complement,0.0002866308403409322,1,0,1,0.0003195938070855248
1860,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.0089446191845924,0,0,1,0.009973263500654361
1861,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.010088713522600566,1,0,1,0.01124893036439487
1862,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.0089446191845924,0,0,1,0.009973263500654361
1863,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.010088713522600566,1,0,1,0.01124893036439487
1864,FHR5,Regulation of Complement cascade,0.001035578804484188,0,0,1,0.0011546718848136268
1865,FHR5,Regulation of Complement cascade,0.0011147258824891599,1,0,1,0.0012429209927924368
1866,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.015651806983235407,0,1,2,0.34817190950495475
1867,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.01046550759260416,1,1,2,0.23280352015319694
1868,Nuclear signaling by ERBB4,Signaling by ERBB4,0.0028568350688999464,0,1,2,0.06354983307326753
1869,Nuclear signaling by ERBB4,Signaling by ERBB4,0.0036695776089393922,1,1,2,0.08162915914753702
1870,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.006349390659431716,0,1,2,0.14124116611296797
1871,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.005782744161935791,1,1,2,0.12863620661795455
1872,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.0060760183307353305,0,1,2,0.1351600429691684
1873,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.00517666890026686,1,1,2,0.11515416065450713
1874,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.0034162441792971033,0,1,2,0.07599379806530099
1875,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.002553915905765363,1,1,2,0.05681144538632652
1876,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.0005734159657376782,0,1,2,0.012755545218859179
1877,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.0004997302869785701,1,1,2,0.011116419237801106
1878,Initial triggering of complement,Complement cascade,0.0017424499512909276,0,1,2,0.03876051675104235
1879,Initial triggering of complement,Complement cascade,0.0019692094166729778,1,1,2,0.04380474430540432
1880,Terminal pathway of complement,Complement cascade,0.004686901377823005,0,1,2,0.10425936149902082
1881,Terminal pathway of complement,Complement cascade,0.005284226000837965,1,1,2,0.11754675092390982
1882,Activation of C3 and C5,Complement cascade,0.0032893231072714493,0,1,2,0.07317045938939475
1883,Activation of C3 and C5,Complement cascade,0.0037069724710995663,1,1,2,0.08246100179534938
1884,Regulation of Complement cascade,Complement cascade,0.01593620733937416,0,1,2,0.3544983493317926
1885,Regulation of Complement cascade,Complement cascade,0.017864653932092404,1,1,2,0.3973963312251421
1886,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.00018032486885523693,0,1,2,0.004011297480719393
1887,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.0001570678022477101,1,1,2,0.003493947803528785
1888,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,1.5352283169346872e-05,0,1,2,0.00034150905081167555
1889,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,1.3310707426716593e-05,1,1,2,0.0002960945293144493
1890,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.00015761437425148068,0,1,2,0.0035061062091645417
1891,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.00013664204712360715,1,1,2,0.0030395801913893797
1892,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.000402812681434081,0,1,2,0.008960502810821407
1893,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.00034921250137660256,1,1,2,0.007768175492933414
1894,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.00041072290380520594,0,1,2,0.009136464425382162
1895,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.00035777647180319517,1,1,2,0.007958679627028883
1896,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.005030845588487261,0,1,2,0.11191034471894003
1897,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.00438619826741822,1,1,2,0.09757026954587746
1898,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.0013847730497102597,0,1,2,0.030804052047475293
1899,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.0012041150174087276,1,1,2,0.026785343399892032
1900,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.001312619456071708,0,1,2,0.0291990070516044
1901,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.001689056519608977,1,1,2,0.037572788517258295
1902,RHO GTPase Effectors,Signaling by Rho GTPases,0.004430783023755312,0,1,2,0.09856205022432085
1903,RHO GTPase Effectors,Signaling by Rho GTPases,0.004361144332082591,1,1,2,0.09701294881506582
1904,Metabolism of steroid hormones,Metabolism of steroids,2.2382038182275382e-05,0,1,2,0.0004978848116950626
1905,Metabolism of steroid hormones,Metabolism of steroids,0.000368705621963777,1,1,2,0.008201796800959787
1906,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,6.028615795079918e-05,0,1,2,0.0013410558124649322
1907,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,3.966062365485636e-05,1,1,2,0.0008822441450280584
1908,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.000340063993996467,0,1,2,0.007564668429047838
1909,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.00038209957923313856,1,1,2,0.00849974320953078
1910,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.001962026655850829,0,1,2,0.04364496495509393
1911,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.002196530589240955,1,1,2,0.04886146694507601
1912,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.00030398567221314354,0,1,2,0.006762112008534318
1913,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.00034009672889923477,1,1,2,0.007565396611654252
1914,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.00011081040451128416,0,1,2,0.002464959488258084
1915,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.00010457067283589239,1,1,2,0.002326157668471611
1916,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.002247092752154994,0,1,2,0.04998621406400851
1917,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.002106426972024599,1,1,2,0.04685712658404778
1918,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.012094633050472396,0,1,2,0.2690431519156292
1919,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.011195816623451758,1,1,2,0.24904912617627603
1920,FOXO-mediated transcription,Generic Transcription Pathway,0.0005377410302512088,0,1,2,0.011961962061138526
1921,FOXO-mediated transcription,Generic Transcription Pathway,0.0005058256151450166,1,1,2,0.011252008824935942
1922,Arachidonic acid metabolism,Fatty acid metabolism,0.0002683430772697011,0,1,2,0.005969248260951561
1923,Arachidonic acid metabolism,Fatty acid metabolism,0.00013568165069135813,1,1,2,0.003018216328414578
1924,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.0015960207859642501,0,1,2,0.03550322370151694
1925,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.0015456292845447606,1,1,2,0.03438227291986996
1926,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.0007008757443952999,0,1,2,0.015590867336480232
1927,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.0006780632082123515,1,1,2,0.015083406166535102
1928,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.0002891556012901873,0,1,2,0.0064322194845037005
1929,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.00027962584926134916,1,1,2,0.0062202316951996805
1930,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.00019439675571490255,0,1,2,0.004324324323148207
1931,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.00018854605653320227,1,1,2,0.004194176468129708
1932,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.0011483851961904968,0,1,2,0.02554564255955428
1933,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.0013712081425403411,1,1,2,0.030502302886073883
1934,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.00985314868605831,0,1,2,0.2191816955279125
1935,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.01229759542295719,1,1,2,0.27355801699551274
1936,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.00504484653661371,0,1,2,0.11222179354074616
1937,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.00598799157675577,1,1,2,0.1332019020942257
1938,G alpha (q) signalling events,GPCR downstream signalling,0.0021775664440213693,0,1,2,0.04843961260836558
1939,G alpha (q) signalling events,GPCR downstream signalling,0.002983486963592631,1,1,2,0.06636718394303001
1940,G alpha (i) signalling events,GPCR downstream signalling,0.00250760613493995,0,1,2,0.05578129204017991
1941,G alpha (i) signalling events,GPCR downstream signalling,0.0034197273493535,1,1,2,0.07607128061865506
1942,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.003566858560488081,0,1,2,0.07934419056339005
1943,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.003921577400038465,1,1,2,0.08723485365653466
1944,Adherens junctions interactions,Cell-cell junction organization,0.00022493013840034338,0,1,2,0.00500353447215031
1945,Adherens junctions interactions,Cell-cell junction organization,0.00027729188157674236,1,1,2,0.006168312962343927
1946,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.0011722282322654846,0,1,2,0.026076027032574917
1947,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.0016995453342018416,1,1,2,0.037806110497854706
1948,Interleukin-1 family signaling,Signaling by Interleukins,0.001942333893210564,0,1,2,0.04320690264195444
1949,Interleukin-1 family signaling,Signaling by Interleukins,0.002022662088370519,1,1,2,0.044993790323733594
1950,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.009809509181222085,0,1,2,0.21821094181589998
1951,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.010232287017820923,1,1,2,0.22761556626741897
1952,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.00674100486295734,0,1,2,0.1499525605977595
1953,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.005520877759073966,1,1,2,0.12281103092947002
1954,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.009232005678238266,0,1,2,0.20536446999350638
1955,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.008500367874524628,1,1,2,0.18908930563338905
1956,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0048147626481001545,0,1,2,0.10710361473264471
1957,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.004109760421067858,1,1,2,0.09142095445872275
1958,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0009573284167148256,0,1,2,0.021295615466506084
1959,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0008155005950467551,1,1,2,0.018140678560882882
1960,Defective ABCA1 causes TGD,ABC transporter disorders,0.0024787710652416305,0,1,2,0.0551398605883146
1961,Defective ABCA1 causes TGD,ABC transporter disorders,0.0035318162895294956,1,1,2,0.07856468092555022
1962,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.0014811825693421274,0,1,2,0.032948666185679036
1963,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.0017336599251160636,1,1,2,0.03856498404346559
1964,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,0.00028764048935577,0,1,2,0.006398516065091179
1965,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,0.00033691596202575015,1,1,2,0.007494640968090703
1966,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.0001615290600418404,0,1,2,0.003593187760080761
1967,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.00015827442326951684,1,1,2,0.003520788892590339
1968,Signaling by RAS mutants,Oncogenic MAPK signaling,0.0009865620613682849,0,1,2,0.02194591315364765
1969,Signaling by RAS mutants,Oncogenic MAPK signaling,0.0015893196490190757,1,1,2,0.035354157996288486
1970,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0004936822457084967,0,1,2,0.010981881540011854
1971,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.00079530558697418,1,1,2,0.017691443879505348
1972,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0012954588452873303,0,1,2,0.028817272046089207
1973,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0020880623523692778,1,1,2,0.046448608596343616
1974,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.0014344029239498584,0,1,2,0.031908060555949753
1975,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.002310585376094661,1,1,2,0.051398597192693386
1976,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.0015611016985532346,0,1,2,0.034726454261727276
1977,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.002515139631473447,1,1,2,0.05594887344954217
1978,Signaling by RAF1 mutants,Oncogenic MAPK signaling,2.995996840983824e-06,0,1,2,6.664546413800236e-05
1979,Signaling by RAF1 mutants,Oncogenic MAPK signaling,4.828015996254686e-06,1,1,2,0.00010739843331424617
1980,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.010535921517522664,0,1,2,0.23436986650035496
1981,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.01146320547296644,1,1,2,0.25499714779547794
1982,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,8.162194452802164e-05,0,1,2,0.001815666926781534
1983,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,8.647319078840163e-06,1,1,2,0.0001923582113556098
1984,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.011884597871081294,0,1,2,0.2643709533924719
1985,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.012129346456787846,1,1,2,0.2698153460127847
1986,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.0027754662957321973,0,1,2,0.06173979790236138
1987,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.003091856552729217,1,1,2,0.06877784788888407
1988,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.0018319188113211826,0,1,2,0.04075073704134689
1989,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.0017176547482219326,1,1,2,0.03820895147756678
1990,VLDL assembly,Plasma lipoprotein assembly,0.00030632118056737813,0,1,2,0.00681406501333623
1991,VLDL assembly,Plasma lipoprotein assembly,0.00031425862370428097,1,1,2,0.006990632149419786
1992,Chylomicron assembly,Plasma lipoprotein assembly,0.003330898881170084,0,1,2,0.07409530574118905
1993,Chylomicron assembly,Plasma lipoprotein assembly,0.00343769906132074,1,1,2,0.07647105843852015
1994,HDL assembly,Plasma lipoprotein assembly,0.004230151396928821,0,1,2,0.0940990322038402
1995,HDL assembly,Plasma lipoprotein assembly,0.004348476989056232,1,1,2,0.09673116582256114
1996,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.007126287638688726,0,1,2,0.1585231134974629
1997,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.008456340296593827,1,1,2,0.1881099192982864
1998,Chylomicron remodeling,Plasma lipoprotein remodeling,0.0013143058330010063,0,1,2,0.029236520233069503
1999,Chylomicron remodeling,Plasma lipoprotein remodeling,0.0015564051037367135,1,1,2,0.03462197927125552
2000,LDL remodeling,Plasma lipoprotein remodeling,0.0003545577738227449,0,1,2,0.00788708021213874
2001,LDL remodeling,Plasma lipoprotein remodeling,0.0004199487038594935,1,1,2,0.00934169085227669
2002,HDL remodeling,Plasma lipoprotein remodeling,0.003197226595869601,0,1,2,0.07112178742021756
2003,HDL remodeling,Plasma lipoprotein remodeling,0.003774447672654136,1,1,2,0.08396197671758356
2004,HDL clearance,Plasma lipoprotein clearance,7.362844362360139e-05,0,1,2,0.0016378527947453695
2005,HDL clearance,Plasma lipoprotein clearance,0.00011169760598747034,1,1,2,0.0024846951412986706
2006,Chylomicron clearance,Plasma lipoprotein clearance,0.00023858206758226055,0,1,2,0.005307219424104143
2007,Chylomicron clearance,Plasma lipoprotein clearance,0.0003598662209666826,1,1,2,0.008005165758465153
2008,LDL clearance,Plasma lipoprotein clearance,0.000621239094260061,0,1,2,0.013819362961690621
2009,LDL clearance,Plasma lipoprotein clearance,0.0009367854283205614,1,1,2,0.02083864001927305
2010,VLDL clearance,Plasma lipoprotein clearance,0.0008051790654306604,0,1,2,0.017911077807481263
2011,VLDL clearance,Plasma lipoprotein clearance,0.0012138556415555992,1,1,2,0.027002022005283656
2012,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.00038919057673885137,0,1,2,0.008657481299740002
2013,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.001258133262356949,1,1,2,0.02798697050351485
2014,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.001484154814587656,0,1,2,0.03301478329942579
2015,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0018426284637038993,1,1,2,0.04098897152278527
2016,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0022507396380428454,0,1,2,0.05006733844949831
2017,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0027940368743563024,1,1,2,0.06215289741394442
2018,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.002400337872352871,0,1,2,0.05339512692491717
2019,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0029790972316616387,1,1,2,0.06626953506771066
2020,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.00127189724573436,0,1,2,0.02829314808288576
2021,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.001577645501679882,1,1,2,0.035094468480868134
2022,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0026069354043045142,0,1,2,0.05799085553795591
2023,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0032271361199860725,1,1,2,0.07178711993646762
2024,Parasite infection,Leishmania infection,0.002706953584731317,0,1,2,0.06021574375065303
2025,Parasite infection,Leishmania infection,0.0034121756249512543,1,1,2,0.07590329373330686
2026,Cell recruitment (pro-inflammatory response),Leishmania infection,0.0034721826920701957,0,1,2,0.07723814121545201
2027,Cell recruitment (pro-inflammatory response),Leishmania infection,0.004382466916412218,1,1,2,0.09748726624752445
2028,Leishmania parasite growth and survival,Leishmania infection,0.00596066902046456,0,1,2,0.13259411625795411
2029,Leishmania parasite growth and survival,Leishmania infection,0.007522902524464056,1,1,2,0.16734574734839103
2030,Potential therapeutics for SARS,SARS-CoV Infections,0.004749198014150877,0,1,2,0.10564514007712641
2031,Potential therapeutics for SARS,SARS-CoV Infections,0.005288459440354972,1,1,2,0.11764092309981186
2032,SARS-CoV-2 Infection,SARS-CoV Infections,0.0005755863644375087,0,1,2,0.012803825386159763
2033,SARS-CoV-2 Infection,SARS-CoV Infections,0.0006405954895913512,1,1,2,0.01424994283856021
2034,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.00045714952156055376,0,1,2,0.010169217012546684
2035,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.0004707368676500443,1,1,2,0.01047146532407708
2036,Cytoprotection by HMOX1,Cellular response to chemical stress,9.36313389820895e-05,0,1,2,0.002082813959935574
2037,Cytoprotection by HMOX1,Cellular response to chemical stress,9.643160933939812e-05,1,1,2,0.002145105520167473
2038,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.0010653912811542615,0,1,2,0.023699456371185836
2039,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.0010729679364145299,1,1,2,0.02386799783942998
2040,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.002731199039122019,0,1,2,0.06075507995388296
2041,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.002752172763679607,1,1,2,0.06122163705725563
2042,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.011601838786869845,0,1,2,0.2580810233936404
2043,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.011302995734091605,1,1,2,0.25143330812092235
2044,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0014390336468293587,0,1,2,0.03201107023585897
2045,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0020774952161848434,1,1,2,0.046213544364637066
2046,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.003099590472544254,0,1,2,0.06894988768165967
2047,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.003693924470594651,1,1,2,0.08217075113893098
2048,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.003187545726887885,0,1,2,0.07090643805878971
2049,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.00348111771027775,1,1,2,0.07743689924729574
2050,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.005257352843377034,0,1,2,0.11694896189177945
2051,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.004895893343011923,1,1,2,0.10890835389133419
2052,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00573253852401555,0,1,2,0.1275193903397237
2053,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006020666600553768,1,1,2,0.13392875270266055
2054,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.003507660599244966,0,1,2,0.07802734151031317
2055,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.002929071085162894,1,1,2,0.0651567115470591
2056,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.005791913561493814,0,1,2,0.12884017842495102
2057,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.00603119058945028,1,1,2,0.13416285712994055
2058,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.006491229079184282,0,1,2,0.14439633877126304
2059,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.005357866527779476,1,1,2,0.11918487251010362
2060,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.004932713720797028,0,1,2,0.10972741722733527
2061,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0047572563738552676,1,1,2,0.10582439698265562
2062,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.0020440053986617406,0,1,2,0.04546856880184866
2063,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.001491054608996896,1,1,2,0.03316826810774407
2064,Integrin cell surface interactions,Integrin cell surface interactions,0.0028350785102690588,0,1,2,0.06306586195281569
2065,Integrin cell surface interactions,Integrin cell surface interactions,0.002546116445362613,1,1,2,0.05663794765380003
2066,ECM proteoglycans,ECM proteoglycans,0.0023152942246428493,0,1,2,0.051503344765439996
2067,ECM proteoglycans,ECM proteoglycans,0.0023173024823765604,1,1,2,0.05154801813322898
2068,Collagen biosynthesis and modifying enzymes,Collagen biosynthesis and modifying enzymes,9.155523513692262e-06,0,1,2,0.0002036631366393719
2069,Collagen biosynthesis and modifying enzymes,Collagen biosynthesis and modifying enzymes,0.00011573202485970006,1,1,2,0.0025744401352148093
2070,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.0024532516297654018,0,1,2,0.05457218488232334
2071,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.002367586094347972,1,1,2,0.05266656893159013
2072,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.0005529486333603051,0,1,2,0.0123002527274596
2073,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.00024840831761707705,1,1,2,0.005525802763494901
2074,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.0019041216861955847,0,1,2,0.0423568782903218
2075,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.0026316246536501856,1,1,2,0.05854006388802907
2076,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.002329776521830269,0,1,2,0.051825501119090595
2077,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.003211206652190512,1,1,2,0.07143277150719561
2078,Neutrophil degranulation,Neutrophil degranulation,0.01686630033286105,0,1,2,0.375188117222897
2079,Neutrophil degranulation,Neutrophil degranulation,0.017368753632733745,1,1,2,0.3863651094411834
2080,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.0014773319227223546,0,1,2,0.03286300917573309
2081,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.0025958962643894724,1,1,2,0.05774529165976413
2082,Heme degradation,Heme degradation,6.122260406254149e-05,0,1,2,0.0013618869044419184
2083,Heme degradation,Heme degradation,9.719296736462504e-05,1,1,2,0.0021620418060381143
2084,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.00018040844101888017,0,1,2,0.004013156529954301
2085,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.00019474648282520225,1,1,2,0.004332103946033228
2086,Scavenging of heme from plasma,Scavenging of heme from plasma,0.016318657287722946,0,1,2,0.3630058864455133
2087,Scavenging of heme from plasma,Scavenging of heme from plasma,0.010235692650733123,1,1,2,0.22769132401956757
2088,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.0006216462336598833,0,1,2,0.013828419711650717
2089,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.0001366125141176327,1,1,2,0.003038923234458173
2090,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.0031949641694754417,0,1,2,0.07107146011177243
2091,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.0023107197974325715,1,1,2,0.05140158737356826
2092,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.00029130179868552445,0,1,2,0.006479961297708365
2093,Scavenging by Class F Receptors,Scavenging by Class F Receptors,3.627034037462738e-05,1,1,2,0.0008068278429547981
2094,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.0004580119975031866,0,1,2,0.010188402650100877
2095,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.0004075139757613915,1,1,2,0.009065082341148977
2096,Retinoid metabolism and transport,Retinoid metabolism and transport,0.013314230704904274,0,1,2,0.29617290406668306
2097,Retinoid metabolism and transport,Retinoid metabolism and transport,0.01473505102731685,1,1,2,0.3277788218528973
2098,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.013314230704904274,0,1,2,0.29617290406668306
2099,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.01473505102731685,1,1,2,0.3277788218528973
2100,Heme signaling,Heme signaling,0.0043077657751111114,0,1,2,0.0958255514668053
2101,Heme signaling,Heme signaling,0.003947244621066214,1,1,2,0.08780581682816649
2102,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.006036122837912837,0,1,2,0.1342725741975737
2103,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.005357271708839785,1,1,2,0.11917164085919817
2104,Syndecan interactions,Syndecan interactions,0.003752737873969669,0,1,2,0.08347904576456099
2105,Syndecan interactions,Syndecan interactions,0.0030317240744665696,1,1,2,0.06744021065617374
2106,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.006044209876351044,0,1,2,0.13445246905688846
2107,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.007166457051407289,1,1,2,0.15941667557274883
2108,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.0008536267508985102,0,1,2,0.018988788718336733
2109,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.0012627202302226796,1,1,2,0.02808900686023455
2110,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.02328959875891561,0,1,2,0.518073349625456
2111,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.023419032535415156,1,1,2,0.5209525830051261
2112,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.004887269891498053,0,1,2,0.1087165266100929
2113,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.00623157533958096,1,1,2,0.13862038341833655
2114,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.020804548809272044,0,1,2,0.4627938162712989
2115,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.02345223438284253,1,1,2,0.5216911527198091
2116,Amyloid fiber formation,Amyloid fiber formation,0.019159951051808975,0,1,2,0.4262100057121222
2117,Amyloid fiber formation,Amyloid fiber formation,0.018442043713886875,1,1,2,0.41024027333811053
2118,Platelet sensitization by LDL,Platelet sensitization by LDL,0.0019117551557349733,0,1,2,0.042526683582996536
2119,Platelet sensitization by LDL,Platelet sensitization by LDL,0.0014823728921660067,1,1,2,0.032975144723969306
2120,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,7.875982414560957e-05,0,1,2,0.0017519995227658304
2121,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,9.042016795734971e-06,1,1,2,0.0002011381980955245
2122,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.010868718886522242,0,1,2,0.241772890034118
2123,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.008994933533235444,1,1,2,0.20009083855245435
2124,Formation of the cornified envelope,Formation of the cornified envelope,3.0709828602318757e-06,0,1,2,6.831351598247845e-05
2125,Formation of the cornified envelope,Formation of the cornified envelope,5.332801573327906e-06,1,1,2,0.00011862730666084384
2126,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,0.001127004086450128,0,1,2,0.025070023238819444
2127,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,0.001236597405060484,1,1,2,0.02750790884847606
2128,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.000333301653838599,0,1,2,0.007414241268272806
2129,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),4.491342416840004e-05,1,1,2,0.0009990918410805343
2130,Signaling by PDGF,Signaling by PDGF,0.004137781775730212,0,1,2,0.09204428495149954
2131,Signaling by PDGF,Signaling by PDGF,0.004292671542031753,1,1,2,0.09548978269842079
2132,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,0.0003208913024255751,0,1,2,0.007138175012553693
2133,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,2.310435101098493e-05,1,1,2,0.0005139525434976012
2134,Peroxisomal protein import,Peroxisomal protein import,2.14518332676526e-05,0,1,2,0.00047719255413643024
2135,Peroxisomal protein import,Peroxisomal protein import,1.60413093298903e-05,1,1,2,0.00035683632607594557
2136,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.006926288926802197,0,1,2,0.15407417456723912
2137,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.0042670742760741315,1,1,2,0.09492037566598567
2138,Late endosomal microautophagy,Late endosomal microautophagy,0.00887002533837103,0,1,2,0.19731227600275378
2139,Late endosomal microautophagy,Late endosomal microautophagy,0.005428381299625762,1,1,2,0.12075346218082501
2140,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.014347436579571392,0,1,2,0.31915640128715717
2141,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.015466691691014021,1,1,2,0.3440540498328848
2142,Atorvastatin ADME,Atorvastatin ADME,0.0015253869632532553,0,1,2,0.03393198576360583
2143,Atorvastatin ADME,Atorvastatin ADME,0.0008986756437429619,1,1,2,0.019990894038159342
2144,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.0032633376885290817,0,2,3,0.10452417770981662
2145,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.004892134188857142,1,2,3,0.15669426585357704
2146,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,0.0039584787058963055,0,2,3,0.12678943192732448
2147,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,0.005119725675422094,1,2,3,0.1639839843128637
2148,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,0.0005474422068999356,0,2,3,0.01753448523608198
2149,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,0.0005746342543414469,1,2,3,0.018405442112246206
2150,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.001148882288201142,0,2,3,0.03679851364500513
2151,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.001207548277003449,1,2,3,0.038677575766172985
2152,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,0.0019721994825503287,0,2,3,0.06316923005483252
2153,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,0.0025405240956012983,1,2,3,0.08137257537830651
2154,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0034076791471770286,0,2,3,0.10914741125614708
2155,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0030943160767534735,1,2,3,0.09911044285542694
2156,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,4.088922467029292e-05,0,2,3,0.0013096752447279646
2157,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,2.6259670410926284e-05,1,2,3,0.0008410929908605478
2158,ECM proteoglycans,ECM proteoglycans,0.00099497159099369,0,2,3,0.03186877893722356
2159,ECM proteoglycans,ECM proteoglycans,0.0014992871972146122,1,2,3,0.04802192613733129
2160,Post-translational protein phosphorylation,Post-translational protein modification,0.008159561484144182,0,2,3,0.2613494330055941
2161,Post-translational protein phosphorylation,Post-translational protein modification,0.0075949110708119286,1,2,3,0.2432637717041232
2162,Integrin cell surface interactions,Integrin cell surface interactions,0.002418229024861556,0,2,3,0.07745548406655903
2163,Integrin cell surface interactions,Integrin cell surface interactions,0.001769815684748806,1,2,3,0.05668690978459137
2164,Metabolism of steroids,Metabolism of lipids,0.00012602071059618776,0,2,3,0.004036422953032037
2165,Metabolism of steroids,Metabolism of lipids,0.00015566413164942866,1,2,3,0.004985896929012889
2166,Retinoid metabolism and transport,Visual phototransduction,0.007985240507090489,0,2,3,0.2557659603395085
2167,Retinoid metabolism and transport,Visual phototransduction,0.007997196736717513,1,2,3,0.25614891643831106
2168,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.0026458427353108186,0,2,3,0.08474591435326131
2169,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.003240988391127448,1,2,3,0.10380833333321125
2170,Antimicrobial peptides,Innate Immune System,0.00625338840326823,0,2,3,0.20029501790430168
2171,Antimicrobial peptides,Innate Immune System,0.0065537996190563495,1,2,3,0.20991714049842794
2172,SARS-CoV Infections,Infectious disease,0.002797124256573335,0,2,3,0.08959143698128637
2173,SARS-CoV Infections,Infectious disease,0.004076279159461932,1,2,3,0.130562561378828
2174,GPCR downstream signalling,Signaling by GPCR,0.004183867895504879,0,2,3,0.1340086111717308
2175,GPCR downstream signalling,Signaling by GPCR,0.004768425096106411,1,2,3,0.15273188364579945
2176,Signaling by Interleukins,Cytokine Signaling in Immune system,0.009141287627454805,0,2,3,0.2927939623984516
2177,Signaling by Interleukins,Cytokine Signaling in Immune system,0.009176725571193235,1,2,3,0.2939290339976938
2178,Apoptotic execution phase,Apoptosis,0.012566250229082665,0,2,3,0.4024949599018352
2179,Apoptotic execution phase,Apoptosis,0.00902158113058646,1,2,3,0.2889597826886202
2180,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.002946049683016584,0,2,3,0.09436149427378826
2181,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.0021920823398810445,1,2,3,0.07021204236805573
2182,Collagen biosynthesis and modifying enzymes,Collagen formation,4.705630635858652e-05,0,2,3,0.0015072058725278436
2183,Collagen biosynthesis and modifying enzymes,Collagen formation,0.00010209817343597027,1,2,3,0.0032701879617243086
2184,Clathrin-mediated endocytosis,Membrane Trafficking,0.0018935385809635919,0,2,3,0.060649734115087325
2185,Clathrin-mediated endocytosis,Membrane Trafficking,0.0020592120829448783,1,2,3,0.06595622955494634
2186,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,0.0001264398705599856,0,2,3,0.004049848578795148
2187,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,7.314331314628256e-05,1,2,3,0.0023427684754968848
2188,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.002206573954196797,0,2,3,0.0706762064278667
2189,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.002977932311661724,1,2,3,0.09538268970632802
2190,Fatty acid metabolism,Metabolism of lipids,1.2000608364690867e-05,0,2,3,0.0003843775425834793
2191,Fatty acid metabolism,Metabolism of lipids,1.4906975453270598e-05,1,2,3,0.0004774680097835191
2192,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.004311978097876292,0,2,3,0.13811196020795813
2193,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.003991066250387551,1,2,3,0.1278332057002633
2194,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.0028311901794326705,0,2,3,0.0906825629739516
2195,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.002826485925259852,1,2,3,0.09053188647458707
2196,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0011181574744745008,0,2,3,0.03581440283681231
2197,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.001658248007910306,1,2,3,0.05311341516234311
2198,Late endosomal microautophagy,Late endosomal microautophagy,0.00720388197127881,0,2,3,0.23073917296799548
2199,Late endosomal microautophagy,Late endosomal microautophagy,0.003596437840992866,1,2,3,0.11519332165212957
2200,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",0.0006935882123259055,0,2,3,0.022215518123490364
2201,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",0.0007533970262898369,1,2,3,0.02413118474951984
2202,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.004916179232352957,0,2,3,0.1574644247029757
2203,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.004884755846181575,1,2,3,0.15645793873250224
2204,Syndecan interactions,Non-integrin membrane-ECM interactions,0.002668805465658981,0,2,3,0.08548140688780677
2205,Syndecan interactions,Non-integrin membrane-ECM interactions,0.001991036781106004,1,2,3,0.06377258567712295
2206,Transferrin endocytosis and recycling,Iron uptake and transport,0.00014575475819211345,0,2,3,0.004668501301865208
2207,Transferrin endocytosis and recycling,Iron uptake and transport,0.00014141208416398768,1,2,3,0.004529406155982153
2208,Toll-like Receptor Cascades,Innate Immune System,0.0029931904265475414,0,2,3,0.09587140465527368
2209,Toll-like Receptor Cascades,Innate Immune System,0.0031359914054071856,1,2,3,0.10044529688344483
2210,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.016398276072483103,0,2,3,0.5252341271207621
2211,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.018137093338112167,1,2,3,0.5809281625607263
2212,Heme signaling,Cellular responses to stress,0.0032534722998761845,0,2,3,0.1042081909088317
2213,Heme signaling,Cellular responses to stress,0.003470291753592458,1,2,3,0.11115288290036145
2214,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.004055782545424369,0,2,3,0.12990605815035658
2215,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.003918521247991921,1,2,3,0.1255096010212214
2216,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,0,2,3,0.0
2217,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,1,2,3,0.0
2218,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.0010774420890965167,0,2,3,0.03451029563646606
2219,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.0012613176091423126,1,2,3,0.040399798767358615
2220,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.004382022758612633,0,2,3,0.14035547934854978
2221,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.004488902602885042,1,2,3,0.14377882345283777
2222,Leishmania infection,Infectious disease,0.006509289608620244,0,2,3,0.20849149207195872
2223,Leishmania infection,Infectious disease,0.009489019099266497,1,2,3,0.30393174513013216
2224,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,1.4162469461302438e-05,0,2,3,0.0004536216034235388
2225,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.0005716057593218403,1,2,3,0.01830843990719236
2226,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.015349820683624237,0,2,3,0.4916522707989007
2227,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.01749344139581644,1,2,3,0.5603120950797934
2228,Generic Transcription Pathway,RNA Polymerase II Transcription,0.012148500310388912,0,2,3,0.3891144976550706
2229,Generic Transcription Pathway,RNA Polymerase II Transcription,0.010023645033787595,1,2,3,0.3210557272373434
2230,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,0.0001387948245282671,0,2,3,0.004445575753680118
2231,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,3.4660558859859774e-05,1,2,3,0.0011101720874686781
2232,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.0028632993416606435,0,2,3,0.09171101424046539
2233,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.0036997200688752324,1,2,3,0.11850143468603021
2234,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.0047045174156172395,0,2,3,0.15068493098872301
2235,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.0028049935321902207,1,2,3,0.08984348860497157
2236,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.013772408066293207,0,2,3,0.4411280001066044
2237,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.008788891055962705,1,2,3,0.281506757279458
2238,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00042651508615235975,0,2,3,0.01366120914106242
2239,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00027392877407870337,1,2,3,0.008773894274649916
2240,Formation of the cornified envelope,Keratinization,2.032969436677893e-07,0,2,3,6.5115681844659395e-06
2241,Formation of the cornified envelope,Keratinization,4.371759946637906e-06,1,2,3,0.00014002676314292403
2242,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.004154639075062563,0,2,3,0.13307241678617884
2243,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.003248101158488234,1,2,3,0.10403615411995995
2244,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.012720808507687361,0,2,3,0.40744543653690335
2245,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.0120567451214117,1,2,3,0.38617559381065275
2246,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.002119297899538164,0,2,3,0.06788076853033717
2247,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.0021221802386683455,1,2,3,0.06797308938592073
2248,Platelet sensitization by LDL,Platelet homeostasis,0.0016591113228908436,0,2,3,0.05314106700136744
2249,Platelet sensitization by LDL,Platelet homeostasis,0.0006954342799114977,1,2,3,0.022274647369311
2250,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.0005976324478576105,0,2,3,0.019142070526319947
2251,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.0007730931157845233,1,2,3,0.024762047306517123
2252,Diseases of glycosylation,Diseases of metabolism,0.004431292059160027,0,2,3,0.1419335670665804
2253,Diseases of glycosylation,Diseases of metabolism,0.00412437293659477,1,2,3,0.13210299727225064
2254,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.002166320172930681,0,2,3,0.06938688433247299
2255,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0013910051258113033,1,2,3,0.04455366892511247
2256,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.0047483594444811,0,2,3,0.15208918407360392
2257,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.005689547737719318,1,2,3,0.1822352926932034
2258,Cell-cell junction organization,Cell junction organization,0.00011428250631205148,0,2,3,0.0036604501706559004
2259,Cell-cell junction organization,Cell junction organization,0.00020957954510151012,1,2,3,0.006712798891004979
2260,Molecules associated with elastic fibres,Elastic fibre formation,0.0012925912129818638,0,2,3,0.041401487233998745
2261,Molecules associated with elastic fibres,Elastic fibre formation,0.0016962098889172015,1,2,3,0.05432932806357649
2262,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.0010622180857678017,0,2,3,0.03402267327517046
2263,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.0012959937034296807,1,2,3,0.04151046845205463
2264,Cellular response to chemical stress,Cellular responses to stress,0.0005524724576993099,0,2,3,0.017695603354604284
2265,Cellular response to chemical stress,Cellular responses to stress,0.0005916947167273713,1,2,3,0.018951885959754302
2266,Complement cascade,Innate Immune System,0.01561034801298487,0,2,3,0.499996918969415
2267,Complement cascade,Innate Immune System,0.01628564384045762,1,2,3,0.5216265349682652
2268,MAPK1/MAPK3 signaling,MAPK family signaling cascades,3.640796203779326e-06,0,2,3,0.00011661411282893798
2269,MAPK1/MAPK3 signaling,MAPK family signaling cascades,1.7152373777578656e-05,1,2,3,0.0005493877544989634
2270,Neutrophil degranulation,Innate Immune System,0.01264178012846376,0,2,3,0.4049141703479575
2271,Neutrophil degranulation,Innate Immune System,0.013172593956574582,1,2,3,0.4219160513041671
2272,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.008461736384362357,0,2,3,0.27102804612641
2273,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.009137501746020923,1,2,3,0.2926727012291971
2274,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.005954731446808629,0,2,3,0.19072908395238908
2275,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.00698031511014689,1,2,3,0.2235783626095947
2276,Heme degradation,Metabolism of porphyrins,0.00010618673394140744,0,2,3,0.0034011438926259243
2277,Heme degradation,Metabolism of porphyrins,4.5970290264070804e-05,1,2,3,0.001472420952886246
2278,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,8.576520146778414e-05,0,2,3,0.002747045514489055
2279,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,7.926823115842998e-05,1,2,3,0.0025389486075776437
2280,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.0010092395127591124,0,2,3,0.03232577816087148
2281,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.0014175714449780614,1,2,3,0.045404583825964656
2282,SLC transporter disorders,Disorders of transmembrane transporters,0.000976648366401924,0,2,3,0.03128188902074977
2283,SLC transporter disorders,Disorders of transmembrane transporters,0.0011757367466743642,1,2,3,0.03765865760118307
2284,Assembly of collagen fibrils and other multimeric structures,Collagen formation,1.3837094990751523e-05,0,2,3,0.0004431999118218245
2285,Assembly of collagen fibrils and other multimeric structures,Collagen formation,3.0021259882196955e-05,1,2,3,0.000961576092486384
2286,Peroxisomal protein import,Peroxisomal protein import,9.991063066207318e-05,0,2,3,0.0032001213209195975
2287,Peroxisomal protein import,Peroxisomal protein import,1.3226529959470712e-05,1,2,3,0.00042364361274271786
2288,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0001910769945568746,0,2,3,0.0061201651933002026
2289,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0001225819330093635,1,2,3,0.003926279463789965
2290,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0035455192156607796,0,2,3,0.11356240632833128
2291,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0034464821985379143,1,2,3,0.1103902667076025
2292,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.009307644549281752,0,2,3,0.2981223476652965
2293,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.00818743514047251,1,2,3,0.26224222170402567
2294,Amyloid fiber formation,Amyloid fiber formation,0.016217319596538802,0,2,3,0.5194381204997404
2295,Amyloid fiber formation,Amyloid fiber formation,0.016059559163789292,1,2,3,0.5143850793859597
2296,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.00010686926849752784,0,2,3,0.0034230053639311437
2297,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.00011640604041128712,1,2,3,0.003728466623976552
2298,ABC transporter disorders,Disorders of transmembrane transporters,0.0022045442133673244,0,2,3,0.07061119415778801
2299,ABC transporter disorders,Disorders of transmembrane transporters,0.0026564449832603,1,2,3,0.08508550263819134
2300,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.0023881012723824106,0,2,3,0.07649049703343742
2301,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.0025068079019433588,1,2,3,0.08029265115532806
2302,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.00027275142496065895,0,2,3,0.008736183973054852
2303,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.00028669771737145346,1,2,3,0.009182881460557596
2304,GPCR ligand binding,Signaling by GPCR,0.00878051432186856,0,2,3,0.28123845184292223
2305,GPCR ligand binding,Signaling by GPCR,0.010054207017192457,1,2,3,0.32203462261669774
2306,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.005078745641820502,0,2,3,0.16267140047277154
2307,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.006585136289219164,1,2,3,0.2109208489691895
2308,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.001736212047281628,0,2,3,0.055610590718176055
2309,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0015758618020922642,1,2,3,0.05047459833133227
2310,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.003493625480659221,0,2,3,0.11190025839972573
2311,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.004088872480650004,1,2,3,0.13096592341716248
2312,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.00820842871346608,0,2,3,0.2629146424473821
2313,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.005942830145405851,1,2,3,0.19034788719571427
2314,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.00015325124589515187,0,2,3,0.00490861258903789
2315,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.00015370556057643964,1,2,3,0.004923164214709368
2316,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.0019763852944784427,0,2,3,0.0633033009330539
2317,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.0009245239507489008,1,2,3,0.029612352428233443
2318,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.004235367187840517,0,2,3,0.13565812516562162
2319,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.00383483970143715,1,2,3,0.1228292946361762
2320,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,0.00182288589248816,0,2,3,0.05838673994447453
2321,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,0.0022453752629029507,1,2,3,0.07191900606237328
2322,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.0033574895948468414,0,2,3,0.10753984802253602
2323,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.0036875566705959523,1,2,3,0.11811184300884407
2324,Atorvastatin ADME,Atorvastatin ADME,0.0014154880837404073,0,2,3,0.045337854102895
2325,Atorvastatin ADME,Atorvastatin ADME,0.0007932754366567567,1,2,3,0.025408483775798584
2326,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.002760852480144831,0,2,3,0.08842965785600909
2327,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.0033310204285868683,1,2,3,0.10669204491355555
2328,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.00376381541200436,0,2,3,0.12055439814707503
2329,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.004337850096546027,1,2,3,0.13894063613572658
2330,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.0040659554367628616,0,2,3,0.1302318942125652
2331,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.004059712430173453,1,2,3,0.13003193172247762
2332,O-linked glycosylation,Post-translational protein modification,0.005216937040438734,0,2,3,0.16709764859226994
2333,O-linked glycosylation,Post-translational protein modification,0.004823391663558406,1,2,3,0.1544924539001885
2334,Cytokine Signaling in Immune system,Immune System,0.004655736580479225,0,3,4,0.24246233492929306
2335,Cytokine Signaling in Immune system,Immune System,0.004837045104118876,1,3,4,0.25190455469932305
2336,Amyloid fiber formation,Metabolism of proteins,0.01029365298209126,0,3,4,0.5360748173456212
2337,Amyloid fiber formation,Metabolism of proteins,0.01032971992331186,1,3,4,0.5379531183686581
2338,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,0.00010266304320496137,0,3,4,0.0053465054854670594
2339,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,0.00010893209782357275,1,3,4,0.00567298650395959
2340,Integration of energy metabolism,Metabolism,0.0015852499273341296,0,3,4,0.08255694715192882
2341,Integration of energy metabolism,Metabolism,0.0016748545365763918,1,3,4,0.08722339303041741
2342,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.0018644885080724173,0,3,4,0.09709918705700056
2343,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.002483446690921734,1,3,4,0.12933340899869603
2344,"Platelet activation, signaling and aggregation",Hemostasis,0.0060121835078575875,0,3,4,0.3131036359424982
2345,"Platelet activation, signaling and aggregation",Hemostasis,0.005927758233893448,1,3,4,0.3087069204714773
2346,Keratinization,Developmental Biology,1.776199151081435e-06,0,3,4,9.250123713535013e-05
2347,Keratinization,Developmental Biology,2.0208059489148737e-06,1,3,4,0.0001052399164650489
2348,Platelet homeostasis,Hemostasis,0.0004282684764689293,0,3,4,0.022303447153055905
2349,Platelet homeostasis,Hemostasis,0.0004230475803993955,1,3,4,0.022031552334790212
2350,Platelet Adhesion to exposed collagen,Hemostasis,0.0015941825585653717,0,3,4,0.08302214241973463
2351,Platelet Adhesion to exposed collagen,Hemostasis,0.0015807226475304881,1,3,4,0.08232117461344983
2352,Degradation of the extracellular matrix,Extracellular matrix organization,0.0013227919685073605,0,3,4,0.06888861166561047
2353,Degradation of the extracellular matrix,Extracellular matrix organization,0.0006492490868287139,1,3,4,0.03381171739896802
2354,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.01171206740272371,0,3,4,0.6099432732556685
2355,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.0066549069753442935,1,3,4,0.34657551089652266
2356,Post-translational protein modification,Metabolism of proteins,0.010201029715019072,0,3,4,0.5312511652306662
2357,Post-translational protein modification,Metabolism of proteins,0.010268912335580986,1,3,4,0.5347863692522105
2358,Chaperone Mediated Autophagy,Autophagy,0.003987855876752546,0,3,4,0.2076803166426997
2359,Chaperone Mediated Autophagy,Autophagy,0.0012047617536087886,1,3,4,0.06274181169060666
2360,Cell surface interactions at the vascular wall,Hemostasis,0.004992538607909173,0,3,4,0.26000237495689693
2361,Cell surface interactions at the vascular wall,Hemostasis,0.004966511938165324,1,3,4,0.2586469531009899
2362,ECM proteoglycans,Extracellular matrix organization,0.00038607638349275395,0,3,4,0.020106159312190928
2363,ECM proteoglycans,Extracellular matrix organization,0.00018879618674193726,1,3,4,0.009832163712854463
2364,Visual phototransduction,Sensory Perception,0.005223880624597593,0,3,4,0.2720502484918193
2365,Visual phototransduction,Sensory Perception,0.005707998245189156,1,3,4,0.2972622179922419
2366,Cell junction organization,Cell-Cell communication,0.0001054590573951482,0,3,4,0.005492116844127381
2367,Cell junction organization,Cell-Cell communication,0.00018681078504090125,1,3,4,0.009728767585542586
2368,Cellular responses to stress,Cellular responses to stimuli,0.002653686263216101,0,3,4,0.13819917781579857
2369,Cellular responses to stress,Cellular responses to stimuli,0.0025990541559570584,1,3,4,0.13535403654563427
2370,Metabolism of carbohydrates,Metabolism,0.0021404680951891642,0,3,4,0.11147170447255009
2371,Metabolism of carbohydrates,Metabolism,0.0022589151495568892,1,3,4,0.11764021269269073
2372,Diseases of metabolism,Disease,0.0017411204938076318,0,3,4,0.09067440415161734
2373,Diseases of metabolism,Disease,0.0022396654981510907,1,3,4,0.11663772568644683
2374,Diseases of programmed cell death,Disease,0.0006463903596294634,0,3,4,0.033662840060296774
2375,Diseases of programmed cell death,Disease,0.0008416185235578209,1,3,4,0.04382996950410993
2376,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.00497185635885196,0,3,4,0.2589252808577533
2377,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.004917336655785121,1,3,4,0.25608599339448435
2378,Dissolution of Fibrin Clot,Hemostasis,0.0010482629476483577,0,3,4,0.05459163711545777
2379,Dissolution of Fibrin Clot,Hemostasis,0.0010392490182935571,1,3,4,0.05412220798851441
2380,Diseases of Immune System,Disease,0.002186944680351172,0,3,4,0.11389212091216759
2381,Diseases of Immune System,Disease,0.002841813693021124,1,3,4,0.1479965138777279
2382,Metabolism of porphyrins,Metabolism,6.064152127163847e-05,0,3,4,0.0031581006758059356
2383,Metabolism of porphyrins,Metabolism,6.455243351576383e-05,1,3,4,0.003361773907317799
2384,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.002474229221223318,0,3,4,0.12885337985903453
2385,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.0012097265792282276,1,3,4,0.06300037082328037
2386,Integrin cell surface interactions,Extracellular matrix organization,0.002731686807152838,0,3,4,0.14226130497478606
2387,Integrin cell surface interactions,Extracellular matrix organization,0.00133303656118569,1,3,4,0.06942213151112794
2388,ABC-family proteins mediated transport,Transport of small molecules,0.003098686586534133,0,3,4,0.16137398927063276
2389,ABC-family proteins mediated transport,Transport of small molecules,0.0038337149254631933,1,3,4,0.19965293487145871
2390,Signaling by Nuclear Receptors,Signal Transduction,6.709579102698809e-05,0,3,4,0.003494227363408288
2391,Signaling by Nuclear Receptors,Signal Transduction,8.896500160332038e-05,1,3,4,0.004633136270245995
2392,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.005005110209377487,0,3,4,0.26065708120866127
2393,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.006218657363423262,1,3,4,0.3238564206537745
2394,Sensory processing of sound,Sensory Perception,0.0084879545330882,0,3,4,0.44203731016379944
2395,Sensory processing of sound,Sensory Perception,0.009218298706764737,1,3,4,0.48007231291590774
2396,RNA Polymerase II Transcription,Gene expression (Transcription),0.010109380666065973,0,3,4,0.5264782486321652
2397,RNA Polymerase II Transcription,Gene expression (Transcription),0.00885086014772125,1,3,4,0.46093677776937925
2398,Membrane Trafficking,Vesicle-mediated transport,0.0012303896393139576,0,3,4,0.06407646559551826
2399,Membrane Trafficking,Vesicle-mediated transport,0.0006996241231059536,1,3,4,0.0364351581170574
2400,Disorders of transmembrane transporters,Disease,0.0016874466857062865,0,3,4,0.08787916936720877
2401,Disorders of transmembrane transporters,Disease,0.002182952095856819,1,3,4,0.11368419433767836
2402,Signaling by GPCR,Signal Transduction,0.008536133520876949,0,3,4,0.44454638465112534
2403,Signaling by GPCR,Signal Transduction,0.011382559270261649,1,3,4,0.5927830860771408
2404,Peptide hormone metabolism,Metabolism of proteins,0.003276170911979321,0,3,4,0.17061705171991792
2405,Peptide hormone metabolism,Metabolism of proteins,0.003279371528510154,1,3,4,0.17078373403620978
2406,Metabolism of lipids,Metabolism,0.0022686366188166504,0,3,4,0.11814648921734376
2407,Metabolism of lipids,Metabolism,0.002376175410531283,1,3,4,0.12374691486082398
2408,Gene Silencing by RNA,Gene expression (Transcription),0.00014704197410789278,0,3,4,0.007657679887710183
2409,Gene Silencing by RNA,Gene expression (Transcription),0.0001331915265024017,1,3,4,0.006936373643640519
2410,Metabolism of vitamins and cofactors,Metabolism,0.0024200450727216026,0,3,4,0.12603156747021396
2411,Metabolism of vitamins and cofactors,Metabolism,0.0025429761207414556,1,3,4,0.13243359396440418
2412,Iron uptake and transport,Transport of small molecules,8.289961110393837e-05,0,3,4,0.004317261710481547
2413,Iron uptake and transport,Transport of small molecules,0.00010256852830464501,1,3,4,0.0053415833205163205
2414,Late endosomal microautophagy,Autophagy,0.004899855546365971,0,3,4,0.25517560885411045
2415,Late endosomal microautophagy,Autophagy,0.0014834776455409605,1,3,4,0.0772568309086439
2416,SLC-mediated transmembrane transport,Transport of small molecules,0.0009361802580132577,0,3,4,0.04875457349205055
2417,SLC-mediated transmembrane transport,Transport of small molecules,0.001159951557514445,1,3,4,0.06040817777771985
2418,Elastic fibre formation,Extracellular matrix organization,0.0013335662353351656,0,3,4,0.06944971598220219
2419,Elastic fibre formation,Extracellular matrix organization,0.0006507025702480191,1,3,4,0.03388741218485934
2420,Adaptive Immune System,Immune System,0.004734072238387332,0,3,4,0.24654191421740368
2421,Adaptive Immune System,Immune System,0.004901253866768088,1,3,4,0.2552484308499034
2422,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.009676908719614083,0,3,4,0.5039558923700443
2423,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.009801170518149872,1,3,4,0.5104272219426464
2424,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.0020138475383444546,0,3,4,0.10487753503621668
2425,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.0026067499529615888,1,3,4,0.13575481972539663
2426,Miscellaneous transport and binding events,Transport of small molecules,0.010532744527794886,0,3,4,0.5485262723261751
2427,Miscellaneous transport and binding events,Transport of small molecules,0.013256563579499602,1,3,4,0.6903778388366755
2428,Infectious disease,Disease,0.006296299265929666,0,3,4,0.32789987041615726
2429,Infectious disease,Disease,0.008217453012355219,1,3,4,0.42795008053104133
2430,Collagen formation,Extracellular matrix organization,9.487923120464915e-06,0,3,4,0.0004941138644018291
2431,Collagen formation,Extracellular matrix organization,4.705394575913068e-06,1,3,4,0.0002450484334579943
2432,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.0016378108883230342,0,3,4,0.08529422687280719
2433,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.002025654121275739,1,3,4,0.10549240050714091
2434,Reversible hydration of carbon dioxide,Metabolism,0.001326670407616158,0,3,4,0.06909059375500594
2435,Reversible hydration of carbon dioxide,Metabolism,0.0014050456363890113,1,3,4,0.07317223382213524
2436,Peroxisomal protein import,Protein localization,0.00021216810688636032,0,3,4,0.011049331014320323
2437,Peroxisomal protein import,Protein localization,0.00018556933296505284,1,3,4,0.0096641150082737
2438,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.0028005167680293973,0,3,4,0.14584584476537374
2439,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.00371510099969106,1,3,4,0.19347573629058862
2440,Factors involved in megakaryocyte development and platelet production,Hemostasis,0.00184132458170848,0,3,4,0.09589285169518498
2441,Factors involved in megakaryocyte development and platelet production,Hemostasis,0.001827729319185145,1,3,4,0.09518483502834743
2442,Innate Immune System,Immune System,0.021021855739309633,0,3,4,1.0947802005102119
2443,Innate Immune System,Immune System,0.021440792199232027,1,3,4,1.1165976531310688
2444,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.003303786394951575,0,3,4,0.17205521609324753
2445,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.003672934598540223,1,3,4,0.19127978643348895
2446,Diseases of hemostasis,Disease,0.0028555662682085347,0,3,4,0.14871272310339825
2447,Diseases of hemostasis,Disease,0.003710528933993539,1,3,4,0.1932376313838121
2448,MAPK family signaling cascades,Signal Transduction,5.8595924927255964e-05,0,3,4,0.003051569720411815
2449,MAPK family signaling cascades,Signal Transduction,7.787614646386805e-05,1,3,4,0.004055648763741158
2450,Apoptosis,Programmed Cell Death,0.012339676684147784,0,3,4,0.6426280287539519
2451,Apoptosis,Programmed Cell Death,0.008291409253475381,1,3,4,0.43180158771892063
2452,Integrin signaling,Signal Transduction,0.003125965905045469,0,3,4,0.16279464680724484
2453,Integrin signaling,Signal Transduction,0.004164614214457368,1,3,4,0.2168855709643951
2454,Atorvastatin ADME,Drug ADME,0.0007190166927359005,0,3,4,0.03744508804575449
2455,Atorvastatin ADME,Drug ADME,0.0007497246729190871,1,3,4,0.039044304076875286
2456,Disease,root,0.0022908752033411937,0,4,5,0.29509578405333914
2457,Disease,root,0.0059865107655539315,1,4,5,0.7711437469524103
2458,Protein localization,root,0.00013528755757688434,0,4,5,0.017426871536950328
2459,Protein localization,root,2.1974562883211307e-05,1,4,5,0.002830621612994453
2460,Transport of small molecules,root,0.004927660852966718,0,4,5,0.634749523166665
2461,Transport of small molecules,root,0.010015692378665878,1,4,5,1.2901569631592311
2462,Immune System,root,0.016951046533233247,0,4,5,2.183524602280178
2463,Immune System,root,0.011947583901960511,1,4,5,1.539010782407508
2464,Gene expression (Transcription),root,0.0032869997669160984,0,4,5,0.4234101325059321
2465,Gene expression (Transcription),root,0.0016044440172993573,1,4,5,0.20667414120337274
2466,Metabolism of proteins,root,0.015528231105451835,0,4,5,2.0002466857825985
2467,Metabolism of proteins,root,0.020196784256257285,1,4,5,2.6016196241348566
2468,Vesicle-mediated transport,root,0.008640587334037322,0,4,5,1.1130247908311477
2469,Vesicle-mediated transport,root,0.006149644731290454,1,4,5,0.7921576133797643
2470,Autophagy,root,0.0040886026757648635,0,4,5,0.5266674546599983
2471,Autophagy,root,0.0005634208664824765,1,4,5,0.0725762460146964
2472,Hemostasis,root,0.0058117121534477624,0,4,5,0.7486273159326525
2473,Hemostasis,root,0.00509133699492062,1,4,5,0.6558332292412113
2474,Cell-Cell communication,root,1.254913178776514e-05,0,4,5,0.0016164983054066855
2475,Cell-Cell communication,root,0.00023849394122525653,1,4,5,0.030721252940881457
2476,Programmed Cell Death,root,0.007408071906157831,0,4,5,0.9542600942568988
2477,Programmed Cell Death,root,0.0015865833941539568,1,4,5,0.20437345080212949
2478,Drug ADME,root,1.347234993364972e-05,0,4,5,0.0017354213188535705
2479,Drug ADME,root,0.0006677906043856582,1,4,5,0.08602048321847822
2480,Developmental Biology,root,0.0009436750192441903,0,4,5,0.12155813607361281
2481,Developmental Biology,root,0.0005614968256564307,1,4,5,0.07232840347168727
2482,Sensory Perception,root,0.008651792846246235,0,4,5,1.114468212719073
2483,Sensory Perception,root,0.009070841850141904,1,4,5,1.1684474055537628
2484,Metabolism,root,0.004775481260639803,0,4,5,0.6151467285451458
2485,Metabolism,root,0.0054072571208145315,1,4,5,0.6965280244500138
2486,Signal Transduction,root,0.0036170255742772536,0,4,5,0.46592193072132
2487,Signal Transduction,root,0.006207249340878281,1,4,5,0.7995778680521333
2488,Cellular responses to stimuli,root,0.0010189332340944694,0,4,5,0.13125241443731733
2489,Cellular responses to stimuli,root,0.0020372713868801328,1,4,5,0.2624281743344216
2490,Extracellular matrix organization,root,0.0030988895364495424,0,4,5,0.3991789845730278
2491,Extracellular matrix organization,root,0.0009570983961050219,1,4,5,0.12328724899674946
